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Abstract 
Inflammatory chemokine signalling is implicated in a broad range of pathologies and has 
been intensely researched. However, chemokine receptors remain poorly druggable. This 
may be due to the complexity of chemokine signalling; multiple chemokines can bind a 
single receptor, and an individual chemokine can bind multiple receptors. Additionally, 
many receptors demonstrate signalling bias, where different ligands elicit diverse 
responses. Bias signalling is an area of emerging interest with relevance in drug 
development, and there is a call to better characterise chemokine signalling bias. CCR4, 
CCR7 and CCR10 share a similar molecular evolution; each interacts with a ligand pair 
resultant from gene duplication, with one ligand in each pair being “dominant” in receptor 
activation, i.e. able to fully activate the receptor triggering recruitment of G-proteins and b-
arrestin. It may be possible, with a greater understanding of the underlying biology of 
biased signalling, to generate future antagonists of these receptors that selectively inhibit 
individual signalling pathways, as has been demonstrated previously with other GPCRs. 
Biased signalling is believed to result from slight variation in ligand/receptor binding that 
lock the receptor in specific conformations for coupling to signalling apparatus. In an effort 
to visualise these subtle differences, a novel unnatural amino acid (UAA) capture based 
methodology was attempted. An expression vector for a UAA compatible 
tRNA/Synthetase pair, as well as mutants of 16 residues of CCR7, were generated. UAA 
integration was observed with all 16 mutants, however protein level and ligand binding 
varied significantly between sites of integration. UV crosslinking of ligand and receptor 
was attempted, but no combination of chemokine and substitution site demonstrated 
successful chemokine capture. 
In an effort to fully profile the bias of CCRs 4, 7 and 10, BRET based methods were 
employed to assess b-arrestin and G-protein recruitment by the receptors in response to 
their cognate ligands. These data confirmed the reported bias, that CCL22, 19 and 21 
trigger b-arrestin recruitment to CCR4, 7 and 10 respectively, but CCL17 and CCL28 
failed to trigger recruitment, and CCL21 did so at poorer efficiency than CCL19. 
Interestingly, this pattern remained at the level of G-protein recruitment also, in contrast to 
the previously reported signalling properties of these chemokines. 
Recently, CCR7 was identified as a target of ST8sia4 mediated polysialylation, with 
significant effects on the biological activity of CCL21. As such, the role of ST8sia4 in 
chemokine biology was further examined. These data revealed that HEK293T cells, as well 
17 
 
as other adherent cell lines, demonstrate little to no expression of ST8sia4. Reintroduction 
of polysialic acid modification of CCR7 restored the capacity of CCL21 to compete with 
labelled CCL19 on HEK293T cells, resulting in a partial phenocopy of primary cells in the 
same assay, and resulted in a shift in potency of CCL21 for b-arrestin recruitment. This 
was mirrored at the level of G-protein recruitment, indicating that the previously noted lack 
of G-protein in response to CCL21 was most likely due to the lack of polysialylation of 
CCR7. Conversely, inclusion of ST8sia4 expression in the assessment of CCR4 signalling 
demonstrated no change from previous experiments. CCR10 however was revealed to be a 
previously undescribed target of ST8sia4 mediated polysialylation, with implications for 
the signalling potential of both of its cognate ligands.  
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1 Introduction 
1.1 Overview 
Since their initial identification in the 1980s, chemokines have emerged as perhaps the key 
instigators of directed cellular migration, in a process referred to as chemotaxis (Rot and 
von Andrian, 2004). In this capacity they are best described for their role in the immune 
system, giving rise to their title of chemotactic cytokines, abbreviated to chemokines. 
Although diverse in physiological function all chemokines share a number of traits. They 
all adopt a conformation maintained by a tetracysteine motif (with the exception of the 
XCL chemokines), are all quite small at an average molecular weight of around 10 kDa, 
and signal through coupling with a group of class A G-protein coupled receptors (GPCRs) 
known as the chemokine receptors . Beyond their role in the immune system a number of 
chemokines have demonstrated additional functional roles. The CXCR4/CXCL12 
signalling axis is often regarded as the primordial chemokine/receptor pairing in the 
system, and its genetic ablation results in a 100% mortality rate of offspring and a number 
of defects in the cardiovascular system, in the urinary tract and in the central nervous 
system (Ara et al., 2005; Takabatake et al., 2009; Zhu and Murakami, 2012). This would 
indicate extensive developmental functions of CXCL12/CXCR4. Chemokines are also 
important  in the processes of angiogenesis and wound healing, mediating their effects 
either through the recruitment of cells capable of tissue remodelling, or through direct non-
chemotactic signalling events downstream of chemokine receptors (Behm et al., 2012). 
It is in their function in the immune system, however, that chemokines are most studied. 
As demonstrated by the utilisation of CXCR4 blockade to free hematopoietic stem cells 
(HSC) into circulation for collection and transplant, the CXCL12/CXCR4 axis is important 
in directing and maintaining HSC residence in the bone marrow under basal conditions, a 
form of homeostatic signalling (Devine et al., 2008). In the context of insult or injury 
chemokine signalling spatially and temporally coordinates the reaction of the immune 
system. An example could be the breaking of the skin barrier introducing pathogen, 
resulting in the release of an initial wave of Toll like receptor (TLR) dependent danger 
signals. These include CXCL1 secreted by keratinocytes, signalling through CXCR2 and 
contributing to neutrophil recruitment, in an initial attempt to contain infection (Sanz and 
Kubes, 2012). This would be an example of inflammatory chemokine signalling. If the 
pathogen is not cleared by the innate response, an adaptive immune response may be 
required. Dermal or epidermal dendritic cells (DCs) uptake antigen, upregulating CCR7 
expression and leading to their recruitment to lymph nodes (LNs) (Ohl et al., 2004). Here 
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they can interact with naïve T-cells basally recruited by CCR7 ligands, initiating an 
adaptive immune response (Förster, Davalos-Misslitz and Rot, 2008). In this context CCR7 
signalling could be considered both inflammatory for DCs, as they do not express CCR7 
basally, and homeostatic for naïve T-cells, which routinely travel in and out of secondary 
lymphoid organs (SLOs), surveying for DCs presenting their specific antigen.  
Chemokines can also be considered pathogenic under a number of contexts. CCR5 is used 
as a co-receptor for human immune deficiency virus (HIV) cellular entry, with maraviroc 
(a CCR5 antagonist) being effectively used in disease management (Tan et al., 2013). 
Other viruses have become highly adept at manipulating the chemokine system for their 
own gain. Kaposi’s sarcoma-associated herpesvirus encodes a viral chemokine, vMIP-II, 
capable of antagonising CXCR4 and promiscuously binding CC and CXC receptors (Qin 
et al., 2015). Others like human cytomegalovirus encode viral chemokine receptors like 
US28, a constitutively active receptor capable of binding CC, CXC and CX3C chemokines 
and sculpting the immune system as a result (Burg et al., 2015). In cancer, aberrant 
chemokine signalling can aid in the development of disease in a number of ways. 
Recruitment of tumour associated macrophages (TAMs) and other inflammatory mediators 
aids tumorigenesis through upregulation of angiogenesis and tissue remodelling (Allavena 
et al., 2008). This process is necessary for the expansion of tumour size beyond certain 
metabolic limitations and is considered a hallmark of cancer development (Hanahan and 
Weinberg, 2011). The deposition of metastatic lesions is also linked with chemokine 
signalling, for example metastasis of breast cancer to the bone marrow, lungs and LNs is 
often linked to CXCR4:CXCL12 signalling (Gangadhar, Nandi and Salgia, 2010). 
Inflammatory signalling is also very important in various autoimmune diseases. In 
rheumatoid arthritis (RA) an influx of leukocytes is recruited and retained in the joint 
synovium, a process heavily associated with aberrant chemokine signalling, inducing 
inflammation and damaging the surrounding tissue (Szekanecz et al., 2006). 
Despite extensive study, in the 3 decades since their discovery, there is still a great deal we 
do not fully understand about the chemokine system.  
1.2 The chemokines 
As stated previously, chemokines share a few common features, such as their size (~8-14 
kDa) and general 3D structure. They can however be sub-divided for characterisation 
based on a number of further criteria. The distinctive structure of chemokines is maintained 
through disulfide bonding between highly conserved cysteine residues. Generally, there are 
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4 conserved cysteine residues found in chemokines, giving the tetracysteine motif typical 
of the family, with 2 found near the N-terminus, 1 near the C-terminus and a fourth in-
between, forming 2 disulfide bonds (figure 1.2.1). The absence or addition of amino acid 
residues between the 2 N-terminal cysteines allows for the classification of chemokines as 
either CC, CXC or CX3C. Additionally, there are the XC chemokines, which lack 2 of the 
4 cysteines but maintain a similar structure (figure 1.2.1) (Zlotnik and Yoshie, 2000). At 
present 28 CC, 17 CXC, 1 CX3C and 2 XC chemokines have been identified (summarised 
in table 1.2.1) (Hughes and Nibbs, 2018). CXC chemokines can also be referred to as a-
chemokines, and CC as b-chemokines.  
Due to their shared structure and sequence homology, the extensive repertoire of 
chemokines identified today are thought to have derived from duplication events of a 
single ancestral chemokine (Zlotnik, Yoshie and Nomiyama, 2006). This principle of 
chemokine evolution is supported by the observation that the genes for chemokines are 
frequently clustered in common genomic loci, with a cluster of CXC chemokine genes 
found on chromosome 4 in humans and a cluster of CC chemokine genes on chromosome 
17. These clusters represent the largest groupings of genes for their respective families, 
though smaller mini-clusters for others are also observed as are non-clustered chemokine 
genes (summarised in figure 1.2.2).  
CXC chemokines can also be further subdivided as either ELR+ or ELR- (Belperio et al., 
2000). This classification refers to a 3 amino acid motif  consisting of glutamic acid, lysine 
and arginine, which is present at the N-terminus of these chemokines next to the CXC 
motif. These include CXCL1, 2, 3, 5, 6, 7 and 8, and which bind CXCRs 1 and 2. These 
ELR+ positive chemokines are considered pro-angiogenic, contributing to the re-
vascularisation of injured or ischemic tissue, as well as neo-vascularisation of lesional 
tissues (Bizzarri et al., 2006). ELR- CXC chemokines, conversely, are broadly considered 
angiostatic, i.e. they have either no or even inhibitory effects on angiogenesis (Airoldi and 
Ribatti, 2011). Interestingly, mutagenesis of CXCL8 to remove this ELR motif results in a 
functional switch from angiogenic to angiostatic (Strieter et al., 1995). The primary 
cellular mediators of these angiogenic effects are vascular endothelial cells, which express 
CXCR2, migrate in response to ELR+ chemokines in vitro and promote the vascularisation 
of corneal pockets in vivo.  
Although divisible by sub-family as either CC, CXC, CX3C and XC, chemokines are also 
frequently grouped by function as either homeostatic or inflammatory. 
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1.2.1 Homeostatic chemokines  
As mentioned previously, the CXCL12/CXCR4 signalling axis is considered homeostatic, 
that is CXCL12 expression occurs basally and is generally unaffected by inflammatory 
insult, and subsequent signalling through CXCR4 is constant. Indeed, this signalling axis 
could be considered the archetypal homeostatic signalling axis, as demonstrated by its 
extensive roles both in organogenesis and in the mature immune system (Anders, 
Romagnani and Mantovani, 2014). Disruption of any aspect of this signalling axis is 
perinatally lethal in mice (Ma et al., 1998; Ara et al., 2005; Yu et al., 2011), a rarity 
amongst knockout mouse strains (KO) targeting the chemokine system. It is through this 
signalling axis that HSCs are recruited and retained in the bone marrow, with CXCL12 
expression from CXCL12-abundant reticular (CAR) cells in the bone marrow stroma 
aiding in retention of CXCR4+ HSCs (Rankin, 2012).  CXCL12/CXCR4 signalling is also 
used to maintain stem cell-like properties and tissue localisation of other progenitor cell 
populations as well, such as neural and mesenchymal stem cells (Zhu et al., 2012; Hu et 
al., 2013). During embryogenesis CXCL12/CXCR4 guidance cues are vitally important in 
the development of the cardiovascular and renal systems, ensuring the correct direction of 
cellular movement of cardio, endothelial and epithelial pre-cursors to form these tissues 
(Raman, Sobolik-Delmaire and Richmond, 2011). The dual roles of CXCL12/CXCR4 
signalling in vascular development and the maintenance of stem cell populations in tissues 
also makes this chemokine/receptor interaction vital in wound healing and re-
vascularisation (Bermudez et al., 2011). 
 As well as extensive functions during development, stem-cell renewal and wound healing, 
CXCL12/CXCR4 signalling also has additional immune functions. In concert with 
CCL25/CCR9, CCL17/CCL22/CCR4 and CCL19/CCL21/CCR7, CXCL12/CXCR4 
signalling regulates the step-wise transition of immature lymphocytes through the thymus 
during their development (Takahama, 2006). Somewhat similarly, the sequential 
presentation of the chemokines of CCR7 in SLOs is vital in instigating mature DC; 
naïve/memory T-cell interactions, a critical step in initiating an adaptive immune response 
(Comerford et al., 2013). As well, the CXCL13/CXCR5 signalling axis is a requirement of 
B-cell homing into SLOs, again a critical event in the development of antigen specific 
humoral immune responses (Ansel et al., 2000). Additionally, signalling by CCL17 and 
CCL22 through CCR4, and CCL27 through CCR10, recruits a number of T-cell subsets 
into the skin, and CCL28/CCR10 signalling in mucosal epithelial tissues helps with IgA 
producing plasmablast retention, important for the maintenance of barrier immunity. The 
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functions of CCR4, CCR7 and CCR10 will be discussed in further detail later in this 
Chapter. 
Homeostatic signalling can also be pathogenic in a number of circumstances. 
CXCL12/CXCR4 signalling is arguably the best characterised in this respect, as might be 
expected. In chronic inflammatory conditions for example, CXCL12 can drive the 
formation of tertiary lymphoid organs (TLOs) (Corsiero et al., 2012), which can be 
counter-productive to the resolution of inflammation. CXCL12/CXCR4 signalling is also 
often utilised in the invasion and metastatic dissemination of a number of cancers (Sun et 
al., 2010). CCR7 signalling is also often exploited by cancers to aid in the deposition of 
LN metastasis, and CCR4 driven migration to the skin is a hallmark of adult t-cell 
leukaemia/lymphomas (ATLL). Again, these aspects of CCR4 and CCR7 biology will be 
discussed further in later sections.    
1.2.2 Inflammatory chemokines 
In contrast to the homeostatic chemokines, inflammatory chemokines are rapidly 
upregulated, usually in response to inflammatory insult . These inflammatory chemokines 
are expressed by a plethora of cell-types in response to damage or attack (Rollins, 1997). 
Amongst the CXC chemokines these include CXCL1, 2, 3, 5, 6, 7 and 8 . These 
chemokines signal through the receptors CXCR1 and 2 and in doing so recruit neutrophils 
to the site of damage or infection (Zlotnik and Yoshie, 2012). Amongst the inflammatory 
CC chemokines there are CCL2, 3, 4, 6, 7, 8, 9, and 15 which signal through CCR1, 2, 3 
and 5 (Charo and Ransohoff, 2006). This alludes to an interesting division between the 
inflammatory and homeostatic chemokines. Namely that, for the most part, the homeostatic 
chemokines interact with specific receptors whereas the inflammatory chemokines are able 
to interact with multiple receptors (Culley et al., 2006). The inverse is also true, as the 
inflammatory (but not most homeostatic) receptors themselves similarly bind multiple 
chemokines (Berchiche et al., 2011) (summarised in figure 1.2.3). This considerable 
multiplicity of ligand/receptor combinations and cross-talk is often referred to as 
“redundancy” in the system. The idea being that, in order to ensure a robust immune 
infiltrate to sites of infection, a multitude of chemokines/receptors serving the same 
function has evolved and duplicated to ensure this broad activity (Mantovani, 1999). 
However, it is perhaps hasty to write off this explosion in inflammatory chemokines as 
simple redundancy. As can be seen (figure 1.2.3), chemokines vary in the repertoire of 
receptors they can bind. In addition, they display differing affinities for different receptors 
(Corbisier et al., 2015). When considering this, and the fact that redundancy to this degree 
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is rare in biological systems, it is possible that these chemokines serve non-redundant 
functions that have yet to be fully elucidated.  
Once again, inflammatory chemokine signalling can also be pathogenic in a number of 
contexts. As might be expected, chronic inflammatory conditions are perpetuated by the 
recruitment of cellular mediators of inflammation, which is frequently chemokine driven 
process. In the case of RA, recruitment of inflammatory cells of the myeloid compartment 
to the joint synovium is critical to pathogenesis (Szekanecz et al., 2006). As such, 
pharmacological blockers of CCR1, 2 and 5 have been considered in the treatment of RA, 
however to date no such treatment has been successful in clinical trials (Lebre et al., 2011). 
Developing tumours also benefit from the exploitation of inflammatory chemokines. For 
example, CCL2 and CCL5 can be expressed either by cancer cells or the surrounding 
stroma and recruit TAMs to the tumour site, a critical step in the establishment of the 
tumour microenvironment (Farajzadeh Valilou et al., 2018).  In addition, inflammatory 
chemokine signalling may be utilised in metastasis (Borsig et al., 2014) 
1.3 The chemokine receptors 
Chemokines mediate their actions through the chemokine receptors, a group of class A 
GPCRs (GPCRs). These are grouped as either CCR, CXCR, CX3CR or XCR in 
accordance with the chemokines that signal through them. For the most part a chemokine 
receptor is restricted in the family of chemokines it can bind, i.e. a CCR will bind CC 
chemokines only, and a CXC chemokine can only bind to a CXCR. At present 10 CCRs, 6 
CXCRs, 1  CX3CR and XCR1 have been identified in humans (Zlotnik and Yoshie, 2012). 
These receptors, and the chemokines they bind, are summarised in table 1.1. Chemokine 
receptors belong to the Class A GPCR, or rhodopsin-like, family of GPCRS and share a 
number of structural features consistent with members of this family (Allen, Crown and 
Handel, 2007). These being that they consist of an unstructured N-terminus, with 7 helical 
transmembrane domains (7TM) embedded in cellular membranes, connected by 
extracellular and intracellular loops and finally a C-terminal tail, with extracellular loops 
thought to be involved in ligand interaction, and intracellular loops and the C-terminus 
involved in interaction with signalling pathways. 
1.3.1 Chemokine receptor signalling 
As stated, the chemokine receptors are GPCRs, and therefore belong to the most extensive 
family of signal transduction receptors encoded for by the human genome. Consequently, 
they share a number of common features with other GPCRs in terms of how they translate 
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external stimuli (i.e. interaction with ligands) to internal effects (i.e. cytoskeletal 
rearrangement, modulation of gene expression etc). In general, GPCRs follow a distinct 
series of events in order to mediate intracellular signalling that begins with association of 
the ligand with the receptor (Hanlon and Andrew, 2015). This results in conformational 
changes in receptor structure that facilitate recruitment of heterotrimeric G-protein 
complexes by the receptor and allows it to act as a guanidine nucleotide exchange factor 
(GEF).  These heterotrimeric complexes consist of Ga, Gb and Gg subunits. GPCRs 
activate signalling pathways by acting as a GEF, stripping the low energy and stable 
guanidine diphosphate (GDP) molecule from the Ga subunit and allowing guanidine 
triphosphate (GTP) to bind with it. This dissociates the Ga subunit from the heterotrimeric 
complex, while the Gb and Gg subunits remain in complex with each other. While both the 
(now GTP bearing) Ga subunit and the remaining Gbg complex can signal through the 
activation of secondary messenger pathways, it is the Ga subunit that confers selectivity of 
receptor signalling through the activation of different secondary messengers. The 
repertoire of Ga proteins available to GPCRs is extensive (Cotton and Claing, 2009), 
however with the chemokine system it is generally accepted that signalling of chemokine 
receptors is predominantly through coupling to Gi or Go a sub-units. This is due to the 
observation that chemotaxis is pertussis toxin (PTX) sensitive, a hallmark of Gi/o 
signalling (Katada, 2012). Although there is increasing evidence of other G-
protein/chemokine receptor couplings, and therefore variable signalling outcomes as a 
result, only Gi/o signalling will be considered in this introduction.  The free Gi/o subunit 
inhibits adenylate cyclase and reduces cellular cAMP levels as a result, initiating the 
downstream signalling cascade that results from GPCR/ligand interaction.  
The remaining Gbg complex has been shown to recruit GPCR kinases (GRKs) to the 
receptor (Luttrell et al., 1999), however it has also been suggested that disassociation of 
the heterotrimeric G-protein complex from the receptor following Ga activation is 
sufficient for GRK/GPCR interaction (Palczewski et al., 1991). In either case, GRKs 
phosphorylate key residues on the C-terminus of receptors. This leads to recruitment of b-
arrestin 1 and/or 2 to the receptor (Peterson and Luttrell, 2017). This will either trigger 
receptor internalisation, leading to degredation of bound ligand followed by cycling back 
to the membrane, or receptor desensitisation; where b-arrestin remains bound to the 
receptor and inhibits subsequent signalling events. (summarised in figure 1.3.1). The 
mobilised Gbg complex is also considered to be critical to instigating chemotaxis. Over-
expression of Gbg sequestering proteins was sufficient to abrogate chemotaxis to CXCL8 
by HEK293 cells expressing it’s receptor (Ourne, 1997). Additionally, singular rescue of 
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Gb expression in the model organism Dictyostelium discoideum, restored the chemotactic 
phenotype of these cells, whereas similar rescue experiments with Ga subunits failed to do 
so (Janetopoulos, Jin and Devreotes, 2016). 
1.3.2 Atypical chemokine receptors 
In addition to the classic chemokine receptors, there are other chemokine binding receptors 
that are not involved in G-protein signalling. These are the atypical chemokine receptors 
(ACKRs), of which 4 have been identified thus far. Like the GPCRs, these atypical 
receptors have a 7TM structure but lack what is known as the DRYLAIV motif (Ulvmar, 
Hub and Rot, 2011). This is a conserved peptide sequence on the second intracellular loop 
of GPCRs that facilitates G-protein binding. As such they do not interact with G-proteins 
and are sometimes referred to as “silent” receptors. This may be something of a misnomer 
however, as ACKRs have been shown to associate with the b-arrestins, which can activate 
signalling cascades independently of G-protein activity such as the mitogen-activated 
protein kinase (MAPK) pathway (Peterson and Luttrell, 2017). However, ACKRs are 
instead thought to facilitate their immunomodulatory activates by scavenging of the 
chemokines they bind, thereby removing them from the local environment and sculpting 
the immune system as a result (Nibbs and Graham, 2013). Some ACKRs, like ACKR2, 
scavenge an extensive number of chemokines and can therefore have a broad impact on 
immune activity. The known ACKRs, and the chemokines they bind, are listed in table 
1.2.1. 
1.3.3 Chemokine/receptor interaction 
As mentioned before, chemokine receptor (and indeed all GPCR) signalling results from 
structural changes in the receptor following binding to ligand. Chemokines are said to 
follow what is known as a 2-site binding model, dependent on the shared structural 
features of chemokines (Rajagopalan and Rajarathnam, 2006). In this model, the N-loop 
(the unstructured chain of amino acids that runs from the N-terminus to the first b-sheet) 
interacts with the N-terminus of the receptor. This interaction is believed to anchor the 
chemokine/receptor binding and denote receptor selectivity, as mutagenesis studies of 
CXCL10 (a cognate ligand of CXCR3) indicated that swapping the N-loop region of this 
chemokine with that of CXCL8 allowed it to interact with CXCRs 1&2 (Clark-Lewis et 
al., 1994). The N-terminus of the chemokine then interacts with transmembrane domains 
of the receptor. It is believed that this interaction initiates signalling functions of the 
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receptor, as alteration of the N-terminus has previously been shown to mitigate function 
while having little effect on receptor binding of CCL5 (Proudfoot et al., 1996). 
While undoubtedly useful in assessing the relationship between chemokines and their 
receptors, the 2-site model may be something of an over-simplification. Recent work 
characterising the interactions of CXCL12/CXCR4 indicated that, while both monomeric 
and dimeric versions of CXCL12 could bind the receptor, monomeric CXCL12 bound a 
wider area of the receptor beyond what would be described in the traditional 2-site model 
(Ziarek et al., 2017). The functional consequence of this was that monomeric CXCL12 was 
capable of triggering G-protein and b-arrestin recruitment by the receptor. However, 
dimeric CXCL12, which more closely followed a 2-site binding model, triggered 
recruitment of G-proteins alone by CXCR4. As well as providing insight into the structural 
requirements of full receptor activation, this study could also indicate that biased agonism 
may be dependent on structural differences in receptor/ligand binding. Signalling bias will 
be discussed in greater detail in subsequent sections. 
Chemokine receptors, like many other proteins, also undergo additional post-translational 
modifications (PTMs). Some are critical to simply maintaining structure, for example the 
formation of disulfide bonds between cysteine residues of the extracellular portions of 
chemokine receptors is critical to receptor stability (Rummel et al., 2013). Others however 
can affect chemokine/receptor interactions. For example, sulfation of tyrosine residues in 
the N-terminus of CCR5 has been shown to improve affinity of CCL3 and CCL4 for the 
receptor (Farzan et al., 1999).  In addition, chemokine receptors can carry large 
carbohydrate modifications. This is referred to as glycosylation and is known to occur on 
asparagine (N-linked) or serine/threonine residues (O-linked) of the receptor N-terminus 
(Szpakowska et al., 2012).  However, the exact impact of this PTM is not entirely clear, as 
many chemokine receptors show little impact on ligand binding or functional outcomes 
from deglycosylation, such is the case with CXCL12 binding to mutants of CXCR4 
lacking N-terminal asparagine residues (Huskens et al., 2007). However, glycans can be 
additionally decorated with other sugar groups, such as sialic acid, and the presence of 
sialic acid on O-linked glycans of CCR5 also improved CCL3 and CCL4 affinity (Bannert 
et al., 2001). It is clear that the interaction between chemokine and receptor is highly 
complicated and can be influenced by a wide array of factors, and that a holistic 
understanding of chemokine binding as it relates to the biology of these molecules is still 
lacking. Like many GPCRs, chemokine receptor are frequently phosphorylated on their C-
terminus, with selective deletion of serine and threonine residues, or complete ablation of 
the C-terminus, significantly attenuating receptor internalisation and desensitisation (Stone 
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et al., 2017). The chemokine receptor CXCR4 is also ubiquitinated (Marchese and 
Benovic, 2001), a PTM that serves to promote receptor degredation in lysosomes but has 
little effect on receptor internalisation. Finally, CCR5 is also modified by palmitoylation 
(Percherancier et al., 2001), dependent on a cluster of three cysteine residues in the 
receptors C-terminus. Mutation of all three residues blocks receptor palmitoylation and 
impairs cell surface trafficking of the receptor.  
1.3.4 Pharmacological targeting of the chemokine system 
With extensive involvement in embryogenesis, the function of the immune system, in the 
development of cancer and spread of metastasis, and in the pathophysiology of various 
inflammatory conditions, the chemokine system is a demonstrably attractive target for 
therapeutic intervention. Indeed, targeting of GPCRs for therapeutic effect is a highly 
successful strategy. Case in point; at present around 34% of drugs approved for use by the 
US Food and Drug administration target GPCRs (Hauser et al., 2017). As mentioned 
before, various viruses have evolved  to exploit chemokine biology to their own advantage. 
The Kaposi’s sarcoma associated virus encodes a highly promiscuous viral chemokine 
(vMIPII), while the human cytomegalovirus encodes a constitutively active chemokine 
receptor (US28), and in doing so each successfully sculpt the immune response to their 
advantage. So, manipulation of the chemokine system is clearly feasible and advantageous 
in a number of contexts, however at present there are very few widely available drugs that 
target chemokine receptors.  
Interest in targeting the chemokine system arguably ramped up with the discovery that 
HIV utilised chemokine receptors to elicit cellular entry, namely CCR5 and CXCR4 
(Berger, Murphy and Farber, 1999). Indeed, the observation that peoples of northern 
European descent that carried a natural mutation that effectively ablated CCR5 expression 
(known as D32 CCR5) were highly protected from HIV transmission confirmed the 
validity of targeting chemokine receptors in the treatment of the disease (Chatterjee et al., 
2012). Intensive research efforts lead to the development of maraviroc, a small molecule 
CCR5 antagonist that effectively blocked cellular entry of HIV, that is still used in HIV 
treatment (Tan et al., 2013). HIV is known to switch receptor tropism from CCR5 to 
CXCR4 during the development of the disease. As such, efforts were made to develop 
antagonists of CXCR4 that would similarly inhibit viral entry (Hendrix et al., 2004). While 
ultimately not useable in the treatment of HIV, the CXCR4 antagonist plerixafor did prove 
useful in the mobilisation of HSCs from the bone marrow into the circulation, where they 
could be collected for transplantation into immune-compatible recipients (Devine et al., 
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2008). Additionally, there is mogamulizumab, a humanised monoclonal antibody against 
CCR4 (Yoshie and Matsushima, 2015). mogamulizumab was licensed for the treatment of 
relapsed ATLL in Japan in 2012 and is thought to initiate immune destruction of cells 
expressing CCR4 by relying on the same mechanisms as the humoral arm of the immune 
system. Side-effects have been noted with mogamulizumab treatment, presumably 
associated with non-specific destruction of CCR4 expressing cells. However as of August 
of 2018, it was approved for use by the U.S. food and drug administration, potentially 
indicating more widespread use of anti-CCR4 treatment in the near future.  
These success stories however are very much the minority, and many more compounds 
targeting the chemokine system have been developed but never made it through clinical 
trials. This is particularly true of targeting inflammatory chemokine receptor signalling, as 
at present no compounds that target inflammatory chemokine receptors are licensed for use 
in inflammatory disease. Various antagonists of CCR1, 2 and 5 have been trailed in the 
treatment of RA for example, but ultimately failed to deliver improved patient outcomes 
(Horuk, 2009; Lebre et al., 2011). This discrepancy between the great potential in targeting 
of the chemokine system, and the reality that to date no drugs targeting inflammatory 
chemokine signalling are available, could be attributable to a number of factors.  
Chemokine signalling is highly sensitive, needing only a minor amount of ligand/receptor 
interaction to elicit physiological responses. As such a compound targeting chemokine 
receptors may require over 90% receptor coverage before achieving any effect in some 
cases (Dairaghi et al., 2011). Small molecule inhibitors are well known to suffer from non-
specific binding to protein and lipid in sera, and as such achieving this high dosing may 
prove difficult. As well, the previously noted complexity of shared receptors amongst the 
inflammatory chemokines, and the highly complex inflammatory environment established 
in diseases such as RA (Szekanecz et al., 2006), can limit the effectiveness of targeting 
specific chemokine receptors. Further complicating the chemokine system is the 
observation of signalling bias by some chemokine receptors.  
1.3.5 Biased agonism in chemokine biology 
Biased agonism is an area of increasing focus in GPCR research, and stems from the 
understanding that, rather than simply adopting an “on” or “off” structural conformation, 
GPCRs can occupy multiple active states due to their dynamic nature in the membrane 
(Kenakin and Christopoulos, 2013). These different active states then recruit different 
repertoires of signalling partners (i.e. G-proteins and the b-arrestins) as a result. Active 
29 
 
states generally need to be stabilised by binding of ligand to receptor, and it is proposed 
that subtle structural differences in the ligand/receptor interface help to shape these 
different active conformations (Anderson, Solari and Pease, 2016). This is referred to as 
ligand bias and can be described as 2 or more ligands interacting with the same receptor, 
generating unique signalling profiles as a result that cannot be attributed to different ligand 
affinites. Further forms of bias have been described, such as receptor bias (where the same 
ligand generates a different signalling profile when binding different receptors), or tissue 
bias (where the signalling profile of the same ligand/receptor combination changes 
depending on the cellular context examined) (Jørgensen, Rosenkilde and Hjortø, 2018), 
however ligand bias will be the focus going forward.   
Functional selectivity of ligands for certain GPCRs may be integral to their biology. The 
serotonin 5HT2A receptor activates Akt signalling pathways in response to serotonin but 
not N-methyltryptamines, a metabolite of serotonin (Schmid and Bohn, 2010). Treatment 
with either ligand causes head twitching behaviour in mice, however in b-arrestin 2 KO 
animals this behaviour is selectively lost with serotonin treatment, indicating the 
requirement of this signalling partner for the receptor’s activity in response to serotonin. 
As well, the μ-opioid receptor has been demonstrated to selectively recruit b-arrestin 2 
upon interaction with morphine but recruits both b-arrestin 1 and 2 in response to 
enkephalin (Groer et al., 2011). Such examples could indicate that biased agonism 
functions as a means of fine-tuning signalling responses of certain GPCRs in complex 
environments.    
Targeted activation or inhibition of one signalling pathway over another is an exciting 
prospect as it may provide more targeted therapies than are currently available with fewer 
side-effects. For example, the k opioid receptor presents a promising target for treatment 
for pain management with selective agonists. The variable outcomes of signalling through 
this receptor are considered to be dependent on the recruitment of different signalling 
partners, with activation of the G-protein pathway resulting in the desired analgesic 
properties of receptor agonism, and activation of b-arrestin resulting in the undesirable 
side-effect of dysphoria (Zhou et al., 2013). As such, a number of small molecule agonists 
that selectively activate G-proteins to the receptor have been developed (Zhou et al., 2013; 
Lovell et al., 2015). The angiotensin 2 type 1 receptor (AT1R) represents another potential 
target for pathway selective treatment. Signalling by angiotensin 2 through the receptor is 
both harmful and protective, with G-protein signalling considered to mediate the 
deleterious vasoconstrictive effects of angiotensin 2, and b-arrestin signalling mediating 
the beneficial inotropic effects of the ligand (Violin, Soergel and Lark, 2012). 
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Consequently, compounds that selectively inhibit G-protein signalling, but leave b-arrestin 
signalling pathways available, have already been evaluated in a model of heart failure 
(Violin et al., 2010). Here they demonstrated improved physiological outcomes when 
compared with a  pan-AT1R antagonist.   
Biased agonism has been described with a number of chemokine receptors, namely CCRs 
1, 2, 4, 5, 7 and 10, CXCR3 and ACKRs 2 and 3 (Anderson, Solari and Pease, 2016). 
Signalling bias can manifest itself with these receptors in a number of ways. For example, 
CCL5 appears more potent than either CCL3 or 4 in activating Ca2+ flux in cells expressing 
CCR5 (Oppermann et al., 1999). This would indicate that CCL5 is dominant in receptor 
activation despite having similar receptor affinity to the other 2 chemokines. However, 
Ca2+ flux could be completely abrogated by PTX treatment for CCL5 and CCL4, but not 
CCL3 (Leach, Charlton and Strange, 2007). This could indicate that CCL3 can signal 
through CCR5  through Gi/o independent G-protein/receptor couplings. In addition, the 
chemokines binding CCR2 all display broad recruitment profiles of b-arrestin 1 and 2, with 
the exception of  CCL13 which showed little capacity to initiate b-arrestin 1 recruitment by 
CCR2 (Berchiche et al., 2011). CCL21 is capable of signalling through interactions with 
CCR7 via a pathway that is both G-protein and b-arrestin independent, whereas CCL19 
does not. Here, oligomers of CCR7 allowed for receptor phosphorylation by Src kinase. 
This phosphorylation of CCR7 allowed CCL21 to signal through the SHP2 pathway and 
enhanced chemotaxis to the chemokine (Hauser et al., 2016).  
However, many GPCRs demonstrate a form of bias that is perhaps clearer-cut than these 
examples. The interaction of monomeric and dimeric CXCL12 with CXCR4 (as discussed 
previously in this chapter) demonstrated a form of signalling bias that resulted from 
effectively the same ligand. This was namely that one “ligand” was able to activate both G-
protein and b-arrestin signalling by CXCR4 and was therefore balanced (monomeric 
CXCL12), whereas the other was biased toward G-protein signalling only (dimeric 
CXCL12). While it is interesting that oligomerisation state had this effect on CXCL12 
activity, it does follow what in some respects is an archetypal form of bias. This being a 
receptor interacting with both balanced ligands, and with those biased towards G-protein 
signalling (summarised in figure 1.3.2).  This has been demonstrated with a number of 
chemokine/receptor combinations, however is arguably most interesting when discussing 
CCRs 4, 7 and 10. Unlike the inflammatory chemokine receptors, which bind multiple 
chemokines and demonstrate significant cross-talk, or other homeostatic receptors, which 
often interact with a single chemokine, all 3 of these receptors interact with only a pair of 
ligands. These are CCL17 and 22 with CCR4, CCL19 and 21 with CCR7 and CCL27 and 
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28 with CCR10 (Mariani et al., 2004; Rajagopal et al., 2013; Corbisier et al., 2015). 
Within each pairing it has been reported previously that one ligand is balanced (CCL22, 
CCL19 and CCL27), and the other is G-protein biased (CCL17, CCL21 and CCL28). The 
fact that such a model of biased agonism in ligand pairs has emerged on at least 3 separate 
occasions, and with receptors that demonstrate such distinct expression and functional 
profiles, could indicate an evolutionary advantage in forming a ligand pair with diverse 
signalling properties. As such further study of the signalling bias of these receptors is 
warranted.  
1.4 CCR4 in health and disease 
CCR4 emerged relatively recently in the evolution of the chemokine system, being found 
in reptiles along with the likes of CCR5 and CX3CR1 (Nomiyama, Osada and Yoshie, 
2011). In terms of its expression on mature cells of the immune system, CCR4 is 
considered the dominant chemokine receptor expressed by T-cells of the T-helper 2 (Th2) 
and regulatory T-cell (Treg) lineages (Bonecchi et al., 1998; Hirahara et al., 2006), and it 
is through these cells that most of the physiological effects of CCL17 and CCL22 are 
exerted. CCR4 expression has also been reported in cutaneous lymphocyte antigen positive 
(CLA+) T-cells, Th17 cells, Th22 cells, some subsets of natural killer (NK) cells and 
airway eosinophils as well (Yoshie and Matsushima, 2015).  However, for simplicity’s 
sake, the immune-developmental functions of CCR4 signalling and its roles in Th2 and 
Treg activity and associated pathology will be discussed here.  
Both CCL17 and CCL22 are expressed in the thymus (Imai et al., 1996; Godiska et al., 
1997), and their signalling through CCR4 is thought to be important in T-cell development. 
In essence, immature thymocytes undergo sequential expression of chemokine receptors 
during various stages of selection and development (Takahama, 2006). The cognate 
ligands of these receptors are expressed differentially by the thymic stroma, depending on 
the tissue microenvironment, and therefore guide developing thymocytes through the 
thymus. Immature thymocytes enter the cortex of the thymus, where they interact with 
stromal cells and travel through the thymic cortex in a CXCR4/CCR7 dependent manner . 
At this stage they express neither CD4 nor CD8 and are therefore referred to as double 
negative thymocytes (DNTs). Expression of CXCR4/CCR7 is down-regulated as CCR9 is 
upregulated, leading to migration of  DNTs from the cortex to the subcapsular zone. Here 
they will undergo selection and either start to express CD4 and CD8, becoming double 
positive thymocytes (DPT), or will undergo apoptosis. DPTs that survive then undergo 
further differentiation and highly self-reactive DPTs undergo deletion at this time, 
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eventually becoming single positive (i.e. CD4+ or CD8+) thymocytes (SPTs). SPTs 
upregulate expression of CCR4 and CCR7 during differentiation (Cowan et al., 2014), and  
expression of the ligands of these receptors by stromal cells of the thymic medulla draws 
these cells into this region to continue selection. In the medulla, SPTs are again exposed to 
self-antigens by medullary thymic epithelial cells (mTECs), and those SPTs that are auto-
reactive are either destroyed or pushed into a regulatory phenotype. The ligands of CCR4, 
however, are predominantly produced by medullary thymic DCs in the thymus (Hu et al., 
2015). These cells help to discern auto-reactive SPTs by presenting self-antigens from all 
tissues of the body, serving to identify those auto-reactive SPTs that strongly bind self-
antigen (which are destroyed), those which demonstrate no binding (which continue the 
differentiation programme) and those that demonstrate lower affinity binding (which can 
develop into Tregs). As such, CCR4 signalling appears critical in the process of immune 
education and the establishment of central tolerance. Those SPTs that do not react to self-
antigen however can continue to develop and leave the thymic medulla and enter the 
circulation as naïve T-cells. This final egress from the thymus however is not thought to be 
mediated by upregulation of a chemokine receptor, but instead the Sphingosine-1-
phosphate 1 receptor (S1P1R) (Matloubian et al., 2004). 
In this context, CCR4 signalling is homeostatic, but could be argued to serve a redundant 
function with CCR7 in recruitment of SPTs into the medulla. However, expression of 
CCR4 and CCR7 are temporally distinct, with CCR4 expression seen earlier in SPT 
development. Deletion of CCR7 does not completely block medullary entry of SPTs either, 
whereas PTX treatment does (Ehrlich et al., 2009), indicating the involvement of other 
chemokine receptors in this process. In addition, genetic ablation of CCR4 results in the 
accumulation of self-reactive T-cells in secondary lymphoid organs (Hu et al., 2015), such 
as the LNs, however it has no effect on the levels of Treg subtypes (Cowan et al., 2014). 
This could indicate that CCR4 and CCR7 serve non-redundant functions in the 
development and maturation of T-cells and in the maintenance of central tolerance.  
CCR4 expression is detectable during the earliest stages of in vitro differentiation of Th2 
cells (Morimoto, 2005). In addition, generation of DCs from monocytes by treatment with 
granulocyte-macrophage colony stimulating factor (GM-CSF) (a common cytokine of both 
Th1 and Th2 cells) and Interleukin 4 IL-4 (a Th2 specific cytokine) enhanced the 
production of CCL17 by these cells (Imai et al., 1999). This would indicate that skewed 
differentiation conditions can alter the chemokine production of antigen presenting cells 
(APCs), and therefore the kind of T-cells they can attract with them. Th2 driven immune 
responses are also generally associated with allergic reactions. Indeed, nasal antigen 
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challenge resulted in an increased number of CCR4+ T-cells found in biopsies taken from 
patients suffering from allergic rhinitis compared to healthy controls, and allergen 
challenge in the lungs of asthma sufferers was shown to increase the levels of CCR4 
ligands (Banfield et al., 2010). Additionally, blockade of CCR4 activity using small 
molecule antagonists has demonstrated some protective effects in mouse models of allergic 
asthma (Y. Zhang et al., 2017). As such, it appears that pharmacological intervention with  
CCR4 antagonists could be effective in the treatment of some allergic pathologies and 
would presumably exert their effects through attenuating Th2 recruitment.  
However, such a treatment strategy would need to account for the noted expression of 
CCR4 on Treg cells. Loss of CCR4 expression by Tregs reduces their prevalence in the 
skin and lungs of mice, and can exaggerate the immune response to antigen challenge, 
resulting in an increase in lymphocytic infiltration in these tissues (Sather et al., 2007). In 
addition, recruitment of tolerising Tregs into cardiac allografts in mice has been 
demonstrated to be CCR4 dependent (Lee et al., 2005). However, the activity of Tregs can 
be pathogenic in a number of contexts. Tregs are frequently recruited into the tumour 
microenvironment, where their immunomodulatory activities are exploited to sculpt the 
immune response to the developing tumour (Ondondo et al., 2013). They are recruited, in 
part, by the expression of CCL17 and/or CCL22 by tumour cells themselves or infiltrating 
innate immune cells (Mizukami, 2008; Maolake et al., 2016). Tregs can be selectively 
recruited and activated in primary breast cancers for example in a CCL22 dependent 
manner (Gobert et al., 2009), and the presence of CCR4+ Tregs often correlates with a 
poorer prognosis for patients in the diagnosis of multiple different cancers (Curiel et al., 
2004; Watanabe et al., 2010; Svensson et al., 2012).  
As stated previously, CCR4 is one of the few chemokine receptors that is successfully 
targeted for therapeutic effect, and the humanised anti-CCR4 antibody mogamulizumab 
has been licensed for the treatment of relapsed and chemotherapy resistant ATLL in Japan 
for many years now (Makita and Tobinai, 2017). CCR4 expression is frequently high in 
ATLL cells, leading to the notion that these cancers are derived from cells of either the 
Th2 or Treg lineage (Yoshie et al., 2002). This is in keeping with the frequency with which 
ATLL lesions form in the skin, as the expression of the ligands of CCR4 is frequently 
associated with the skin, hence the strong correlation of CCR4 expression in skin-tropic T-
cells (Soler et al., 2003; Yoshie and Matsushima, 2015).  FOXP3 is a transcription factor 
critical to Tregs, and its expression is also frequently elevated in ATLL (Karube et al., 
2004), which could indicate that Tregs are the most likely source. However, infection of T-
cells with Human T-lymphotropic virus 1 (HTLV-1) is a frequent event in ATLL 
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pathogenesis (Malpica et al., 2018), and has been shown to elevate expression of FOXP3 
(Miyazato and Matsuoka, 2014). It might therefore be hasty to attribute ATLL solely to 
Treg cells. As well as being used in the treatment of ATLL, mogamulizumab has also been 
considered as an adjuvant to targeted vaccination with tumour antigens, with enhanced 
induction of antigen specific responses in vitro from peripheral blood mononuclear cells 
(PBMCs) of melanoma patients following Treg depletion (Sugiyama et al., 2013). In 
addition, a small molecule antagonist of CCR4 was also successfully evaluated as an 
adjuvant to immunotherapy in  mouse models of cancer, with an increased production of 
antigen specific CD8+ T-cells resulting from anti-CCR4 treatment (Pere et al., 2011). 
Although targeting of CCR4 has been successful, particularly in treatment of ATLL, there 
have been complications associated with depletion of Treg cells, including at least one 
fatality (Ishida et al., 2013). Given the observation of bias of CCR4 ligands (Mariani et al., 
2004), as well as a noted distinct conformation of the receptor that can only bind CCL22 
(Viney et al., 2014a), it may be possible to more selectively target CCR4 in the future. As 
such, further characterisation of CCR4, its ligands and their biased agonism, is of interest. 
1.5 CCR7 in health and disease 
CCR7 is more evolutionarily ancient than CCR4, first emerging in jawed, bony vertebrates 
(Nomiyama, Osada and Yoshie, 2011). As stated previously, CCR7 demonstrates a number 
of roles in the maturation of lymphoid cells in the thymus, helping to aid navigation 
through the thymus at various stages of development (as discussed previously). It is also 
potentially involved in the initial migration into the thymus of T-cell precursors in a 
CCL21 dependent manner. CCR7 and its ligands also act in the development of SLOs as 
well, as the genetic deletion of CCR7, or loss of CCR7 ligands in the plt/plt mouse line, 
results in significantly reduced LN size, and a loss in demarcation between 
microanatomical regions (Förster et al., 1999; Gunn et al., 1999). CCR7 does appear to 
share this function with another homeostatic chemokine axis, that of CXCR5/CXCL13, as 
a double KO of these receptors results in greater disruption to healthy LN development 
than either single KO (Ohl et al., 2003).  
While the developmental functions of CCR7 and its ligands are obviously important, with 
its genetic ablation resulting in significant loss of naïve T-cell development in the thymus 
(Cowan et al., 2014), the functions of CCR7 are arguably best described in their role in 
adaptive immunity. Following maturation, naïve T-cells express CCR7 and use the 
receptor to survey SLOs throughout the body, and genetic ablation of CCR7 results in near 
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complete loss of naive T-cell in LNs and generally altered tissue distribution (Förster et al., 
1999). B-cells also use CCR7 signalling to navigate to, and within, LNs (Park et al., 2012), 
however they do not display as severely altered tissue distribution as naïve T-cells in KO 
animals. DCs express CCR7 upon encountering antigen and undergoing maturation 
(Sallusto et al., 1998). In the skin mature DCs migrate in response to functional gradients 
of CCL21 into afferent lymphatics vessels to reach the LN (Weber et al., 2013), where 
they can interact with naïve T-cells that possess a compatible T-cell receptor to the antigen 
the DCs are presenting. In addition, CCR7 is expressed on central memory T-cells (Tcm) 
but not effector memory T-cells (Tem), as the former survey SLOs in case of encounter 
with their corresponding antigen again whereas the latter do not enter SLOs (Sallusto et al., 
2014). Interestingly, in addition to CCR4 expression, CCR7 expression has also been 
demonstrated on Tregs, and is a requirement for their regulatory effects in the LNs 
(Schneider et al., 2007). It is clear therefore that CCR7 signalling is critical in the functions 
of nearly all aspects of the adaptive immune system at some stage and a fundamental link 
between the innate and adaptive immune systems. 
Within LNs, CCR7 intricately co-ordinates the movement of  cells to facilitate antigen 
presentation. Naive T-cells and Tcms enter the LN via the high endothelial venules 
(HEVs), and are drawn to the T-cell zone via expression of CCL19 and CCL21 by the 
fibroblastic reticular cells which also produce IL-7, a critical cytokine in naïve T-cell 
survival (Link et al., 2007). B-cells, conversely, migrate to the B-cell follicles in response 
to CXCL13/CXCR5 signalling. Within the T-cell zone, naïve T-cells remain very motile so 
as to increase the probability of encountering their cognate antigen. This has been shown to 
be CCR7 dependent, as T-cells from CCR7 KO mice demonstrate decreased motility in 
wildtype (WT) LNs, and WT T-cells demonstrate decreased motility in the LNs of plt/plt 
mice (Worbs et al., 2007). Residence of naïve T-cells in the T-cell zone is determined by a 
balance between CCR7 and S1P1R (Comerford et al., 2013), as constant signalling 
through CCR7 is thought to not only desensitise the receptor, but also promote expression 
of S1P1R by the cells and subsequent egress from the LN (Shannon et al., 2012). DCs 
enter the LN via a slightly different route: they migrate into afferent lymphatics in a 
CCL21 dependent manner and then drain into the subcapsular sinus of the LN. From here 
they follow gradients of CCR7 ligands, maintained by the atypical chemokine receptor 
ACKR4, to the paracortical area of the LN (Ulvmar et al., 2014). Here they can present 
antigen to naïve and central memory T-cells. DCs themselves can also express CCL19 in 
order to attract naïve T-cells in the LN (Katou et al., 2003). 
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Due to its extensive functions in the immune system, aberrant CCR7 activity can cause 
considerable harmful effects. TLOs form in areas of persistent inflammatory insult, and 
CCR7 KO animals spontaneously form TLOs in mucosal tissues (Davalos-Misslitz et al., 
2007). However, CCR7 KO animals are also protected from further TLO formation in the 
joint synovia during models RA (Wengner et al., 2007). Over-expression of CCL21 has 
been shown to enhance the formation of TLOs in various tissues, including the liver (Grant 
et al., 2002). This disparity between a damaging phenotype at rest and protective 
phenotype during inflammation is most likely attributable to developmental defects in the 
T-cell compartment that promote an autoimmune environment in peripheral tissues at rest. 
As stated earlier, CCR7 expression by tumours is frequently associated with metastasis of 
various cancers to the LNs, and consequently poorer prognosis for patients (Dai et al., 
2017; Xiong et al., 2017). As well as directing cancerous cells to the LNs, CCR7 signalling 
has also been shown to directly enhance epithelial to mesenchymal transition (EMT) of 
tumour cells (Li et al., 2016; Xu et al., 2017; Zhong et al., 2017), a critical step in 
establishing an invasive and migratory phenotype. CCR7 has demonstrated other 
additional effects in cancer, as its inhibition has been shown to encourage apoptosis and 
supress growth in cancer cells (Chi et al., 2015; L. Zhang et al., 2017). CCR7 may also be 
involved in tumour remodelling, as CCR7 over-expression induced vascular endothelial 
growth factor D (VEGF-D) in non-small cell lung cancer cells in vitro, and CCR7 
expression correlates with VEGF-D in vivo (Sun et al., 2015). Consequently, there is a 
constant drive to better understand the biological and pathophysiological functions of 
CCR7.  
1.6 CCR10 in health and disease 
Like CCR7, CCR10 first emerged in in jawed, bony vertebrates (Nomiyama, Osada and 
Yoshie, 2011), and interacts with 2 ligands; CCL27 and CCL28 (Morales et al., 1999; 
Wang et al., 2000). Unlike the ligands of CCRs 4 and 7, CCL27 and CCL28 display 
significant differences in their tissue localisation at rest, with CCL27 expressed almost 
exclusively by epidermal keratinocytes in the skin (Homey et al., 2000), and CCL28 
expressed by the epithelium of various mucosal tissues (Pan et al., 2000), where it 
additionally acts directly as an anti-microbial agent (Hieshima et al., 2003). CCR10 
expression has been reported on a wide variety of cell types (Xiong et al., 2012), however 
broadly speaking CCR10 expressing cells can grouped as; skin-tropic subtypes of various 
T-cell lineages including Th22 cells, dg T-cells, Tem and Treg cells (Eyerich et al., 2009; 
Jin et al., 2010; Xia et al., 2014), IgA producing B-cells of the mucosal epithelia (Morteau 
et al., 2008) and skin-homing mesenchymal stem cells (MSCs) (Alexeev et al., 2013). In 
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this respect, it is clear that CCR10 and its ligands are critical in the maintenance of 
immune homeostasis of barrier tissues.  
In the skin the functions of CCR10 appear to be both distinct from, and overlapping with, 
those of CCR4, depending on the study. For example, in one instance expression of CCL27 
could be induced by the application inflammatory cytokines, and direct injection of CCL27 
recruited lymphocytes to the skin whereas antibody neutralisation of the chemokine 
attenuated recruitment following inflammatory insult (Homey et al., 2002). Conversely, 
other studies have demonstrated through adoptive transfer experiments that CCL27 
neutralisation had little effect on WT CD4+ T-cell infiltration into inflamed skin, with 
effects of CCL27 neutralisation only noted when CCR4 KO T-cells were analysed (Reiss 
et al., 2001). In another study, neutralisation of both CCR4 and CCR10 ligands 
demonstrated a cumulative protective effect in multiple models of inflammation compared 
with targeting either receptor individually (Mirshahpanah et al., 2008). This discrepancy 
between studies is concerning, however, CCR4/CCR10 co-expression has been 
demonstrated on the T-cell infiltrate of atopic dermatitis lesions, but not in psoriatic 
lesions, where CCR10 expression alone is observed  (Vestergaard et al., 2003). This could 
indicate that the requirements of CCR4 and CCR10 are disease, and context, specific.  
The role of CCL28/CCR10 in the biology of IgA plasmablasts is arguably more consistent. 
Immunisation via mucosal tissues increased the prevalence of antigen-specific IgA 
producing B-cells compared to the more traditional route, and that migration of these cells 
into mucosal tissues could be blocked by the administration of CCL28 neutralising 
antibodies (Cha et al., 2011). Additionally, the inclusion of CCL27 expression elements in 
the delivery of a plasmid-based vaccine against HIV increased the prevalence of antigen 
specific IgA plasmablasts in multiple tissues of mice, and increased IgA antibody titre in  
bronchiolar lavage from macaques (Kraynyak et al., 2010). Similarly, co-delivery of a 
CCL28 expression vector and HIV virus like particles (VLP) demonstrated an increase in 
antigen specific humoral responses compared with no chemokine or CCL19/HIV-VLP 
controls (Rainone et al., 2011). Collectively, such studies indicate a critical role for CCR10 
in IgA plasmablast function, and are in agreement with the assessment of CCR10 KO 
animals which demonstrate an absence of such cells in some mucosal tissues (Morteau et 
al., 2008).  
As might be expected, CCR10 expression is frequently upregulated in a number of skin 
associated T-cell lymphomas in a similar manner to CCR4 (Yoshie et al., 2002; 
Notohamiprodjo et al., 2005; Fujita et al., 2006). CCR10 overexpression was also 
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observed in human cutaneous melanoma and glioblastoma samples, and correlated with a 
poorer prognosis for patients (Kühnelt-Leddihn et al., 2012; Chen et al., 2014). 
Additionally, like CCR7, CCR10 signalling can directly promote a more aggressive 
phenotype in breast cancer cells (Lin et al., 2017). Given its extensive roles in barrier 
immunity, and frequent association with cancer, CCR10 biology represents an area of 
increasing research interest.  
1.7 Aims of the project 
The work described herein was intended to assess the bias presented by CCRs 4, 7 and 10 
in unprecedented detail. To this end, 3 main strategies were followed with the following 
goals; 
1: Unnatural amino acids (UAA), integrated in place of individual residues of CCR7, were 
used in an attempt to covalently capture either CCL19 and CCL21. This was done as this 
technology had been used previously to determine the binding pocket of a peptide ligand 
with its cognate GPCR (Coin et al., 2013), so may have been of use in determining the 
binding interface of CCL19 and CCL21. It was hoped that such a map would indicate 
subtle differences in receptor/ligand interaction between the 2 chemokines, and 
consequently reveal a structural basis for their observed selective functions. 
2: Recruitment of signalling apparatus (Gi proteins and the b-arrestins) by CCRs 4, 7 and 
10 in response to their respective ligands was assessed utilising bioluminescence resonance 
energy transferred (BRET) based methods. It was hoped that, using such methods, it would 
be possible to build a signalling profile of these receptors in previously undescribed detail 
(for CCR4 and CCR10).   
3: Finally, recent publications indicated that polysialylation of CCR7 was critical to 
CCL21 instigated migration, and that in its absence CCR7 expressing cells were almost 
completely refractory to CCL21 (Kiermaier et al., 2016). Observations made during the 
course of these studies indicated that CCR7 expressed in HEK293T cells may be similarly 
refractory to CCL21. As such, assessment was made of ST8sia4 expression (a 
polysialyltransferase required for CCR7 polysialylation) in HEK293T, and the role this 
restricted PTM may have in signalling behaviour of CCR7 ligands was evaluated. Potential 
polysialylation of CCR4 and CCR10 was also assessed.  
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Figure 1.2.1 Schematic representation of chemokines 
Representations of chemokines of the (a) CC, (b) CXC, (c) CX3C and (d) XC subfamilies 
are shown 
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Figure 1.2.2 Genomic loci of chemokine gene clusters 
The genomic loci of the major (a) CXC, (b) CC, and (c) minor gene clusters for human 
chemokines are shown. Adapted from Zlotnik, Yoshie and Nomiyama, 2006.   
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Figure 1.2.3 Inflammatory chemokine/receptor cross-talk 
Inflammatory chemokines and their receptors demonstrate considerable promiscuity. 
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Figure 1.3.1 Signalling events during GPCR activation 
Schematic representation of the sequential recruitment of signalling machinery following 
ligand/GPCR interaction. In brief, association of ligand and receptor initiates GDP/GTP 
transfer on Ga subunits, causing it to disassociate from the  heterotrimeric G-protein 
complex. This frees Ga to initiate secondary messenger signalling events and allows for 
receptor phosphorylation by GRKs. The phosphorylated receptor then recruits b-arrestin, 
triggering receptor internalisation, ligand degradation and/or receptor desensitisation. The 
now inactive receptor traffics back to the cell surface, available to interact with ligand 
again. Adapted from Hanlon and Andrew, 2015. 
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Figure 1.3.2 Basic representation of biased agonism of chemokine receptors 
Biased agonism, refers to the ability of distinct ligands to activate different signalling 
pathways from the same receptor. Frequently, this manifests as one or more ligands being 
balanced, i.e. able to recruit G-proteins and b-arrestin and able to trigger receptor 
internalisation and desensitisation, and  another which signals predominantly or entirely 
through G-protein coupling and does not desensitise or internalise the receptor. 
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Table 1.2.1 Human chemokines receptors and the chemokines they bind 
Table listing all chemokines receptors identified in humans to date and their cognate 
ligands. Generated with data from Zlotnik and Yoshie, 2012. 
  
45 
 
2 Materials and Methods 
2.1 RNA extraction and cDNA conversion 
The methods employed in RNA extraction varied depending in the biological source. For 
all extractions from cellular suspension (from cell lines or PBMCs), up to 1x107 cells were 
washed x1 in Dulbecco’s phosphate buffered saline, calcium and magnesium free (DPBS, 
Invitrogen), then disrupted in 350 µl buffer RLT (Qiagen RNeasy mini kit) supplemented 
with 1% v/v b-mercaptoethanol. Disrupted cells were passed through a 25-gauge needle 5 
times to shear genomic DNA. From here, the Qiagen RNeasy mini kit was utilised in 
accordance with manufacturer’s instructions, with the inclusion of an additional on-column 
DNA digestion step (RNase free DNase Set, Qiagen). RNA was eluted in 30 µl nuclease 
free water (Qiagen). RNA/DNA concentration was quantified using the Nanodrop 1000 
spectrophotometer (ThermoFisher Scientific). 
For RNA extraction from tissues, tissue was initially fixed in RNAlater (ThermoFisher 
Scientific) overnight at 4 oC, then transferred to a 2 ml RNase/DNase free reaction tube 
with 2x 5 mm stainless steel balls and 1 ml Qiazol lysis reagent (Qiagen). Tissue was 
homogenised for 15 minutes using the TissueLyser LT (Qiagen), then left to rest at room 
temperature for 5 minutes before adding 200 µl chloroform. This was spun at 12000 g for 
15 minutes at 4 oC, and cleared supernatant transferred to a RNeasy mini kit column. From 
here the manufacturer’s instructions were followed as before. In either case purified RNA 
was either kept on ice or stored at -80 oC.  
RNA was converted to cDNA through the use of the High-Capacity RNA-to-cDNA kit, in 
accordance with manufacturer’s instructions (Applied Biosystems). Either 500 ng or 1 µg 
RNA was converted and diluted either 1/5 or 1/10 respectively for downstream use.  
2.2 PCR, DNA digest and purification 
2.2.1 PCR 
Primers for the amplification of genes of interest (GOI) were designed to include 
compatible restriction sites for plasmid ligation and/or epitope tags. All primers designed 
and used for the work described herein were manufactured by Integrated DNA 
Technologies and are listed in table 2.2.1. Q5 high fidelity polymerase (New England 
Biosciences/NEB) was utilised in all PCR reactions unless otherwise stated. 25 µl PCR 
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reactions were prepared as follows; 5X Q5 Reaction Buffer 5 µl, 10 mM dNTPs 0.5 µl, 10 
µM Forward Primer 1.25 µl, 10 µM Reverse Primer 1.25 µl, template DNA 1 µl, Q5 High-
Fidelity DNA Polymerase 0.25 µl, 5X Q5 High GC Enhancer 5 µl and Nuclease-Free 
Water 10.75 µl. PCR reaction was performed in 200 µl flat lid PCR tubes (StarLab) using a 
Veriti 96-well thermocycler (Applied Biosciences) using the following programme; 
STEP TEMP TIME 
Initial Denaturation 98°C 30 seconds 
35 Cycles 
98°C 10 seconds 
*50–72°C 15 seconds 
72°C 30 seconds/kb 
Final Extension 72°C 2 minutes 
Hold 4°C   
* the annealing temperature was primer specific and calculated using the NEB Tm 
calculator, http://tmcalculator.neb.com/#!/main 
PCR products were visualised on gels prepared with Ultra-pure agarose (Invitrogen) 
supplemented with 0.5 µg/ml ethidium bromide. Percentage agarose used was dependent 
on the fragment size to be visualised, but generally followed the following; <500 base pair 
(bp) = 2% w/v, 0.5-2.5 kilo bp (kb) = 1-1.5% w/v, >2.5 kb = 0.75% w/v. Product size was 
determined by the use of a DNA ladder (1 kb or 100 bp ladder depending on target size, 
Promega). Prior to loading of DNA, samples were mixed with an appropriate volume of 
loading buffer (6x blue/orange loading dye, supplied with DNA ladders). Agarose was 
dissolved in 1x Tris-acetate-EDTA (TAE) buffer (Tris-acetate 40 mM, EDTA 0.05 M), 
and ethidium bromide added once the agarose/TAE mix had sufficiently cooled. This was 
then poured into pre-made casters and allowed to set. DNA samples were run (in 1x TAE 
buffer) by gel electrophoresis, at constant 100 volts (V). DNA was visualised by UV 
transillumination using the Alpha Innotech gel dock. Where required, PCR products were 
purified using the Qiaquick PCR purification kit in accordance with manufacturer’s 
instructions (Qiagen), and DNA eluted in 30 µl nuclease free water. 
2.2.2 DNA digests 
Digests were performed using restriction enzymes purchased from NEB. Where available 
high fidelity (HF) versions of these enzymes were used. The quantity of DNA and the 
specific enzyme used varied dependent on the requirements of individual experiments 
(relative figures are annotated with the restriction enzymes used). In general, 25 µl digest 
reactions were prepared as follows;  2.5 µl 10x cutsmart buffer, 0.5-1 µg DNA, 0.5 µl of 
47 
 
each restriction enzyme and nuclease free water up to 25 µl. These reactions were 
incubated at 37 oC unless otherwise stated, and from 1 hour to overnight. Digest products 
were visualised in the same manner as described for PCR products.  
2.3 Cloning and sub-cloning, mutagenesis programme, 
bacterial transformation and culture, and plasmid 
purification 
2.3.1 Cloning and sub-cloning 
Plasmids were prepared from either newly amplified GOI or digested products from pre-
existing plasmids. Where a digest included the plasmid backbone, 1 µl of calf intestinal 
alkaline phosphatase was added (NEB) and sample incubated for a further 30 minutes at 37 
oC to prevent spontaneous ligation. Following digestion, reactions were run on 0.75% 
agarose gels as described above. Digested bands were excised from the gel, and DNA 
purified utilising the QIAquick gel extraction kit (Qiagen) in accordance with 
manufacturer’s instructions. Purified DNA was eluted in 30 µl nuclease free water. 
Ligation of inserts into plasmid backbones was performed utilising T4 DNA ligase 
(Promega), with a 3:1 molar excess of insert to plasmid being employed in all such 
reactions. Ligation reactions were prepared as follows; 1 µl 10x ligase buffer, 100 ng 
plasmid DNA, 3x molar excess insert DNA, 0.5 µl T4 DNA ligase, and nuclease free water 
up to a total volume of 10 µl. Reactions were incubated overnight at 4 oC. 5 µl of this 
reaction was used in subsequent transformations. All new plasmids were prepared in this 
manner, with the exception of tR4-8.3 and TAG substitution mutants of CCR7.  
The specific strategy employed in generating tR4-8.3 is discussed in chapter 3 of this thesis 
(figure 3.2.8), however in brief pAcBac2.tR4-OMeYRS/GFP* (a gift from Peter Schultz, 
Addgene plasmid # 50831 (Chatterjee et al., 2013)), was digested with SfiI and NotI-HF. 
Due to the different temperature requirements of these enzymes digest was carried out 
initially at 37 oC for 1 hour then 50 oC for a further hour. The target fragment featured 
incompatible overhanging ends for ligation, so the reaction was subsequently treated with 
DNA Polymerase I, Large (Klenow) Fragment (NEB), with 0.5 µl each of dNTP and 
Klenow added to the reaction before incubation at 37 oC for a further 30 minutes. This 
reaction was run out on a gel and target fragment extracted and purified as before. Ligation 
reaction was performed as before with the omission of additional insert DNA, and 5 µl 
used in subsequent transformation experiments. 
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2.3.2 Generation of CCR7 TAG substitution mutants 
All TAG substitution mutant plasmids were generated using the GeneArt Site Directed 
Mutagenesis System (Invitrogen). The TAG stop codon was introduced in place of the 
codon corresponding to residues of interest, in accordance with the methodology set out for 
UAA integration previously (Coin et al., 2013). All mutagenesis primer pairs followed the 
same design principle; with 100% complementarity to each other and the mutation in the 
exact middle, flanked by 15-18 nucleotides either side. These are listed in table 2.2.1. PCR 
reactions were prepared as follows; 
10X AccuPrime Pfx Reaction buffer 2.5 µl 
10X Enhancer 2.5 µl 
Primer mix (10 µM each) 0.75 µl 
WT CCR7 plasmid template (20 ng/µl) 0.5 µl 
DNA Methylase 0.5 µl 
25x SAM* 1 µl 
AccuPrime Pfx 0.2 µl 
PCR water 17 µl 
*25x SAM was prepared as a fresh dilution of 200x SAM, provided in the kit 
This kit utilises a single PCR programme that initially methylates the original template 
plasmid before generating linear fragments of the whole plasmid including the desired 
mutation. This allows for the template to be selectively degraded following bacterial 
transformation due to the expression of McrBC endonuclease by the strain used (One Shot 
MAX Efficiency DH5α-T1R Competent Cells, Invitrogen). PCR was performed according 
to the following programme: 
STEP TEMP TIME 
Template methylation 37°C 20 minutes 
Methylase heat inactivation/initial 
denaturation 94°C 2 minutes 
18 cycles 
94°C 20 seconds 
57°C 30 seconds 
68°C 3.5 minutes 
Final Extension 68°C 5 minutes 
Hold 4°C indefinitely 
 
The linear PCR product generated by this reaction then underwent in vitro recombination 
to create a new plasmid. The recombination product was prepared as follows; 2 µl 5x 
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reaction buffer, 2 µl PCR product, 1 µl 10 x Enzymer mix and 5 µl nuclease free water. 
This was incubated at room temperature for 10 minutes before recombination reaction was 
halted by the addition of 0.5 µl EDTA, and 2 µl of the reaction used in subsequent 
transformations.  
2.3.3 Bacterial culture and transformation 
One Shot MAX Efficiency DH5α-T1R Competent Cells were used in all transformation 
experiments, and aseptic technique was employed throughout all preparative and 
experimental procedures. Both Luria-Bertani (LB) Broth and LB agar were prepared in-
house and sterilised by core facility staff. LB agar was melted, allowed to cool before the 
addition of selection antibiotics, and poured into 90 mm petri dishes (Fisher Scientific). 
Once set, agar plates were stored inverted at 4 oC until required. Ampicillin stock was 
created from Ampicillin sodium salt (Sigma-Aldrich) and reconstituted at 50 mg/ml in 
50% ethanol, then stored at -20 oC. Gentamicin was used from a 10 mg/ml commercially 
available solution (Sigma-Aldrich). The ingredients of LB broth, agar plate and SOC 
media (provided with competent cells) are listed below; 
Medium  Component  Concentration  
Luria-Bertani (LB) 
Broth  
Tryptone  1% (w/v)  
Yeast extract  0.5% (w/v)  
NaCl  1% (w/v)  
Sterilize by autoclaving    
LB agar plates  
Agar  15 g/L  
LB-broth  1x  
Ampicillin 50 μg/ml  
Gentamicin (tR4-8.3 
only) 10 μg/ml  
SOC media (provided 
with competent cells) 
Tryptone  2% (w/v) 
Yeast extract  0.5% (w/v)  
NaCl  10 mM 
KCl 2.5 mM 
MgCl2 10 mM 
MgSO4 10 mM 
Glucose  20 mM 
 
Transformations were performed as follows; competent cells were defrosted in their vial on 
ice for no more than 20 minutes before the addition of 2-5 µl ligation/recombination 
reaction, mixed by gently tapping the vial. Vials were then placed in ice for 12 minutes, 
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before heat shocking the cells for 30 seconds at 42 oC in a preheated water bath, then 
returned to the ice for a further 2 minutes. 250 µl SOC media was then added, and cells 
incubated at 37 oC for 1 hour with constant, gentle agitation. A volume sufficient to allow 
for individual colonies to be picked (15-250 µl depending on the plasmid) was spread on to 
pre-dried agar plates using disposable plastic inoculation loops (VWR) and allowed to 
grow for 12-18 hours at 37 oC. Individual colonies were picked by sterile pipette tip and 
dispersed in 30 µl sterile water. Plasmid preparations were prepared with either QIAprep 
spin miniprep (Qiagen) or PureLink HiPure Plasmid Midiprep (Invitrogen), depending on 
required yield.  
For mini-preps 5 µl of the bacterial mix was added to 1 ml LB broth, supplemented with 
equivalent selection anti-biotics to those used when setting up agar plates, and incubated 
for 1 hour at 37 oC under constant agitation. This was then transferred to an additional 4 ml 
LB broth and incubated overnight at 37 oC in a shaking incubator before DNA harvest 
using the QIAprep kit in accordance with manufacturer’s instructions. Plasmid was eluted 
in 50-100 µl nuclease free water. Midi-preps were prepared by adding the entire 
bacteria/water mix to a total volume of 50-100 ml LB (+selection antibiotics) and 
incubated overnight at 37 oC in a shaking incubator. DNA was then harvested in 
accordance with the manufacturer’s instructions, and DNA reconstituted in 0.5-1 ml 
nuclease free water at 37 oC until completely dissolved. All new plasmids were evaluated 
by restriction digest and PCR against inserted GOI where applicable. Newly developed 
plasmids were sent for sanger sequencing by Eurofins Genomics to evaluate their open 
reading frames (ORFs) for any point mutations and determine if mutagenesis reactions 
inserted the desired changes to sequence. Plasmids used in this study are listed in table 
2.3.1. 
2.4 Mammalian cell culture, transfections and stable cell 
line generation 
Although multiple cell lines have been used in the works described in this thesis, common 
handling and incubation conditions were used. Sterile technique was employed throughout, 
with all procedural steps conducted in a laminar flow hood with HEPA filtration, regularly 
sterilised with 70% ethanol throughout, and using sterile equipment, plastics and reagents. 
Cells were incubated under temperature, humidity and atmospheric controlled conditions, 
namely 37 oC, 5% CO2 and 95% humidity. As stated, multiple cell lines have been 
employed here, however these can be broadly grouped in to 2 categories.  
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2.4.1 Culturing of adherent cells 
HEK293T, COS-7 and 3T3 cell lines were obtained from pre-existing stocks held by the 
group. RAW cells were kindly gifted by Jennifer Mitchell, and all adherent cell lines were 
maintained in either 75 or 150 cm2 tissue culture (TC) treated, vented cap flasks (Corning). 
HEK293T, COS-7 and 3T3 cells were maintained in Dulbecco’s minimal essential medium 
(DMEM) plus 10% heat inactivated foetal calf serum (FCS), 2mM L-glutamine and 1% 
streptomycin and penicillin (all Invitrogen), subsequently referred to as DMEM+. RAW 
cells were maintained in RPMI-1640 (Invitrogen), with the same additional components as 
DMEM+, here referred to as RPMI+. All media and reagents were pre-warmed before use. 
Typically, cells were grown until 70-80% confluent before passage. Cells were lifted from 
their flasks by first aspirating and discarding the spent media then washing the cell layer 
carefully with DPBS. Following aspiration of the DPBS, 2-4ml Trypsin-EDTA (0.25%) 
was added, depending on flask size, and the flask returned to the incubator for 5-10 
minutes until all cells detached and were in a single cell suspension. 8-16ml DMEM+ or 
RPMI+ was then added to neutralise the trypsin, and 1/10 of the total volume transferred to 
a new flask with fresh media. Where cells had to be lifted from 10 cm2 or multi-well tissue 
culture plates for downstream applications, the same basic conditions were used, with a 
volume of trypsin sufficient to completely cover the cell layer applied, and 4x this volume 
of DMEM+ added to neutralise it. Please note that Flp-In T-REx 293 cells, and the stable 
cell lines generated from them, are maintained in the same manner however require the 
addition of selection anti-biotics to the media. This will be detailed further in sections 
relating to the establishment of stable cell lines. 
2.4.2 Culturing of cells in suspension 
Non-adherent cell lines (HUT78, U937, THP1, Jurkat, and L1.2) were all maintained in 25 
or 75 cm2 vented cap TC flasks, using RPMI+ media, in a total volume of 5-20 ml. When 
cell number reached a density exceeding 1x106/ml (initially determined by count with a 
haemocytometer then visually), 1/10th of the total volume was transferred to fresh flasks 
with new media.  
2.4.3 Freezing down and recovery of cell lines 
In order to maintain cell stocks, cell lines would be regularly frozen down. For adherent 
cell lines this initially required cells to be lifted into a single cell suspension, and then 
transferred to a 50 ml centrifuge tube (Greiner). Suspension cells were transferred directly 
to 50 ml tubes. Cells were pelleted by centrifugation at 300 g for 5 minutes. Supernatant 
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was discarded, and pellet resuspended in DPBS then spun down again. Supernatant was 
again discarded, and cells resuspended in freezing media (10% DMSO v/v in FCS) at a 
density of 1-10x106 cells/ml. 1 ml of this cell suspension was transferred to 2 ml cryo-vials 
(Alpha Laboratories) and placed in a Mr Frosty freezing container freezing vessel 
(ThermoFisher Scientific), containing isopropanol. The vessel was placed in the -80°C 
freezer overnight to allow gradual cooling (1°C per minute), and the now frozen vials 
transferred to liquid nitrogen tanks for long-term storage. 
Recovery of frozen cells was performed as follows; frozen vials were rapidly defrosted at 
37 oC, and the entire volume of cell suspension transferred to a labelled 15 ml centrifuge 
tube (Greiner) containing 10 ml of either DMEM+ or RPMI+. Cells were pelleted as 
before and supernatant discarded. The cell pellet was then dispersed in 10 ml DMEM+ or 
RPMI+ before being spun down again. Supernatant was again discarded, with cells 
resuspended in fresh media then transferred to a fresh TC flask. 
2.4.4 Transfection of mammalian cells with plasmid DNA 
2.4.4.1 Transfection of HEK293T cells with Lipofectamine 2000 
Transfection of cells for flow cytometry, western blotting and UAA integration was 
conducted with Lipofectamine 2000 transfection reagent (Invitrogen). HEK293T cells 
were seeded on to 12 or 6 well TC plates or 10 cm2 TC dishes (Corning) at a density 
sufficient to give ~90% confluence when transfected 24 hours later. Lipofectamine 2000 
was used in a 3:1 excess of plasmid DNA, i.e. for every 1 µg plasmid 3 µg lipofectamine 
2000 was used. The quantity of plasmid used varied depending on experiment, but 
generally was 0.5-1 µg per well of a 12-well plate, 1.25-2.5 µg with 6-well plates and 4-10 
µg per 10cm2 dish, diluted in 125, 250 or 500 µl Opti-mem (Invitrogen) respectively. 
Lipofectamine 2000 reagent was diluted in an equivalent volume of Opti-mem, then 
combined with the plasmid dilution. The plasmid/lipofectamine mix was then incubated at 
room temperature for 5 minutes, during which time the media on cells was refreshed. The 
plasmid/lipofectamine mix was then added to the media, and cells analysed 48 hours later.  
2.4.4.2 Transfection of HEK293T and Flp-In T-REx 293 cells with 
Polyethylenimine (PEI) 
Transfection of cells for b-arrestin recruitment and immunoprecipitation (IP) experiments 
and for the generation of stable cell lines using the Flp-In system were performed using 
PEI (25kD linear, Polysciences). In all cases, cells were seeded on to 10 cm2 TC dishes as 
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described previously, and transfection conducted 24 hours after seeding. Transfection for 
the generation of stable cell lines will be discussed in greater detail in a later section. PEI 
was used at a 6:1 excess of plasmid DNA. For b-arrestin recruitment assays 4 µg receptor-
YFP expressing plasmid and 1 µg b-arrestin 1 or 2-rLuc expressing plasmid (±4 µg 
ST8sia4-HA expressing plasmid) was used and diluted in 500 µl sterile 150 mM NaCl. For 
IP experiments 4 µg each of receptor expressing plasmid and either empty vector or 
ST8sia4-HA expressing plasmid was diluted in the same volume. PEI was diluted in 500 µl 
150 mM NaCl also and combined with the plasmid dilution. The plasmid/PEI mix was 
incubated for 10 minutes at room temperature while the media on cells was refreshed, then 
applied into the refreshed media. Transfected cells were utilised 48 hours later.  
2.4.5 Generation of stable cell lines using the Flp-In system  
Stable cell lines for the inducible expression of systematic protein affinity strength 
modulation (SPASM) biosensors of Gi1/2 and Gi3 recruitment to CCRs 4, 7 and 10, were 
generated using the Flp-In T-REx methodology (Ward, Alvarez-Curto and Milligan, 2011). 
Flp-In T-REx 293 cells were maintained in DMEM+ supplemented with the selection 
antibiotics Blasticidin S HCl (Invitrogen, used at 5 µg/ml final concentration) and Zeocin 
(Invitrogen, used at 50 mg/ml final concentration). 10 cm2 TC dishes were seeded with 
Flp-In T-REx 293 cells at sufficient density to be >90% confluent 24 hours later. When 
>90% confluent cells were transfected with SPASM biosensors for each receptor/G-protein 
combination in a 1:8 ratio with pOG44 plasmid, using PEI as the transfection reagent as 
described above. Following 2 days incubation transfected cells are replated at a lower 
density in 75 cm2 TC flasks, and successful transfectants were selected for with DMEM+ 
supplemented with Blasticidin S HCl (Invitrogen) at 5 µg/ml and Hygromycin Gold 
(Invivogen) at 200 µg/ml for ~2 weeks, exchanging spent media every 5-7 days, which 
removes non-adherent dead cells. Surviving cells are then pooled and maintained in the 
same selection media from this point.  
2.5 Flow cytometry, generation of biotinylated 
chemokines and competition assays 
2.5.1 Flow cytometry 
Expression of chemokine receptors of interest was evaluated by flow cytometry. When 
assessing adherent cells (HEK293T) these were prepared as a single cell suspension as 
described (Section 2.4.1), washed x2 in PEB (DPBS, 0.5% w/v BSA, 2 mM EDTA), and 
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resuspended at 5x106 cells/ml in PEB and kept at 4 oC. Non-adherent cells (BMDCs) were 
washed x2 in PEB and resuspended at 5x106 cells/ml in PEB and kept at 4 oC. All 
proceeding washes and staining steps are conducted at 4 oC. Cells were stained utilising a 
novel chemokine-based detection method (Le Brocq et al., 2014). For analysis of CCR7, 
site-specific biotinylated CCL19 (Almac Sciences) was prepared at a stock concentration 
of 1 µM in 0.5% BSA and stored at -20 oC. Staining with the chemokine was performed at 
a concentration of 25 nM, meaning that in a staining volume of 100 µl, 2.5 µl of 
biotinylated CCL19 is used. Prior to staining, the chemokine was conjugated to either 
streptavidin-PE (SAPE) or streptavidin-BV421 (SABV421) (both from Biolegend) in a 
ratio of 2.5 µl chemokine to 5 µl SAPE/SABV421 and incubated at 4 oC for 30 mins. Cells 
were stained by adding 7.5 µl CCL19-SAPE to a total volume of 100 µl cell suspension 
and incubated for 30 mins at 4 oC. For CCR4, CCL22 directly conjugated to the 
fluorophore AF647 (Almac) was used at a staining concentration of 25 nM as well and was 
added directly to a total volume of 100 µl cell suspension. After staining cells were washed 
twice, resuspended in 500 µl PEB buffer, with 1 µl DRAQ7 live/dead discriminant 
(Biostatus) added immediately before analysis. Samples were analysed with the 
MACSQuant bench top cytometer. Post-acquisition analysis was carried out using FlowJo. 
Where quoted, MFI represents Geometric mean of all single, live cells in the relevant 
channel. 
2.5.2 In-house biotinylation of chemokines 
Human CCL19, CCL22 and CCL27 (Peprotech) were biotinylated using the One-Step 
Antibody Biotinylation Kit (Miltenyi), in accordance with manufacturer’s instructions. In 
brief, chemokines were reconstituted in DPBS at a concentration of 100 µg/ml, and 100 µl 
of mixed with the lyophilised reagent provided. This was then incubated for 24 hours at 18 
oC. Remaining non-biotinylated chemokine was incubated under the same conditions for 
use as a control in subsequent experiments. Following this, chemokine was diluted with 
0.5% BSA to a final concentration of 1 µM and stored at -20 oC. In-house biotinylated 
chemokines were either used in the same manner as those purchased from Almac, with 
pre-conjugation to SAPE/SABV421 before staining, or were used unconjugated to label 
cells. In this 2-step process cells were incubated with the in-house biotinylated chemokine 
first for 30 minutes, washed x1 in PEB, stained with an equivalent of 5 µl SAPE/100 µl 
stain for a further 30 minutes, then prepared and analysed as before.   
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2.5.3 Competition assays 
CCL17, 19, 21 and 22 (Peprotech) were reconstituted in 0.5% BSA at a concentration of 
10 µM. Where site-specific biotinylated CCL19 was used this was pre-conjugated to SAPE 
as described above. CCL22-AF647 was used directly. In-house biotinylated CCL22 was 
used in a 2-step staining process as described in section 2.5.1. In all instances a mix of 
unlabelled cold competitor and labelled chemokines was created as follows; 
  Starting concentration: Volume: 
Final Concentration 
(in 100 µl stain): 
Labelled Chemokine 1 µM 2.5-7.5 µl 25 nM 
Unlabelled Chemokine 10 µM-0.3 nM 10 µl 1 µM-0.03 nM 
PEB n/a up to 20 µl n/a 
 
20 µl of these mixes was used to stain prepared cells in a total volume of 100 µl and 
prepared and analysed as described in section 2.5.1. IC50 values were calculated from the 
MFI values obtained using an XY table in Prism 6 software (GraphPad), and the following 
equation; Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))). pKi values were generated 
using the Cheng-Prusoff equation, as described previously (Lazareno and Birdsall, 1993). 
2.6 Protein analysis; western blotting, UV crosslinking 
and IPs 
The following buffers were produced in house for use in protein analysis. 10x PBS was 
produced by core facility staff.  
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Solution  Component  Concentration  
10 x PBS  
NaCl  1.37 M  
KCl  27 mM  
Na2HPO4  100 mM  
KH2PO4  17.6 mM  
1x PBS 10x PBS 10% (v/v)  
PBST (0.05%)  PBS  1x  
Tween 20 0.05% (v/v)  
5% Milk PBST  
PBST 1x  
Skimmed milk powder 
(Marvel)*  5% (w/v)  
Triton X lysis 
buffer 
Trtiton X-100 1% (v/v) 
Tris (pH 8) 10 mM 
EDTA (pH7.4) 5 mM 
NaCl  150 mM 
SDS-Urea lysis 
buffer 
Tris (pH 6.8) 100 mM  
Sodium dodecyl sulfate (SDS) 4% (w/v) 
Urea 8 M 
Glycerol 20% (v/v) 
EDTA (pH 7.4) 20 mM 
bromophenol blue 0.014% (v/v) 
RIPA buffer 
Tris-HCl (pH 7.4) 50 mM 
NP-40 1% (v/v) 
deoxycholate 0.25% (w/v) 
NaCl  150 mM 
EDTA (pH 7,4) 1 mM 
1 M DTT Dithiothreitol 1 M 
Coomassie blue 
buffer 
Methanol 50% (v/v) 
Acetic acid 10% (v/v)  
Coomassie blue R-250 0.25% (w/v) 
Coomassie destain 
buffer 
Methanol 5% (v/v) 
Acetic acid 7.5% (v/v) 
Glycine elution 
buffer Glycine 
200 mM (pH 
adjusted to 2.5) 
Tris Base Tris 1 M (pH adjusted 
to 10.4) 
Unless otherwise stated, all buffers are prepared in dH2O 
2.6.1 Preparation of protein lysates 
Please note that extraction of protein from HEK293T cells is conducted at 4 oC throughout 
all stages. Whole cell lysate was obtained with Triton X lysis buffer and RIPA buffer as 
follows; 1 Pierce protease inhibitor mini tablet (ThermoFisher Scientific) was dissolved in 
10 ml of lysis buffer. TC media was aspirated, and cell layers washed once with PBS. Cell 
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layers were then lifted by mechanical disruption in PBS and transferred to 1.5 ml reaction 
tubes (Greiner). Cells were pelleted at 300 g for 5 minutes, supernatant removed, and 
pellets disrupted in lysis buffer (50-200 µl depending on cell number), and constantly 
agitated for 15 minutes. Lysate was then cleared by centrifugation at 17000 g for 15 
minutes, and supernatant transferred to fresh reaction tubes. 
Whole cell lysate was obtained with SDS-Urea lysis buffer as follows; 1 Pierce protease 
inhibitor mini tablet was dissolved in 10 ml of lysis buffer. TC media was aspirated, and 
cell layers washed once with PBS. Cells were then disrupted directly in the lysis buffer, 
scraped from the plate with an inverted 1000 µl pipette tip, and transferred to 1.5 ml 
reaction tubes. Lysate was passed through a 25-gauge needle 5 times to shear genomic 
DNA.  
Protein concentration was determined using the Pierce BCA protein assay kit 
(ThermoFisher Scientific), in accordance with manufacturer’s instructions. An equivalent 
volume of cleared lysis buffer was added to each BSA standard sample to account for 
background reactivity with the buffer. Unless used immediately, protein lysates were snap 
frozen in dry ice and stored at -20 oC.  
2.6.2 Western blotting 
Unless otherwise stated here or previously, all reagents used in this section were obtained 
from ThermoFisher Scientific. Lysate sufficient to give 20 µg total protein was made up to 
a standard volume of 13 µl with additional lysis buffer. Samples were denatured with 5 µl 
Bolt LDS sample buffer (Invitrogen), reduced with 2 µl 1 M DTT and incubated at 37 oC 
for 30 mins. 7.5 µl Novex sharp pre-stained protein standard and the entire volume of each 
sample were loaded onto 15 well, 4-12% Bolt Bis-Tris plus gels, and run with1x Bolt MES 
running buffer (5% v/v 20x Bolt MES running buffer) at 200 V and 500 mA for 30-60 
minutes. PVDF membrane was pre-activated by incubation in methanol for 30 seconds. 
Protein was transferred to PVDF membrane in accordance with manufacturer’s instructions 
in transfer buffer (5% v/v 20x Bolt transfer buffer, 10% v/v methanol, 0.1% v/v Bolt 
Antioxidant) at 20 V and 500 mA for 60 minutes. Membranes were blocked in 5% Milk 
PBST for 90 mins then incubated in a dilution of the primary antibody in 5% Milk 
PBST overnight at 4 oC under. Membranes were washed briefly in PBS, then for 10 
minutes in PBST (x3) and then incubated in the secondary antibody diluted in 5% Milk 
PBST for 1 hour at room temperature. Membranes were again washed briefly in PBS, then 
for 10 minutes in PBST (x3), dried and exposed to Pierce ECL western blotting substrate 
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for 2 mins. Proteins of interest were then visualised by exposure to x-ray film (Carestream) 
under dark room conditions, with multiple exposures obtained in all instances, and 
developed using the Konica-Minolta SRX-101A film processor. Where applicable, 
quantification was carried out using ImageJ software and the gel analyser tool by defining 
pixel density in a standardised region of interest and subtracting background pixilation. 
Where required, membranes were stripped using Restore stripping buffer in accordance 
with manufacturer’s instructions. Below is a list of primary and secondary antibodies used 
throughout this thesis.  
Primary/Secondary Epitope/Isotype Clone/Host species Dilution Manufacturer 
Primary  FLAG, IgG1 M2, mouse 1;5000 Sigma Aldrich 
Primary  
GAPDH (human), 
IgG n/a, rabbit 1;5000 Generon 
Primary  CCL19 (human), IgG EPR7044(2), rabbit 1;2000 Abcam 
Primary  CCL21 (human), IgG EPR6218, rabbit 1;2000 Abcam 
Primary  HA, IgG n/a, rabbit 1;5000 SantaCruz 
Primary 
polysialic acid, 
IgG2a 735, mouse 1;5000 
absolute 
antibody 
Primary polysialic acid, IgM 2-2B, mouse 1;1000 Merck 
Primary GFP n/a, sheep 1;10000 
generated in-
house 
Secondary anti-rabbit IgG-HRP n/a, goat 1;5000-10000 
Jackson 
ImmunoResearc
h 
Secondary anti-mouse IgG-HRP n/a, goat 1;5000 R&D Systems 
Secondary anti-goat IgG-HRP* n/a, donkey 1;20000 R&D Systems 
Secondary anti-mouse IgM HRP n/a/goat 1;10000 Abcam 
* anti-goat IgG HRP readily detected sheep antibodies and was the secondary utilised with 
the anti-GFP primary.  
2.6.3 Coomassie blue staining 
Protein gels were prepared and ran as described in 2.6.2, however instead of transfer to 
PVDF, gels were stained in Coomassie blue buffer for 4 hours. Following this, background 
Coomassie staining was removed by incubation in Coomassie de-stain buffer for 4 hours. 
Representative images were captured by camera.  
2.6.4 UAA integration and crosslinking 
When integrating UAA into TAG substitution mutants of CCR7 the transfection protocol 
described in section 2.4.4.1 was followed as described, with the exception that media was 
changed to DMEM+ supplemented with 1 mM p-azidophenyalanine (Bachem) 4-8 hours 
prior to transfection, instead of during transfection. This allowed time for UAA cell 
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loading and for media pH to equilibrate. All steps of this procedure are conducted at 4 oC. 
48 hours following transfections cells were harvested in the same manner as described for 
flow cytometry analysis in section 2.5.1, then split into 2 aliquots and transferred to 1.5 ml 
reaction tubes. Cells were resuspended in 200 µl PEB supplemented with either CCL19 or 
CCL21 (100 nM), incubated for 15 mins then transferred to disposable cuvettes (Fisher 
Scientific) before being exposed to UV radiation (365 nm) for 40 mins by handheld dual 
UV lamp (Fisher Scientific), with occasional agitation. Alternatively, cell layers were 
undisturbed, and instead washed x1 in DPBS, exposed to equivalent conditions as cells 
analysed in suspension (using CCL19 only), then lifted by mechanical disruption of the 
cell layer in DPBS. From this point, protein was extracted in RIPA buffer as described in 
section 2.6.1. 
2.6.5 Immunoprecipitation of chemokine receptors and 
polysialylated proteins 
Lysate was obtained in 500 µl RIPA buffer from whole 10 cm2 TC plates transfected with 
chemokine receptors of interest ±ST8sia4-HA as described in section 2.6.1. Protein L 
agarose beads (SantaCruz) were used in all IP experiments, and all steps are conducted 4 
oC and performed in 1.5 µl reaction tubes, and all incubation steps are performed under 
constant agitation by end over end tumbler. For IP using anti-FLAG (M2) the following 
protocol was used; 20 µl Protein L bead suspension and 1 µl mouse IgG1 isotype control 
antibody (Biolegend) were added to lysates. These were incubated for 30 minutes, then 
beads pelleted by centrifugation at 1000 g for 1 minute. Supernatant was transferred to a 
fresh reaction tube, and 1 µl anti-FLAG (M2) antibody added. Samples were incubated 
with constant agitation for 1 hour, then 20 µl bead suspension added, before being left to 
incubate overnight. Beads were pelleted by centrifugation as before, supernatant discarded, 
and then resuspended in 500 µl RIPA buffer supplemented with protease inhibitor cocktail 
(as described in section 2.6.1). This wash step was repeated 3 additional times, before 
protein was eluted in 25 µl glycine elution buffer by constantly mixing buffer and beads 
for 30 seconds, before neutralising pH with the addition of 2.5 µl Tris base. From here, 
eluted protein was prepared for western blotting as described in section 2.6.2, with the 
exception that protein concentration was not determined, and a standard volume was 
loaded on to gels instead. For IP using anti-pSia (735) adjustments had to be made due to 
the target epitope’s instability. In effect, the same protocol as employed in anti-FLAG IPs 
was used with the following adjustments; no pre-clear step was employed, incubation time 
was shortened from overnight to 4 hours, and protein was eluted by denaturing and 
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reducing of the bead mix in 25 µl of 2xLDS with 100 mM DTT for 15 minutes at 37 oC. 
Beads were again pelleted, and supernatant carefully aspirated and used directly for 
western blotting as described in section 2.6.2.  
2.7 Epifluorescent microscopy 
24 hours following transfection of HEK293T cells on a 12-well plate with CCR4, 7 or 10-
YFP (as described in section 2.4.4.1) cells were harvested as before, resuspended in 1 ml 
DMEM+ and 500 μl transferred to a chamber of 4-chamber microscope slide (Lab-TEK). 
24 hours after this each chamber was washed once with 250 μl DPBS, incubated for 20 
mins in 4% paraformaldehyde at room temperature, washed again with DPBS and allowed 
to air dry. Slides were mounted with mounting medium +DAPI (Vector Laboratories) and 
visualised on the Axio IMager.M2 microscope with a 40x objective (40x/0,75 Ph2), and 
imaged using the AxioCam MRM monochromatic camera. 
2.8 Aldara model and qPCR 
2.8.1 The Aldara model of psoriasiform inflammation 
The Aldara model has been well described previously (van der Fits et al., 2009). In brief, 
8-week-old female C57BL/6 mice had their dorsal skin shaved near the base of the tail. A 
quarter sachet of Aldara cream (Meda AB) (~62.5 mg) or equivalent volume of control 
cream ((Boots Aqueous Cream/10% Vaseline Lanette Cream) was applied daily, up to a 
total of 5 days. Mice were weighed daily and culled if their body weight reduced by over 
20 % during the course of the procedure, in agreement with Home Office Requirements. 
Mice were euthanised 4, 12 and 24 hours after the initial Aldara treatment and 24 hours 
after the 3- and 5-day treatments by rising concentration of CO2. Dorsal skin samples were 
removed, and RNA harvested and converted to cDNA as described in section 2.1 and 2.2. 
The preceding was performed by Louis Nerurkar, who kindly gifted cDNA excess to his 
own requirements for the analysis performed here.  
2.8.2 Determination of relative expression by quantitative reverse 
transcription-PCR (qPCR) 
qPCR primers for GOI were designed from the available main mRNA sequence listed on 
genbank (NCBI), using the Primer3 web tool (Koressaar and Remm, 2007) in accordance 
with the following conditions; primer length between 18 and 23 bp (20 bp optimal), primer 
GC content between 40 and 65% (50% optimal), primer annealing temperature (Tm) 
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between 59.5 oC and 61 oC (60 oC optimal), max self-complementarity of 2, max 3’ self-
complementarity of 1, amplicon size 50-150bp, no more than two G or C bases in last 5 at 
3’ end and no stretches of G or C exceeding 4 nucleotides. Where possible, primers were 
designed to span exon junctions. All primers were checked for specificity using the NCBI 
Primer-BLAST web tool (Ye et al., 2012).  
cDNA was prepared as described in section 2.1. No template (NTC), nuclease free water 
(water) and no reverse transcriptase (-RT) controls were used where appropriate. The 
following reaction mix represents the quantities per individual well and was scaled up as 
required; 5 μl PerfeCTa 2x master mix (Quantabio), 3.85 μl nuclease free water, 0.75 μl 
each of forward and reverse primer (from a 100 mM primer stock). 9 μl of reaction mix 
was dispensed into each required well of a 384 well qPCR plate (StarLab), and 1 ml 
diluted cDNA, water or -RT control was added to the appropriate well, with triplicate 
measures analysed for each sample. qPCR was performed using the QuantStudio7 Flex 
Real-Time PCR system (ThermoFisher Scientific), according to the following programme; 
STEP TEMP TIME 
Initial 
Denaturation 95°C 20 seconds 
40 Cycles 
amplification 
95°C 1 second 
60°C 20 seconds 
Melt curve 
analysis 
95°C 15 seconds 
60°C 1 second 
95°C 15 seconds 
 
For analysis of Aldara experiments and BMDC expression, Ct values were obtained, and 
coefficient of variation between triplicates assessed as follows; triplicates with a 
coefficient of variation >2.5% (standard deviation (SD) = 0.5) had an outlier excluded if 
the indicated Ct value was >1.5 from the median value within each triplicate. Expression 
was expressed relative to a housekeeping gene (TATA binding protein, or TBP), presented 
as 2-DDCt which was calculated for each individual sample as follows; DCt=Ctgoi/CtTBP, 
DDCt= DCtsample-DCtaverage of control group, 2-DDCT=2^ DDCt x -1. 
This methodology was not applicable to the analysis of ST8sia4 expression in cell lines, as 
a control group cannot be assigned when comparing between different cell lines from 
different species. Instead, comparison was made to a defined standard for each gene. 
“Standards” were generated as follows; primers were designed for the amplification of a 
500 bp region of mRNA encompassing the qPCR amplicon, PCR performed, samples run 
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on a gel and the relevant band excised, purified and DNA concentration quantified as 
described in sections 2.2.1 and 2.3.1. DNA copy number was determined as follows; 
concentration/molecular weight x 6.23x1023. The standard was initially diluted 1/100 to 
give a 10-2 stock, then further diluted by 1/10 serial dilution to give a standard range of 10-4 
to 10-9. For human ST8sia4 the expression vector for this gene had already been 
established and was used in a similar copy number to the generated standards. A standard 
curve was generated by analysing 10-4 to 10-9 copies of this standard in triplicate to 
determine the copy numbers of samples. Outliers are excluded as described above, and 
expression conveyed as a function of QTGOI/QTTBP.  
qPCR and standard primers are listed in table 2.2.1. 
2.9 Bioluminescence resonance energy transfer (BRET) 
experiments 
BRET experiments followed a slightly different methodology depending on the signalling 
partners being assessed. For b-arrestin recruitment assays cells were transfected as 
described in section 2.4.4.2, and removed from their 10 cm2 TC plates by washing once in 
DPBS, incubating in 2 ml trypsin-EDTA, neutralising the trypsin with 8 ml DMEM+, 
transferring the cellular suspension to  50 ml centrifuge tubes and diluting this suspension 
with an additional 10 ml DMEM+. 100 μl of these suspensions were seeded onto white 96-
well tissue culture plates (Corning) pre-treated with poly-d-lysine (Sigma-Aldrich), and 
allowed to adhere overnight. For G-protein recruitment assays, cells were lifted in the same 
manner but subsequently resuspended in DMEM+ (without selection antibiotics). Cell 
density was determined and adjusted to 6x105 cells/ml, and expression of the SPASM 
biosensors induced by the administration of 100 ng/ml doxycycline hyclate (Sigma-
Aldrich). 100 µl cell suspension was then seeded as described above and allowed to adhere 
overnight. On the day of analysis cells were washed once with 100 µl Hanks balanced salt 
solution (HBSS, Gibco), then equilibrated in HBSS (80 µl) for >30 mins. 10 µl of a 25 µM 
solution of Coelentrazine h (NanoLight Technology, 301) was added to each well (2.5 µM 
final concentration) and incubated for 10 mins at 37 oC. 10x dilutions of CCLs 17, 19, 21, 
22, 27 or 28 (Peprotech) were prepared such that administration of 10 µl of these dilutions 
gave a final concentration range between 1 µM and 0.01 nM in the well, depending on 
experimental conditions. Chemokine was administered, and plates incubated at room 
temperature for 5-10 minutes. Spectral emission was detected at 475 nm for the donor 
(rLuc/nLuc) and 535 nm for the acceptor (YFP). Gain for YFP and luciferase emissions 
was adjusted based in untreated controls such that the ratio of YFP/luciferase was close to 
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1. Plates were then read on the Pherastar FS plate reader. In b-arrestin recruitment kinetics 
experiments the same basic methodology was followed, except a single final concentration 
of 100 nM of chemokine was used, gain for YFP/Luciferase set at a standard setting of 
3600/3200 (this broadly results in a ratio of 1 for experiments with an rLuc donor), and 
readings taken continually over a 30-minute period.  
All b-arrestin expressing plasmids were kindly gifted by Dr Brian Hudson. In all 
experiments BRET ratio is determined as YFP emission/rLuc emission. pEC50 were 
determined using Graphpad 6 software with the following equation; Y=Bottom + (Top-
Bottom)/(1+10^((LogEC50-X))). Half-time and maximal response values from kinetics 
experiments were determined with the following equation; Y=Y0 + (Plateau-Y0)*(1-exp(-
K*x)). Relative efficacy and bias factors were determined as described previously (Gundry 
et al., 2017). 
2.10 Bone marrow derived dendritic cell (BMDC) 
differentiation 
BMDCs were differentiated from the bone marrow of female C57BL/6 mice. The 
following was performed by Paul Burgoyne, who kindly gifted excess cells at various 
stages of the differentiation protocol for use here. The femurs and tibia were dissected out, 
and muscle and connective tissue removed by washing in ethanol under sterile conditions. 
Sterile conditions were maintained from here forward. Cleaned bones were rinsed in 
DPBS. The bone tips were removed by dissection scissors and bone marrow flushed using 
RPMI+ and a 26-gauge needle and 5 ml syringe. Collected bone marrow was then forced 
through a 40 µm filter (Greiner) and subsequently flushed with an additional 5 ml RPMI+ 
to create a single cell suspension. Cell density was determined, and cells pelleted by 
centrifugation at 300 g for 5 minutes. Cells were suspended at a density of 1x106/ml in 
RPMI supplemented with 20 ng/ml granulocyte-macrophage colony stimulating factor 
(GM-CSF, Miltenyi) and transferred to petri dishes (10ml/petri). Following 2 and 4 days in 
culture, non-adherent cells were transferred to fresh plates, and 2ml RPMI+ with 20 ng/ml 
GM-CSF was added. After 7 days in culture non-adherent cells were pelleted and 
resuspended in RPMI+ supplemented with 100 ng/ml lipopolysaccharide (LPS, Sigma-
Aldrich) and 50 ng/ml tumour necrosis factor alpha (TNFa, Miltenyi), plated on fresh petri 
dishes and incubated overnight. RNA was extracted from unstimulated bone marrow (D0), 
cells at day 4 of the differentiation protocol (D4) and cells at day 7, prior to stimulation 
with LPS/TNFa. Day 8 stimulated cells were used for flow cytometry analysis.  
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2.11 Statistical analysis 
All data were analysed using Prism 6 software. The specific statistical tests applied, and 
replicates analysed are listed in the relevant figure legends or in the appropriate section of 
this chapter (Materials and Methods). Differences were considered significant when 
p=<0.05.  
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Table 2.2.1 List of primers used in this study 
List of primers designed for use in this study, including descriptions of their intended 
function and sequence 
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Table 2.3.1 List of plasmids used in this thesis 
A list of plasmids used in this thesis, including intended function and compatible bacterial 
and mammalian selection antibiotics 
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3 Integration and crosslinking with unnatural 
amino acids 
3.1 Introduction 
Like many GPCRs, some chemokine receptors demonstrate signalling bias (Corbisier et 
al., 2015). This is a phenomenon wherein two or more ligands binding the same receptor 
produce a unique signalling profile. A number of chemokine receptors have demonstrated 
a form of signalling bias that can be broadly described as a pair of ligands binding a 
receptor, with both resulting in recruitment of heterotrimeric G-protein complexes to the 
receptor, but only one also recruiting b-arrestin and resulting in receptor internalisation and 
desensitisation. In this scenario the chemokine that readily recruits both G-proteins and b-
arrestin is considered balanced, whereas the chemokine that selectively recruits G-proteins 
is considered biased toward G-protein mediated signalling. This skewed signalling profile 
is observed with several chemokine receptors interacting with only a pair of ligands, such 
as CCR4 (with CCL17 and CCL22), CCR7 (with CCL19 and CCL21) and CCR10 (with 
CCL27 and CCL28) (Mariani et al., 2004; Rajagopal et al., 2013; Corbisier et al., 2015).  
The ability of different ligands to recruit signalling apparatus in unique ways is considered 
to be a result of subtle variations in receptor:ligand interaction that lead to the adoption of 
distinct active conformations by the receptor  (Ziarek et al., 2017). This could provide the 
opportunity to target GPCRs with compounds that preferentially inhibit one ligand or 
signalling pathway over another, with biased agonism currently being considered in new 
drug development (Rankovic, Brust and Bohn, 2016). However, this requires highly 
detailed structural information of the particular residues involved in ligand binding. Such 
data are typically obtained from crystal structures of the receptor of interest complexed 
with its cognate ligands. This can prove highly technically challenging when evaluating 
GPCRs (as well as other transmembrane proteins), with chemical modifications often 
being required to stabilise the receptor, and frequently obtaining only partial structures or 
structures of a poorer resolution than needed (Ghosh et al., 2015). As all of these factors 
can heavily influence the interpretation of these data there is a call for alternative 
approaches to obtain highly detailed readouts of receptor: ligand interactions that don’t rely 
on crystallography.  
One such approach is to make use of the expanded genetic code. This is an umbrella term 
for the integration of amino acids with unique and useful properties (not found in nature) 
into proteins of interest (Wang and Schultz, 2002). Different UAAs have highly diverse 
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properties, however broadly speaking they are incorporated into target proteins in the same 
manner. The codon of the residue to be replaced is substituted with one that corresponds to 
no natural amino acid, frequently the amber stop codon TAG (Takimoto et al., 2009). This 
stop codon is then suppressed by the exogenous expression of a tRNA and synthetase pair 
capable of charging and integrating UAA into the translated protein product in response to 
the amber stop codon TAG. The result is a protein that, other than the site of UAA 
substitution, is near-identical to the WT, with minimal disruption to structure and ligand 
interaction properties. One such UAA, p-azidophenylalanine, carries the additional 
sidechain modification of an azide group. At rest this azide group is inert, however 
following UV irradiation at 365 nm expels an N2 molecule leaving a highly reactive nitrene 
group behind (Shao et al., 2015). This volatile nitrene group displaces hydrogen from any 
CH, OH or NH bond in the nearby vicinity, resulting in the covalent capture of any such 
molecule within a distance of 8.9 Å of the activated UAA (Coin et al., 2013). The principal 
being that if the substituted residue is involved in ligand binding it will be within this 
distance, resulting in covalent capture of the ligand. Otherwise the nitrene group will 
quench in the aqueous environment surrounding the cell.  
Using this methodology, it has been possible to image the binding pocket of a GPCR (rat 
corticotropin releasing factor receptor, CRF1R) with one of its endogenous protein ligands, 
urocortin 1 (Coin et al., 2013). Here, p-azidophenyalanine was substituted for all residues 
considered apical and therefore potentially ligand binding, and crosslinking performed in 
the presence of Urocortin 1. The resulting receptor:ligand adducts could be visualised by 
western blotting, with both ligand and receptor size-shifting to the same position on the 
blot (summarised in figure 3.1). Those substitution sites demonstrating successful 
crosslinking were then mapped to an available structure of the receptor to visualise the 
binding pocket of Urocortin 1. 
It was hoped that this technique could be utilised to visualise the binding pockets of 
CCL19 and CCL21 on CCR7, highlighting any structural differences that may account for 
the skewed signalling profile between these two chemokines. Described herein is the 
establishment of a CCR7 expression vector introducing the FLAG epitope tag to the C-
terminus, as well as sixteen TAG substitution mutants of CCR7 ranging from the 47th 
(leucine) to the 63rd (isoleucine) amino acids (figure 3.1.2), and the development of 
tRNA/Synthetase expression plasmid suitable for p-azidophenyalanine charging in 
transient transfections. Expression levels of these mutants and their capacity to bind a 
fluorescently labelled CCL19 was evaluated (Le Brocq et al., 2014). However, no 
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successful crosslinking of CCR7 with either CCL19 or CCL21 was demonstrated at any 
site of substitution tested. 
3.2 Establishment and evaluation of CCR7 and 
tRNA/Synthetase expression vectors 
3.2.1 Cloning of CCR7 and plasmid evaluation 
Primers were designed to introduce the FLAG epitope to the C-terminus of CCR7, a new 
TAA stop codon and HindIII and BamHI restriction sites to the 5’ and 3’ ends of the 
transcript respectively. This would allow for ready detection of the receptor by western 
blotting without relying on receptor specific antibodies, allow for TAG codon suppression 
and provide broad compatibility with numerous expression vectors. CCR7 was amplified 
from cDNA generated from human peripheral blood monocytes (PBMCs) from two 
healthy donors (figure 3.2.1a). Interestingly, a second round of PCR from the previous 
PCR product showed poor amplification. This raised concerns as to the nature of the 
original PCR product, however digestion with SacI produced the expected band pattern of 
591, 318 and 273 bp from the predicted transcript (figure 3.2.1b).  
CCR7 transcript and empty pEF6 expression vector were digested with HindIII and BamHI 
and purified, and CCR7 ligated into the vector. Each ligation reaction was transformed 
twice into DH5a max efficiency competent cells. Multiple colonies were picked for each 
transformant. The presence of the insert was confirmed by PCR against CCR7 (figure 
3.2.2a), generating a band of ~1.4 kb, and digestion with PstI, producing the expected band 
pattern of 4.7, 1.7 and 0.5 kb (figure 3.2.2b). One plasmid from each donor (51.2.30.1 & 
52.2.250.1) was sent for sequencing which confirmed no point mutations were present in 
the ORF. Eukaryotic cell expression was evaluated by two separate means.  
Firstly, a fluorescently coupled CCL19 was used to evaluate expression, cell surface 
localisation and ligand binding capacity of CCR7 expressed in HEK293T cells by FACS 
(figure 3.2.3) and demonstrated robust staining in CCR7-FLAG transfected cells only. A 
CCR7 “positive” gate was applied based on the main negative population from empty 
vector transfected cells, which indicated transfection efficiencies of 63.6 % for 51.2.30.1 
and 89.2% for 52.2.250.1. It should be noted that this measure of transfection efficiency 
only assesses surface expression of CCR7 rather than total, and a certain degree of non-
specific background staining with CCL19-SAPE is expected due to glycan binding of the 
chemokine. A single plasmid from one donor (52.2.250.1) was used from this point 
forward. Transfection with increasing quantities of plasmid resulted in an increase in cell 
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surface expression, as determined by CCL19-SABV421 staining at 4 oC. This plateaued 
around 600-800 ng per well of a 12-well plate (figure 3.2.4). Again, a CCR7 positive gate 
was applied based on staining of the empty vector control and indicated increasing 
transfection efficiencies of 29.4, 60.9, 74.1, 80.2 and 83.1 %, ranging from 200 ng to 1 µg.  
Secondly whole cell lysate of cells transfected with either empty vector or CCR7-FLAG 
was harvested in TritonX 100, SDS-Urea or RIPA lysis buffers, and reduced with either 
100 or 400 mM DTT (figure 3.2.5a), in an effort to determine optimal sample preparation 
conditions for the resolution of clean bands. Bands of a size consistent for CCR7-FLAG 
(~45 kDa) were observed with TritonX 100 and RIPA lysis buffers. SDS-Urea buffer 
however failed to produce bands of the correct predicted size, and in fact appear to have 
distorted the relevant lanes of the gel. This could be due to the high urea concentration in 
this buffer. Various denaturing temperatures were also evaluated, with 37 oC for 20 
minutes determined to give the best resolution of bands of the predicted size (figure 
3.2.5b). Two distinct bands were observed, presumed to be the pro and glycosylated forms 
of CCR7 (Schaeuble et al., 2011). Collectively these data indicated that the expression 
vector successfully expressed CCR7, that it trafficked to the cell surface and was capable 
of binding one of its cognate ligands.  
3.2.2 Establishment of a tRNA/Synthetase expressing plasmid 
As mentioned previously, exogenous expression of a compatible tRNA/Synthetase pair is 
required for full length expression of UAA bearing mutant proteins. Recently published 
work on the expanded genetic code utilised viral transduction to introduce a 
tRNA/Synthetase pair capable of charging multiple UAAs along with a TAG mutant of 
GFP to report successful translation (Chatterjee et al., 2013). The genome of this virus is 
available in plasmid form (pAcBac2.tR4-OMeYRS-GFP*) and with the promoters present 
on the tRNA, synthetase and GFP cassettes, is useable in transient transfection (figure 
3.2.6). When analysed by flow cytometry the construct demonstrated limited “leaky” 
expression of GFP in the absence of p-azidophenyalanine (figure 3.2.7a), with cells 
demonstrating GFP fluorescence distinct from empty vector controls, as has been reported 
previously with TAG-codon suppression systems (Chatterjee et al., 2013). Interestingly, in 
terms of transfection efficiency (as determined by applying a GFP+ gate based on empty 
vector transfected cells) there aren’t substantial differences between cells incubated 
without and with UAA, with an increase from 39.1% to 48% transfected cells with the 
inclusion of UAA in the culture media (figure 3.2.7 a&b). However, we observe a clear 
shift in fluorescent intensity when UAA is included in the culture media, with the 
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emergence of a distinct population of high-GFP expressing cells (figure 3.2.7c&d). While 
the GFP reporter is useful in determining successful UAA integration, the addition of 
another TAG bearing mutant transcript could complicate co-transfection with TAG 
mutants of CCR7. Additionally, the large size of the plasmid restricts transfection 
efficiency. A strategy was devised to remove the GFP cassette and some sections of the 
viral genome, utilising SfiI and NotI digestion, Klenow polymerase and blunt end ligation 
(summarised in figure 3.2.8). This should produce a new 8.3 kb expression vector for the 
tRNA/Synthetase pair only, dubbed “tR4-8.3”, which was confirmed by digestion with 
AgeI and NheI (figure 3.2.9). This provided a new tRNA/Synthetase expression system 
that would be more effective in downstream applications.   
3.3 Generation and evaluation of 16 TAG substitution 
mutants of CCR7 
3.3.1 Expression of C-terminal protein products in the absence of 
UAA charging 
Primers were designed for use with the Geneart site-directed mutagenesis kit to introduce 
the TAG stop codon in place of that for a range of 16 amino acids. These encompass a 
region from the N-terminal domain into the first 2 loops of the first transmembrane domain 
(figure 3.1.2), selected due to the high likelihood of involvement in chemokine/receptor 
interaction based on the two-site model of chemokine binding. The resultant plasmids were 
evaluated by restriction digest and sent for sequencing to confirm that the TAG codon 
substitution was successful, and that no other mutations were present in the CCR7 ORF. 
These were transfected into cells (without UAA or tR4-8.3) and evaluated by Western 
blotting to determine if a similar “leaky” expression to that noted when transfecting cells 
with the original pAcBac2.tR4-OMeYRS-GFP* alone could be seen with the mutants of 
CCR7 (figure 3.2.10a). Expression of a protein product of higher than expected molecular 
weight (>260 kDa), unchanged by varying denaturing conditions, was observed. 
Coomassie blue staining indicated that this could not be attributed to non-specific binding 
of the antibody to high quantities of an unknown protein product, potentially revealing in-
frame expression of the C-terminal FLAG tag in the absence of either a tRNA/Synthetase 
pair or UAA (figure 3.2.10b). In order to further evaluate this a C-terminally tagged eYFP 
fused variant of CCR7, compatible with flow cytometric and epifluorescent microscopy 
analysis, was developed, as well as two TAG mutants of this construct at an early (leucine 
47) and later (proline 62) site of substitution. When assessed by FACS analysis it became 
apparent that expression of the C-terminal tag by the TAG mutants exceeded that observed 
with WT CCR7-YFP (figure 3.2.11 a-c), in broad agreement with previous Western blot 
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data. Additionally, epiflourescent microscopy demonstrated altered cellular localisation of 
the mutants compared with WT with a concentrated YFP signal observed near the nucleus 
of the cell, as opposed to the more diffuse distribution of WT CCR7 (figure 3.2.11 d-f). 
This would confirm that, while expression of TAG mutants of CCR7 is observed in the 
absence of UAA or tRNA/Synthetase, the resultant product is not analogous to WT CCR7. 
3.3.2 Evaluation of UAA bearing mutants of CCR7 and attempted 
UV crosslinking with CCL19 or CCL21 
The ORFs for all 16 mutants as well as wild type CCR7-FLAG were excised from the 
pEF6 background using the HindIII and XhoI restriction sites and ligated into the 
pcDNA5/FRT/`TO plasmid backbone. This was done as unpublished observations 
indicated that this background could provide superior expression of inserts, and could also 
be used to generate stable cell lines using the Flp-In system if desired.  Next TAG mutants 
of CCR7-FLAG in this new vector were assessed while co-transfecting with tR4-8.3, and 
when supplemented with p-azidophenyalanine. Full-length receptor expression is 
confirmed with all 16 CCR7 mutants (figure 3.2.12 a). Unlike with the GFP reporter of 
pAcBac2.tR4-OMeYRS-GFP*, no full-length CCR7 is observed when either tR4-8.3 or 
UAA was omitted (figure 3.2.12 b&c). Staining with labelled CCL19 indicated cell surface 
localisation and ligand binding with most UAA bearing mutants (2 examples shown in 
figure 3.2.13 c&d). Expression of these mutants was compared with WT by band 
densitometry (Western blot) and MFI (FACS) (figure 3.2.14). These data indicated 
significant variation in both level of protein and ligand binding between substitution sites, 
but also significant differences between level of expression and ligand binding at some 
substitution sites (summarised in table 3.2.1). These data indicate that stop-codon 
suppression occurs with the new tRNA/Synthetase plasmid, that expression of CCR7 with 
UAA substitution is feasible, and that the resultant receptor is capable of trafficking to the 
cell surface and binding CCL19. It would also appear that expression and chemokine 
binding do not always correlate, potentially indicating altered ligand binding properties 
with UAA integration. 
Finally, UV crosslinking was attempted at each site of UAA integration with CCL19 or 
CCL21 either with cells in suspension in cuvettes (figure 3.2.15, figure 3.2.16), or directly 
on the tissue culture plate with CCL19 only (figure 3.2.17). Staining of chemokine and 
receptor at the same molecular weight was not observed with any of the mutants tested, 
indicating that covalent capture of chemokine by UAA bearing CCR7 has not occurred. 
Staining was only seen with CCL21 at a molecular weight below that predicted for CCR7 
and is most likely representative of an oligomer of CCL21. Interestingly a size shift 
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potentially consistent with the crosslinking of receptors was observed when the assay was 
performed directly on a tissue culture plate (figure 3.2.17). This could indicate successful 
activation of the UAA, followed by non-specific binding to other molecules of CCR7. 
However, no concurrent signal is seen with a-CCL19 staining.   
3.4 Discussion 
At present there are relatively few complete crystal structures of chemokine receptors, 
particularly in an unmodified ligand bound state. An arguably disproportionate number of 
these structures are of CCR5 and CXCR4 (Tan et al., 2013; Qin et al., 2015), presumably 
due to their critical role in HIV pathogenesis making them higher interest targets. Indeed, 
of the few available and efficacious small molecule antagonists against chemokine 
receptors, only maraviroc (CCR5) and plerixafor (CXCR4) are routinely used clinically. 
This correlation between the availability of detailed structural information and 
development of effective antagonists can hardly be considered incidental. Given its 
attractive position as a drug target, and the lack of complete structural information, it was 
hoped that UAA mutants of CCR7 and UV crosslinking with CCL19 or CCL21 could be 
utilised to map the interface between CCR7 and these chemokines. As well as providing 
information on critical residues in ligand binding, it was hoped that this mapping would 
reveal subtle differences between CCL19 and CCL21 binding that might account for the 
biased agonism observed with this receptor.  
To this end a CCR7 expression vector was established and evaluated. Initial attempts at 
amplification of the CCR7-FLAG ORF proved challenging (figure 3.2.1 a), potentially due 
to the long reverse primer (designed to introduce the FLAG tag) having a propensity to 
form complex secondary structures. However once established in a plasmid, digests, PCR 
(figure 3.2.2 a&b) and sequencing confirmed successful insertion of CCR7-FLAG. 
Expression in HEK293T cells was evaluated using fluorescently labelled CCL19 and flow 
cytometry (figure 3.2.3). This indicated not only that the CCR7 protein could be expressed 
in eukaryotic cells, but also that it traffics to the cell surface and can bind one of its natural 
ligands, confirming that our new plasmids expressed WT CCR7. Increasing the amount of 
plasmid transfected into HEK293T did initially increase cell surface expression (figure 
3.2.4), however this experienced a plateau in effect around 600-800 ng plasmid/well. This 
suggested that our planned co-transfection strategy of 500 ng receptor to 500 ng 
tRNA/synthetase should allow for detectable cell surface expression of CCR7. A variety of 
harvesting and denaturing conditions were evaluated (figure 3.2.5), with RIPA lysis buffer, 
100 mM DTT and incubation at 37 oC for 20 minutes being utilised in all subsequent 
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western blotting experiments due to these conditions providing the best resolution of 
CCR7-FLAG at the predicted molecular weight of 43 kDa, with the heavier, glycosylated, 
form of the receptor also observed.  
Integration of UAAs into TAG substitution mutants requires the expression of exogenous 
translational machinery, namely a tRNA to bind the non-canonical amino acid, and a 
corresponding synthetase to charge it (Takimoto et al., 2009). Unfortunately, the 
tRNA/synthetase plasmid utilised in mapping CRF1R could not be obtained. Instead 
another potentially usable construct was obtained. This came from work aiming to develop 
a viral transduction strategy for the evaluation of UAA integration via simultaneous 
delivery of tRNA, synthetase and a TAG mutant of GFP (Chatterjee et al., 2013). The viral 
genome was available in the plasmid repository Addgene (pAcBac2.tR4-OMeYRS-GFP*, 
figure 3.2.6), which could be utilised in transient transfection as well. Transfection of 
HEK293T with this construct indicated that expression of GFP can be observed when no 
UAA is provided (figure 3.2.7 a&b). This is presumably due to limited read through of the 
amber stop codon (Loughran et al., 2018), resulting in integration of an unknown canonical 
residue and ultimately translation of a functional GFP. Although this is in transient 
transfections rather than viral transduction, this is in keeping with observations from the 
original research article (Chatterjee et al., 2013), and a clear shift in fluorescence intensity 
is observed with the inclusion of UAA (figure 3.2.7 c&d). While including GFP as a 
reporter for UAA integration is tempting, stop codon suppression can be inefficient in 
terms of generating protein, with most systems including multiple copies of the tRNA 
cassettes in an attempt to overcome this (Schmied et al., 2014). Consequently, including 
multiple TAG substitution mutants in the transfection could attenuate translational 
efficiency. A two-step restriction and blunt-end ligation strategy was devised in order to 
remove the GFP cassette from the plasmid along with other elements included to aid viral 
transduction that would be less useful here (figure 3.2.8). This has the obvious advantage 
of ensuring all stop-codon suppressing activity is directed towards mutants of CCR7, as 
well as allowing a higher copy number with the same mass of plasmid. Success of this 
strategy was determined by digest (figure 3.2.9), and UAA integration activity (as 
indicated in later experiments).  
16 TAG substitution mutants of CCR7, encompassing the hinge region from the N-
terminal domain down into the first transmembrane domain, were generated. These were 
selected for initial screening in part because of the importance of this region in the classical 
“two-site” model of chemokine binding (Rajagopalan and Rajarathnam, 2006), and the 
observation of successful crosslinking quite deep into the helices of CRF1R with 
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Urocortin1 (Coin et al., 2013). Given previous observations of mutant GFP expression in 
the absence of UAA, a selection of 10 CCR7-FLAG mutants were assessed for translation 
without UAA (figure 3.2.10). These data indicated that a robust FLAG signal could be 
observed by western blotting for all mutants tested, that this was of higher indicated 
molecular weight than WT CCR7 and could not be resolved to a similar size with any 
denaturing condition tested. Staining of an identical gel with Coomassie blue revealed total 
protein distribution and did not show the presence of any large amount of protein product 
in this region that might have led to non-specific binding of the anti-FLAG antibody. YFP-
fused versions of WT CCR7 and 2 TAG mutants were generated and evaluated by flow 
cytometry and epifluorescent microscopy (figure 3.2.11). These data demonstrated a 
similar pattern of increased expression from that seen in WT, as well as altered sub-cellular 
localisation compared to WT.  
This observation of in-frame expression of C-terminal epitope tags and fluorescent 
proteins, downstream of the substituted TAG codon and without UAA, raises a number of 
questions. Primarily, does this represent a read-through past the TAG stop codon, or does 
translation cease at the stop codon but begin again from a subsequent methionine residue 
within the ORF? This is difficult to answer for a number of reasons. The molecular weight 
would indicate the mutants are, if anything, a larger protein than the WT which fits with 
neither scenario. However, it seems unlikely that these proteins result from read-through of 
the TAG codon, as this would be expected to result in very little protein and would 
represent a single site of substitution with a canonical amino acid. As such it would be 
expected, if anything, to generate a full-length version of CCR7 with very similar 
properties to WT, which doesn’t fit with our observations of high expression, altered 
cellular localisation, and increased weight on a Western blot. There is some evidence for 
truncated, intracellular CCR7 in colorectal cancer cell lines and tissues (Na et al., 2008). 
These findings were determined to be the result of truncated mRNA transcripts that lacked 
the coding region for the signal peptide of CCR7, presumed to result from alternative 
splicing or post-transcriptional changes to the mRNA. The loss of this signal peptide would 
account for the intracellular localisation and may be in line with our own findings.  
However, while alternative splicing and posttranslational modifications might be possible 
from endogenous expression, a plasmid-based expression vector obviously does not 
contain a genomic like exon/intron structure and should read as a single ORF after being 
transcribed. It may be possible that in an over-expression system such as this the premature 
stop codon allows for priming from an otherwise internal methionine, resulting in a 
truncated version of CCR7 that lacks the signal peptide and thus accumulates 
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intracellularly (in keeping with our microscopy data), and a smaller, more readily 
translatable transcript that might account for the increased expression observed by flow 
cytometry. However, this doesn’t account for the increase in indicated molecular weight, 
and it is impossible to definitively account for this for the time being. 
Expression of full-length CCR7 was observed for all 16 TAG mutants when both UAA and 
tR4-8.3 are included (figure 3.2.16), with visible differences in expression apparent 
between different sites of substitution. Based on the mapping of CRF1R there is an 
expectation that different sites would be more amenable to UAA integration than others, 
resulting in different levels of expression. As crosslinking is only possible at the cell 
surface, CCL19 staining was once again used to determine if the UAA bearing mutants 
could traffic to the cell surface and bind chemokine (figure 3.2.13). These data indicated 
greater variability in ligand binding inconsistent with total protein expression, as 
determined by western blotting. Expression of each mutant was normalised to the WT 
receptor in each assay and compared between western blotting and flow cytometry (figure 
3.2.14). This revealed several substitution sites where protein level did not correlate with 
ligand binding, with UAA substitution significantly attenuating (leucine 47, cysteine 48), 
or perhaps more surprisingly improving (lysine 50, tryptophan 59, phenylalanine 60, 
isoleucine 63) binding to CCL19. This could not be attributed to any consistent change in 
size, charge or polarity (table 3.2.2) and could be due to slight structural changes affecting 
the interaction with CCL19. This is somewhat concerning, as the rationale for using UAAs 
in this fashion is that they cause minimal disturbance to receptor structure (and 
consequently ligand binding), compared with other methods. However, these data would 
appear to indicate that even relatively minor disturbances to overall receptor structure 
(and/or residue properties) can significantly alter binding profile, making this an important 
caveat to consider when using this methodology to infer structural relationships. 
Finally, crosslinking to CCL19 or CCL21 was attempted with UAA bearing mutants of 
CCR7 (figure 3.2.15, 16 & 17). However successful crosslinking could not be observed at 
any site of substitution. Considerable efforts at optimisation were attempted, including 
altering chemokine concentration, UV irradiation time, performing the assay with cells in 
suspension or directly on the cell layer, however crosslinking could still not be observed. 
When performed on cell layers a size shift of CCR7 that could represent adducts of CCR7 
itself was observed. The region in which these substitution mutants have been generated 
does sit within a predicted CCR7 oligomerisation interface (Hauser et al., 2016). However, 
it isn’t possible to conclusively demonstrate this from these data. More importantly, it still 
does not result in chemokine crosslinking.  
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It is generally reported that crosslinking can only occur when receptor and ligand are 
within a distance of 8.9 Å, otherwise the activated UAA quenches in the aqueous 
environment surrounding the cell. It is possible that none of the 16 sites tested sit in close 
enough proximity to the chemokine, and that a wider screen of substitution sites may result 
in successful crosslinking. Given that the selected region tested is considered important to 
chemokine binding it is perhaps more likely that issues still exist in the methodology that 
prevent successful crosslinking. However, given the surprising effect UAA integration can 
have on ligand binding, and how this could impact on interpretation of crosslinking data, 
important considerations would need to be made before pursuing this methodology further. 
In summary, successful translation of UAA bearing mutants of CCR7 capable of ligand 
binding has been shown. These mutants can demonstrate altered binding properties from 
WT CCR7, although for the most part total expression and chemokine binding capacity are 
not significantly different. However most importantly, crosslinking has not been observed 
at any site of UAA integration.   
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Figure 3.1.1 Graphical representation of UAA charging and incorporation into a 
GPCR and photo-crosslinking with ligand.   
Plasmids expressing a TAG substitution mutant of a GPCR of interest and a 
tRNA/synthetase pair capable of charging and incorporating UAA in response to the TAG 
stop codon are co-transfected into eukaryotic cells in the presence of a UAA such as p-
azidophenylalanine. This results in suppression of the amber stop codon and translation of  
full length receptor including the UAA at the desired site. When ligand is incubated with 
cells expressing this mutant receptor it binds the receptor and the UAA can be activated. In 
the case of p-azidophenylalanine this results in expulsion of a molecule of N2 from the azide 
group, leaving a highly reactive nitrene that can covalently capture proteins within a distance 
of 8.9 Å. The resultant receptor/ligand adduct is visualised by western blotting, and if 
crosslinking has occurred successfully then ligand and receptor are separately detectable at 
the same size. Final panel adapted from Coin et al 2013 
Ab Against Ligand Ab Against Receptor
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Figure 3.1.2 Schematic representation of CCR7 with TAG substitution mutants 
highlighted.   
The selected sites for UAA integration are highlighted in red. Snake plot representation of 
CCR7 was adapted from http://gpcrdb.org/family/001_003_002_007/ 
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Figure 3.2.1 Amplification and digestion of CCR7-FLAG insert from human PBMC 
cDNA 
(a) A band of estimated size 1.2 kb is produced when using CCR7 targeting primers 
against cDNA generated from human PBMC RNA. A second round of PCR from this 
fragment using the same primers does not result in significant amplification. (b) Digestion 
of the predicted CCR7 sequence with SacI produced fragments of size in keeping with the 
predicted bands of 591 bp, 318 bp and 273 bp. Although an additional band of around 500 
bp was also seen in each digestion it is also present in the undigested controls (red arrow). 
This most likely represents a non-specific product from the initial PCR.  
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Figure 3.2.2 Evaluation of CCR7-FLAG (pEF6) plasmids by PCR and PstI digestion. 
(a) PCR from 12 picked and denatured colony products, using a forward CCR7 primer and 
the reverse sequencing primer from the pEF6/V5-His-TOPO kit, generated a 1.4 kb PCR 
fragment, confirming successful insertion of CCR7-FLAG in the correct orientation for 5 
out of 12 clones. (b) Digestion of the resultant plasmids with PstI produced fragments 
consistent with the predicted digestion products of 4.7, 1.7 and 0.5 kb. Images represent a 
baseline and contrast/brightness adjusted version of the same gel capture respectively. Red 
arrows highlight bands of interest. 
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Figure 3.2.3 FACS analysis of CCR7 expressing HEK293T cells indicates cell surface 
expression of the receptor. 
(a) HEK293T cells were analysed by flow cytometry. The gating strategy above was used 
to determine single, live HEK293T cells for analysis of expression of CCR7 (as indicated 
by staining with pre-conjugated biotinylated CCL19: streptavidin PE). From left to right, 
live cells were determined by DRAQ7 exclusion, with a gate applied on non-fluorescent 
cells. The main population of HEK293T cells was determined by comparing size (forward 
scatter) with granularity (side scatter), and single cells evaluated by comparing the height 
and area measures obtained for side scatter. With slight modifications this gating strategy 
was used on all subsequent FACS analysis using fluorescently bound chemokines. Staining 
with CCL19 is shown for HEK293T cells transiently transfected with empty vector (b), 
CCR7 clone 51.2.30.1 (c) and 52.2.250.1 (d). A CCR7 “positive” gate is applied based on 
the empty vector control in order to account for non-specific binding of CCL19 to cell 
surface glycans.  
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Figure 3.2.4 Surface expression of CCR7 plateaus with increasing plasmid 
concentration. 
Increasing quantities of plasmid were transiently transfected into HEK293T cells seeded 
on a 12-well tissue culture plate. Transfected cells were again subjected to FACS analysis 
48 hours post-transfection and stained with fluorescently labelled CCL19 (streptavidin-
BV421) at a concentration of 25 nM. Cell count (Count, y-axis) and the fluorescence 
intensity of chemokine staining (CCL19-SABV421, x-axis) were plotted against each 
other. 
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Figure 3.2.5 Western blotting for CCR7-FLAG confirms receptor expression and 
indicates optimal sample preparation conditions. 
(a) Cells transfected with empty vector or CCR7-FLAG were harvested in either TritonX, 
SDS Urea or RIPA lysis buffer, and reduced with 100 or 400 mM DTT before being 
separated by SDS-PAGE and transferred to PVDF membrane, then incubated with 
antibodies sensitive to FLAG-tag and human GAPDH. (b) Lysate from CCR7-FLAG 
transfected HEK293T cells was subjected to varying denaturing temperatures and 
incubation times at a constant DTT concentration of 100 mM. 
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Figure 3.2.6 Plasmid map of pAcBac2.tR4-OMeYRS-GFP* 
The above plasmid map was generated using CLC Genomics software and the complete 
plasmid sequence, provided by Addgene. Feature sequences are highlighted where possible 
from information provided in the original reference (see text).  
CMV: Cytomegalovirus immediate early promoter 
CAG: synthetic promoter consisting of the CMV early enhancer element, the promoter, 
first exon and first intron of the chicken b-actin gene and the splice acceptor of the rabbit 
b-globin gene.  
VSV-G: viral envelope glycoprotein 
GFP*: amber stop codon bearing mutant of GFP 
WPRE: Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element 
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Figure 3.2.7 Expression of UAA bearing GFP in HEK293T cells. 
HEK293T cells were transiently transfected with pAcBac2.tR4-OMeYRS-GFP* and 
maintained in media either free from (a&b) or supplemented with (c&d) 1 mM p-
azidophenylalanine, and expression of GFP assessed by flow cytometry. GFP+ gate was 
applied based on cells transfected with empty vector only.    
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Figure 3.2.8 Graphical summary of tR4-8.3 restriction strategy. 
The original pAcBac2.tR4-OMeYRS-GFP*  plasmid was subjected to a 2-step digestion 
first with NotI then SfiI. The 8.3 kb linear product that resulted was then purified and 
treated with Klenow polymerase fragment, removing the 3’ overhangs left from the 
restriction reaction. This was then blunt end ligated with T4 DNA ligase, to close this into 
a new plasmid dubbed “tR4-8.3”, ready for bacterial transformation.  
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Figure 3.2.9 Restriction digest of tR4-8.3 with AgeI and NheI. 
To evaluate the new tR4-8.3 construct 3 clones were picked, plasmid prepared, restriction 
digest carried out with 2 different enzymes, AgeI and NheI, and comparison made with the 
unaltered pAcBac2.tR4-OMeYRS-GFP*. This reaction is predicted to result in the 
following fragment sizes: 
AgeI;   pAcBac2.tR4-OMeYRS-GFP = 4.9, 3.8, 3.3 & 1.4 kb.  
  tR4-8.3 = 4.9 & 3.3 kb.  
NheI;   pAcBac2.tR4-OMeYRS-GFP = 13.4 kb.  
  tR4-8.3 = 8.3 kb. 
A single clone, 8.3.250.1, was used from this point forward.  
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Figure 3.2.10 TAG substitution mutants of CCR7 are expressed in the absence of 
both UAA or compatible tRNA/synthetase: western blot & Coomassie blue staining. 
(a) Whole cell lysate from HEK293T transfected with either empty vector, WT CCR7-
FLAG or one of the TAG substitution mutants of CCR7-FLAG were reduced, denatured 
using a final concentration of 100 mM DTT with varying temperatures and incubation 
times, then assessed by western blotting for FLAG (CCR7) and human GAPDH (loading 
control). (b) Coomassie blue staining of an identical gel was also done to reveal total 
protein distribution.   
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Figure 3.2.11 TAG substitution mutants of CCR7 are expressed in the absence of 
both UAA or a compatible tRNA/synthetase pair: FACS and epiflourescence 
microscopy. 
Plasmids expressing WT CCR7-YFP (a&d), Leu47TAG CCR7-YFP (b&e) and Pro62TAG 
CCR7-YFP (c&f), were transfected into HEK293T cells, then evaluated by flow cytometry 
(a-c) or epiflourescence microscopy (d-f). A YFP+ gate was applied based on the empty 
vector control from the same experiment. Images are representative of multiple fields of 
view.  
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Figure 3.2.12 Integration of p-azidophenylalanine into CCR7; western blotting. 
HEK293T cells were transiently transfected with empty vector, CCR7-FLAG or one of the 
16 TAG substitution mutants of CCR7-FLAG, whole cell lysate obtained, and the resultant 
blots probed for full length CCR7 expression (FLAG) and GAPDH. Cells were (a) 
additionally transfected in a 1:1 ratio with tR4-8.3 and media supplemented with 1 mM p-
azidophenylalanine, (b) transfected with tR4-8.3 but not supplemented with the UAA or (c) 
transfected with empty vector in place of tR4-8.3 and media supplemented with UAA. n.b. 
Vehicle and wild type controls were swapped in (c), the loading order is otherwise 
unchanged from (a) and (b).   
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Figure 3.2.13 Integration of p-azidophenylalanine into CCR7; flow cytometry. 
Cell surface expression of CCR7 was once again evaluated utilising labelled CCL19. Here 
exemplar FACS plots from HEK293T cells transiently transfected with tR4-8.3 and either 
empty vector (a), wild type CCR7 (b) or a selection of 2 TAG substitution CCR7 mutants 
(c&d) are shown.  
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Figure 3.2.14 Integration of p-azidophenylalanine into CCR7; western blotting 
compared with flow cytometry. 
Expression as evaluated by both western blotting of whole cell lysate (blue), and 
assessment of binding to fluorescently labelled CCL19 by flow cytometry (red), were 
compared. Band densitometry was determined using the ImageJ gel analyser tool for both 
FLAG (CCR7) and GAPDH (loading control), with relative expression calculated as 
FLAG/GAPDH, which was then expressed as a percentage of wild type CCR7 in the same 
experiment. CCL19 staining was enumerated as a percentage of wild type CCR7 for all 16 
TAG substitution mutants by obtaining mean fluorescence intensity (MFI) values of all 
cells in the live singlet population in the PE channel, and subtracting the MFI from empty 
vector transfected controls from all samples as non-specific chemokine 
binding/background prior to calculating percentage. (n=3 biological replicates ± SD) 
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Table 3.2.1 Integration of p-azidophenylalanine into CCR7; summary of 
differences in receptor expression as determined by Western blotting and flow 
cytometry. 
Evaluation of expression of UAA bearing mutants of CCR7, as determined by either 
Western blotting or flow cytometry, revealed significant differences between the two 
modalities. Here the data presented in figure 3.2.14 is listed and compared. The mean value 
(% of wild type CCR7) of 3 biological replicates obtained from each is listed here, along 
with the “difference” between measures (WB mean - FACS mean = difference), and the 
statistical significance of this difference expressed with the P value (one-way ANOVA 
with post hoc Holm-Sidak correction). 
 
  
Substitution: WB mean: FACS mean: Difference: P value:
47 8.7 1.9 6.8 0.00150
48 6.7 -0.7 7.4 0.00390
50 7.2 22.9 -15.7 0.00276
51 12.6 6.6 6.0 0.06059
52 5.9 8.0 -2.0 0.52253
53 8.8 8.0 0.8 0.63698
54 5.1 1.1 3.9 0.07851
55 7.0 18.5 -11.5 0.05651
56 7.0 11.4 -4.4 0.11028
57 11.6 3.3 8.3 0.09178
58 10.0 15.8 -5.7 0.19697
59 8.5 22.7 -14.2 0.00180
60 4.4 20.9 -16.6 0.02163
61 21.4 16.9 4.6 0.53680
62 5.3 7.4 -2.1 0.11270
63 2.4 19.3 -16.9 0.00864
97 
 
 
Figure 3.2.15 Photoactivation of p-azidophenylalanine fails to capture chemokine at 
any substitution site; CCL19 (cuvette) 
Cells expressing either WT CCR7-FLAG or one of the 16 UAA bearing mutants (selection 
of 12 shown here) were lifted by mechanical disruption of the cell layer in ice-cold PBS, 
incubated with 100 nM CCL19 and transferred to cuvettes before being exposed to UV 
radiation. Whole cell lysate was obtained and evaluated for CCL19, FLAG (CCR7) and 
GAPDH by western blotting. Representative of 3 independent experiments.  
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Figure 3.2.16 Photoactivation of p-azidophenylalanine fails to capture chemokine at 
any substitution site; CCL21 (cuvette) 
Cells expressing either WT CCR7-FLAG or one of the 16 UAA bearing mutants (selection 
of 12 shown here) were lifted, incubated with 100 nM CCL21 and transferred to cuvettes 
before being exposed to UV radiation. Whole cell lysate was obtained and evaluated for 
CCL21, FLAG (CCR7) and GAPDH by western blotting. Representative of 3 independent 
experiments.  
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Figure 3.2.17 Photoactivation of p-azidophenylalanine fails to capture chemokine at 
any substitution site; CCL19 (plate) 
Cells expressing either WT CCR7-FLAG or one of a selection of 10 of the original 16 
UAA bearing mutants were incubated with 100 nM CCL19 before being exposed to UV 
radiation on the tissue culture plate. Whole cell lysate was obtained and evaluated for 
CCL19, FLAG (CCR7) and GAPDH by western blotting.  
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4 Evaluation of the ligand bias of CCR4, CCR7 and 
CCR10 
4.1 Introduction 
Chemokine biology is marked by both a high number of gene duplication events, low 
sequence homology and functional redundancy of ligands (often seen in inflammatory 
chemokine signalling), as well as highly conserved single ligand/receptor couplings that 
have endured more or less unchanged since first emerging. This disparity can be quite 
jarring. For example, CCR2 can bind CCL2, 7, 8, 11, 13, 16 and 26 (Charo and Ransohoff, 
2006), whereas CXCR4, frequently regarded as the primordial chemokine receptor, has 
only ever demonstrated binding to one chemokine, CXCL12 (Gangadhar, Nandi and 
Salgia, 2010). Evolutionary forces have driven extensive gene duplication for the ligands 
of CCR2, presumably pushed by the needs of an increasingly complex immune system, 
while conserving the status quo in the CXCL12/CXCR4 signalling axis (Zlotnik, Yoshie 
and Nomiyama, 2006). Indeed, genetic ablation of either CXCR4 or CXCL12 is perinatally 
lethal, with significant defects in haematopoiesis and bone marrow engraftment, 
angiogenesis and cardiac formation, neurogenesis and renal development, suggesting the 
requirement for conservation over divergence in this coupling (Ara et al., 2005; 
Takabatake et al., 2009; Zhu and Murakami, 2012). Conversely CCR2 knockout animals 
have few overt physiological differences to wild type, with defects in myeloid recruitment 
and a resultant altered phenotype only readily apparent during models of inflammation, 
injury and cancer (Boring et al., 1997; Willenborg et al., 2012; Li et al., 2013).  
However, there are multiple chemokine receptors that have evolved to interact with only a 
pair of ligands. As mentioned previously these include CCR4, CCR7 and CCR10. Perhaps 
more interesting though is that within each signalling axis a very similar pattern of biased 
agonism has developed, with one arrestin (CCL22, CCL19, CCL27) and one G-protein 
(CCL17, CCL21, CCL28) biased chemokine interacting with each receptor (Mariani et al., 
2004; Rajagopal et al., 2013; Corbisier et al., 2015). Additionally, high sequence 
conservation has resulted in chemokines capable of cross-species receptor interaction in 
the case of CCL19 with CCR7 (previous unpublished observations from our group). This 
implies some evolutionary advantage in initially duplicating a single chemokine for each 
receptor and permitting divergence in signalling properties and/or tissue expression pattern 
within this pair. However subsequent to this these chemokine pairs are maintained with 
minor, or no, further duplication events, which has occurred on at least 3 separate 
occasions.  
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We know from knockout studies in mice that loss of CCL19 and CCL21 carry distinct 
phenotypes. Loss of both CCL19 and CCL21(ser) in plt/plt mice results in significantly 
altered secondary lymphoid organ (SLO) architecture, with the distinction between T-cell 
and B-cell zones lost, and an attenuation of recruitment of T-cells and DCs to SLOs 
resulting in impaired/delayed antigen specific immune responses (Gunn et al., 1999). 
CCL19 knockout alone however demonstrates normal SLO structure and cellular 
recruitment to SLOs in these animals, but poorer naive T-cell survival, as demonstrated by 
adoptive transfer experiments (Britschgi, Favre and Luther, 2010). Additionally, CCL19 
and CCL21 have distinct tissue distributions. Due to its avid glycan binding capacity, 
CCL21 gradients have been demonstrated within the lymphatic vessels of the skin (Weber 
et al., 2013) and the roof of the subcapsular sinus of LNs, maintained by the atypical 
chemokine receptor ACKR4 (Ulvmar et al., 2014), in one of the only demonstrations of 
chemokine gradients in vivo. CCL21 is expressed by HEVs and fibroblastic reticular cells 
of the T-cell zones (Carlsen et al., 2005). Basal expression of CCL19 however is restricted 
to just fibroblastic reticular cells of the T-cell zone (Link et al., 2007). This, in conjunction 
with their unique signalling profiles, would indicate that duplication of an ancestral 
chemokine in this case was not to introduce redundancy into the system and has instead 
resulted in functionally distinct ligands for CCR7.  
The ligands of CCR10 have an even more disparate tissue distribution at rest; CCL27 is 
expressed almost exclusively by keratinocytes in the skin (Morales et al., 1999) and drives 
the recruitment of a selection of skin-tropic T-cell subsets to this organ. CCL28 on the 
other hand is expressed by the mucosal epithelium of various tissues (Pan et al., 2000), 
where it is thought to act to retain IgA producing plasmablasts in these tissues and may 
additionally act directly as an anti-microbial agent due to its elongated and charged C-
terminus. These distinct tissue distributions also fit well with the presumed biased agonism 
of CCR7 and CCR10; with a G-protein biased agonist retaining/guiding cells into tissues, 
and a b-arrestin biased agonist guiding cells within tissues, eventually leading to 
desensitisation of their cognate receptors and loss of localisation cues from these 
chemokines.  
Given the intriguing and complex evolutionary history of this 2-chemokine model, as well 
as the potential implications in both healthy and disease states, there is a need to further 
evaluate receptors that demonstrate this curious property. This is particularly true of CCR4, 
which lacks the more detailed signalling data available for CCR7 and CCR10 (Rajagopal 
et al., 2013; Corbisier et al., 2015). Like CCR7, distribution of the cognate ligands of 
CCR4 is presumed to follow a similar pattern of a G-protein biased agonist (CCL17) 
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providing initial guidance cues, in this case resulting in extravasation of CCR4 expressing 
T-cells from the blood into skin, and an arrestin biased agonist (CCL22) providing 
guidance within the tissue before desensitising these cells to CCR4 signalling (Yoshie and 
Matsushima, 2015).   
Expression of CCL17 and CCL22 was evaluated in inflamed tissues compared to 
untreated, in order to determine if the normally controlled expression of these homeostatic 
chemokines is altered in response to inflammatory insult and determine what (if any) 
bearing this might have on CCR4 activity. The recruitment of specific signalling apparatus 
to CCR4, CCR7 and CCR10 as a result of interaction with their cognate ligands was 
assessed, with the intention to create a more complete signalling profile than that currently 
available, in particular for CCR4. Bioluminescence resonance energy transfer (BRET) 
based assays were used to evaluate the association of signalling machinery and chemokine 
receptors in response to chemokine. BRET is described as the non-radiative transfer of 
energy from a ‘donor’, typically a luciferase, to an ‘acceptor’ fluorescent protein whose 
excitation spectrum overlaps with the emission spectrum of the ‘donor’, like YFP (Brown, 
Blumer and Hepler, 2015). This is in fact a natural process of some marine species (Ward 
and Cormier, 1979). If the distance between the two closes to less than 10 nm then the 
luciferase, instead of emitting light, directly transfers the energy required for light emission 
by a non-radiative process to YFP. This results in a reduction in luciferase output and 
emission from YFP.  
It is possible in HEK293T cells to express both a ‘donor’ and ‘acceptor’ fused to proteins 
of interest in order to analyse the interaction between the two. In the case of b-arrestin 
recruitment, a fusion of renilla luciferase with either b-arrestin 1 or 2 is co-transfected with 
C-terminally yellow fluorescent protein (YFP) tagged CCR4 or CCR7. Luciferase and YFP 
signal can be detected separately, and at rest the gain for each channel is adjusted such that 
the ratio of YFP/Luciferase signal is as near to 1 as possible. Association of chemokine 
with the receptors triggers for b-arrestin recruitment, closing the distance between ‘donor’ 
and ‘acceptor’ to below 10 nm, resulting in BRET and consequently an increase in YFP 
emission. This increases the ratio above 1 giving a “BRET signal”, with this increase being 
proportional to amount of chemokine applied, allowing for the determination of pEC50 
values of recruitment for each ligand (summarised in figure 4.1.1).  
The recruitment of Ga subunits to GPCRs by their ligands can also be assessed utilising 
BRET based methods, however this requires some additional considerations. In this 
instance, a single molecule construct (known as a systematic protein affinity strength 
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modulation, or SPASM, biosensor) is used in place of two separate fusion proteins (Malik 
et al., 2017). Here the chemokine receptor is linked to a fluorescent ‘acceptor’, nano-
luciferase ‘donor’ and a peptide fragment of a Ga subunit sufficient for recruitment to the 
receptor, with each separated by linker regions that maintain flexibility. Due to the plasmid 
background in which these constructs sit (pcDNA5/FRT/TO) it is possible to generate 
stable cell lines using the Flp-In T-Rex system (Ward, Alvarez-Curto and Milligan, 2011). 
In brief, compatible cell lines (in this case HEK293) have a defined genetic locus into 
which the plasmid is placed when it is co-transfected with a second plasmid expressing Flp 
recombinase. The Flp-in T-Rex 293 cell line stably express Tet repressive protein (TetR), 
which binds compatible elements in the SPASM biosensors promoter, effectively silencing 
expression. Treatment with doxycycline binds TetR, releasing expression. While it is 
possible to perform BRET experiments utilising a similar separate luciferase fused G-
protein donor (Corbisier et al., 2015), this SPASM system holds a number of advantages. 
Once established expression is induced by the treatment of doxycycline, saving on the cost 
and variability of utilising transient transfections, insures a consistent level of expression 
between cells in a population, with expression level controllable by the administration of 
varying concentrations of doxycycline where required. As well, the SPASM biosensor 
guarantees a 1:1 stoichiometry of donor to acceptor, reducing the chances of excessive 
background donor signal that could result from using a multi-plasmid transfection strategy.  
Expression of the biosensor is induced 24 hours prior to analysis, and from here the 
methodology is much the same as that used to assess b-arrestin recruitment. In essence the 
gain for ‘donor’ and ‘acceptor’ are again adjusted to a ratio of 1. Association of chemokine 
with receptor initiates recruitment of the Ga peptide causing a change in structural 
conformation that closes the distance between ‘donor’ and ‘acceptor’ below 10 nm, 
resulting in BRET. Again, the change in ratio relative to concentration of chemokine 
applied can be measured (summarised in figure 4.1.2). Sensors were already available 
capable of measuring recruitment of Gi1/2 and Gi3 to other receptors (due to sequence 
conservation Gi1 and Gi2 specific reporters are not available). As such constructs 
expressing sensors for Gi1/2 and Gi3 recruitment to either CCR4 or CCR7 were created, 
and stable cell lines generated. Using these, recruitment of signalling apparatus resulting 
from binding of CCL17 and CCL22 to CCR4, CCL19 and CCL21 to CCR7 and CCL27 
and CCL28 to CCR10 was evaluated.   
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4.2 Assessment of CCR4 ligand expression and biased 
signalling 
4.2.1 Imiquimod treatment of skin decreases expression of the 
CCR4 ligand CCL22 
Daily imiquimod treatment of mouse skin is a well-established model, giving rise to the 
formation of a psoriasis like skin lesion characterised by hyperkeratosis and an extensive 
immune cell infiltrate (van der Fits et al., 2009). The latter aspect of imiquimod treatment 
was of interest as the ligands of CCR4 are frequently associated with trafficking of a 
number of T-cell subtypes to the skin and expression may be disrupted by the heavy 
inflammatory insult inflicted by imiquimod treatment. RNA was extracted from lesional 
skin tissue at various time points as well as from vehicle treated control skin, normalised 
by RNA concentration and converted to cDNA. Primers were designed for the 
amplification of CCL17 and CCL22, and expression relative to a housekeeping gene (TBP) 
determined by qPCR utilising the 2-DDCT method of comparative analysis (figure 4.2.1 
a&b). Interestingly there was a significant drop (p=0.0265) in expression of CCL22 with 
imiquimod treatment at the 4 and 24-hour timepoints (4h Veh=1.03±0.18, 4h 
Imq=0.39±0.03, 24h Veh=1.07±0.29, 24 Imq=0.27±0.01. Units are fold change in all uses 
of 2-DDCT comparative analysis. n=3±SEM for 4h and 1d timepoints, n=4±SEM for all 
others ) (figure 4.2.1 b). Although significant differences were not noted at any other 
timepoint evaluated, there is a trend to lower expression of CCL22 in treated animals 
compared with vehicle controls. CCL17 expression however appeared unchanged by the 
treatment conditions across all timepoints (figure 4.2.1 a). These data indicate that CCL22 
expression can be modulated by inflammatory conditions despite being characterised as a 
homeostatic chemokine. 
4.2.2 CCL17 and CCL22 demonstrate signalling bias at the level 
of b-arrestin and G-protein recruitment 
The capacity of CCL17 and CCL22 to enlist either b-arrestin 1 or 2 to CCR4 was 
compared by treatment with a ligand concentration range from 0.01 nM to 1 µM (figure 
4.2.2). These data indicated that while both CCL17 and CCL22 could recruit either b-
arrestin 1 or 2, with recruitment following a clear dose-response relationship, CCL22 
generated a considerably higher Emax of 0.223±0.007 with b-arrestin 1 and 0.280±0.028 
with b-arrestin 2 (n=3±SEM. This is consistent for all BRET experiments unless otherwise 
stated). CCL17 generated Emax values of 0.025±0.002 and 0.033±0.002 in the same 
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assays. Indeed, values for CCL17 recruitment need to be plotted separately in order to 
more readily reveal this response (figure 4.2.2 c&d). pEC50 of b-arrestin recruitment 
differed between the two, with a significant drop (p=0.012) between CCL17 and CCL22 
potency from 7.63±0.09  to 8.02 ± 0.01  for recruitment of b-arrestin 1, and from 
7.72±0.11  to 7.99±0.10  for b-arrestin 2 recruitment (figure 4.2.3 a). When comparing 
pEC50 of b-arrestin 1 or 2 recruitment for each chemokine no significant differences are 
apparent. Emax achieved by either chemokine within each assay was compared (referred to 
as Emax here, figure 4.2.3 b) and revealed significant differences in Emax obtained by 
each chemokine (b-arrestin 1; p=<0.0001. b-arrestin 2; p=0.001). Again, no significant 
difference is noted between b-arrestin 1 or 2 Emax with either CCL17 or CCL22.  
By treating cells with a single concentration of chemokine, in this instance 100 nM, and 
taking repeated measures over a 30-minute period it is possible to determine the kinetics of 
b-arrestin 2’s association with CCR4 in response to its ligands (figure 4.2.4 a). Kinetics of 
b-arrestin 1 recruitment were not analysed as the data reported above indicated little 
appreciable difference between b-arrestin 1 or 2 recruitment. These data indicated that 
while CCL22 instigated a rapid and lasting association of b-arrestin with CCR4, CCL17 
appears to initiate only a short-lived association before becoming indistinguishable from 
the no-chemokine (NC) control treated cells. BRET ratio values obtained were constrained 
to the first 3 minutes of measurement (as this was consistently the timepoint at which 
CCL22 response peaked) and the time to half-maximal signal (half-time) compared 
between CCL17 and CCL22, assuming a one-phase association (figure 4.2.4 b). This 
revealed that CCL17 has a significantly lower halftime of 0.60±0.08 minutes compared to 
CCL22’s halftime of 1.00±0.12 minutes (n=3±SEM. This is consistent for all kinetic 
experiments). Collectively these findings indicate that, while both CCL17 and CCL22 can 
recruit either b-arrestin, CCL22 is clearly the more potent ligand in this regard. Indeed, 
CCL17 incubation appeared to result in only minor and momentary recruitment of b-
arrestin to CCR4. 
Recruitment of Gi1/2 or Gi3 by CCL17 and CCL22 was also evaluated, in this instance 
using a ligand concentration range from 0.1 nM to 300 nM. Interestingly this revealed that 
while CCL22 readily recruited both Gi1/2 and Gi3, with an pEC50 of 8.05±0.03 , and 
8.08±0.06  respectively, CCL17 appeared completely incapable of doing so at any 
concentration tested (figure 4.2.5 a). Comparison of pEC50 for recruitment of Gi1/2 and 
Gi3 by CCL22 revealed no significant differences (figure 4.2.5 b). This indicated that, in 
addition to being a poor ligand in terms of b-arrestin recruitment, CCL17 is also attenuated 
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in its ability to recruit Gi-proteins to CCR4 when compared to CCL22. Relative efficacy 
(RA) was calculated as described previously (Gundry et al., 2017), with values listed in 
table 4.2.1. 
4.3 Assessment of the ligand bias of CCR7 
4.3.1 CCL19 appears dominant in both b-arrestin and Gi 
recruitment 
b-arrestin recruitment to CCR7, induced by either CCL19 or CCL21, was evaluated in the 
same manner as CCR4. CCL19 and CCL21 were both readily capable of initiating b-
arrestin 1&2 recruitment to CCR7 (figure 4.2.6 a&b), with broadly similar Emax values 
obtained by both chemokines (b-arrestin 1; CCL19=0.868±0.213, CCL21=0.804±0.251. b-
arrestin 2; CCL19=0.718±0.040, CCL21=0.652±0.061). pEC50 values were significantly 
different between CCL19 and CCL21 with both b-arrestin 1 (7.77±0.10 and 7.17±0.08  
respectively, p=0.0106) and b-arrestin 2 (7.85±0.08 and 7.18±0.01  respectively, 
p=0.0012) (figure 4.2.6 c). Similar to assessment of CCR4, no significant difference in 
pEC50 between b-arrestin 1 or 2 recruitment is noted with either CCL19 or CCL21. 
Analysis of the kinetics of b-arrestin 2 recruitment following treatment with 100 nM of 
either CCL19 or CCL21 revealed that, unlike CCL17 with CCR4, association of b-arrestin 
2 and CCR7 in response to CCL21 is sustained and is clearly distinct from vehicle controls 
(NC) (figure 4.2.7 a). Half-time measurements were again taken and indicated that CCL19 
has a significantly lower half-time (p=0.0013) than CCL21 in terms of b-arrestin 2 
recruitment to CCR7 (CCL19 = 3.22±0.12 minutes, CCL21 = 6.45±0.39 minutes 
n=3±SEM, figure 4.2.7 b). It does appear though that, in terms of BRET ratio, there are 
some differences in these assays compared with what was previously demonstrated in 
figure 4.2.6 b. CCL19 appears to generate a higher BRET ratio at 100 nM than observed 
previously (over 2.0 compared with ~1.75), whereas CCL21 conversely generates a lower 
signal than previously at this concentration (~1.2 compared with ~1.5). This variability is 
somewhat concerning, however may be attributable to batch variability between different 
experiments as batch number was not matched between these different sets of experiments. 
Regardless, it would appear that, while both CCL19 and CCL21 readily cause association 
of b-arrestin 1 or 2 with CCR7, CCL19 is both faster acting and more potent than CCL21 
in these assays. 
Recruitment of either Gi1/2 or Gi3 to CCR7 in response to either CCL19 or CCL21 was 
evaluated in the same manner as previously shown for CCR4 (figure 4.2.8 a&b). These 
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data indicated a striking difference in the G-protein recruitment profiles of CCL19 and 
CCL21. Although there is increasing response with rising concentrations of CCL21 for 
both Gi1/2 and Gi3, the Emax generated is significantly lower than that seen with CCL19 
with both G-protein reporters (Gi1/2; CCL19 = 0.113±0.007, CCL21 = 0.017±0.005, 
p=0.0003. Gi3; CCL19 = 0.175±0.010, CCL21 = 0.043±0.004, p=0.0002. figure 4.2.8 c). 
Consistent pEC50 values were obtained with CCL19 between experiments (Gi1/2 = 
7.67±0.03 , Gi3 = 7.67±0.06 ), with no significant differences noted between Gi1/2 and 
Gi3 recruitment (figure 4.2.9 d). pEC50 of CCL21 mediated Gi-protein recruitment was 
more variable between repeat experiments (Gi1/2 = 7.24±0.30 , Gi3 = 7.00±0.15 . figure 
4.2.9 d), and once again no significant differences were noted in pEC50 of recruitment of 
either Gi1/2 or Gi3 instigated by CCL21. CCL19 did however appear to be a significantly 
more potent ligand than CCL21 in terms of Gi3 recruitment (p=0.0132, figure 4.2.9d). RA 
was calculated as before and used to assign a bias factor to CCL21, using CCL19 as the 
reference ligand, and assigning b-arrestin 2 and Gi3 recruitment as pathway a and b 
respectively (Gundry et al., 2017). This generated a bias factor of 0.59±0.12. Previous 
work assessing the ligand bias of CCR7 in a similar manner determined a biased ligand as 
having a factor greater than 1 (Corbisier et al., 2015). Based on these criteria these data 
would appear to indicate that CCL21 is a poorer ligand for CCR7 in both signalling 
pathways, rather than a G-protein biased agonist as reported previously.  
4.4 Assessment of the ligand bias of CCR10 
Once again, BRET based methods were used to interrogate the signalling profile of the 
cognate ligands of CCR10, CCL27 and CCL28. Initially, recruitment of b-arrestin 2 was 
assessed in the same manner as previously conducted, transfecting ‘acceptor’ (CCR10-
YFP) and ‘donor’ (b-arrestin 2-rLuc) into HEK293T cells at a ratio of 4:1 (as used in 
CCR4 and CCR7 b-arrestin analysis) in response to a concentration range of CCL27 and 
CCL28 of 0.1-300 nM (figure 4.2.9 a). This resulted in a similar signalling profile to that 
seen with CCR4/CCL17&22. CCL27 appeared capable of readily instigating recruitment 
of b-arrestin 2 to CCR10 with an pEC50 of 7.12±0.25  (n=2±SEM), whereas CCL28 
appeared incapable of this. However, assessing b-arrestin recruitment in this manner 
proved difficult to reliably repeat, with significant variation in pEC50 of CCL27 mediated 
recruitment between two repeat measures, and considerable difficulty in obtaining a third. 
In BRET experiments the best “BRET signal”, and consequently best data quality, is 
obtained when there is no excess of ‘donor’ proteins (i.e. the luciferase fused with b-
arrestin 2) to ‘acceptor’ (the C-terminal YFP moiety fused to receptors of interest) at the 
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cell membrane. In an effort to improve data quality and reproducibility an increased 
‘acceptor’ to ‘donor’ ratio of 9:1 was used when transfecting cells, utilising the same 
chemokine range (figure 4.2.9 b). These data again indicated that, while CCL27 triggered 
b-arrestin 2 recruitment by CCR10 with an pEC50 of 6.99±0.01  (n=2±SEM), CCL28 
remained incapable of doing so. However, while this ratio resulted in more consistent 
pEC50 values for CCL27 between experiments, again obtaining a suitable number of repeat 
experiments proved difficult. It is unclear as to why this might be, however could be 
attributable to poor expression and/or cell surface localisation of CCR10 compared with 
CCR4 and CCR7.  
Finally, a b-arrestin 2-nanoluciferase (nLuc) expression vector was used in place of the b-
arrestin 2-rLuc construct used previously. A fusion of b-arrestin 2 with nanoluciferase 
results in a ‘donor’ capable of producing considerably greater luciferase signal, allowing 
for higher ‘acceptor’: ‘donor’ ratios to be attempted than are possible when using renilla 
luciferase-based ‘donor’s. CCR10-YFP and b-arrestin 2-nluc were transfected into 
HEK293T cells in a ratio of 4.9 µg to 100 ng, and recruitment of b-arrestin 2 in response to 
a range of CCL27 and CCL28 concentrations from 0.3 nM- 1 µM was assessed (figure 
4.2.9 c). Treatment with CCL27 mediated b-arrestin 2 recruitment by CCR10 with an 
pEC50 of 6.99±0.06 , with improved signal (increased BRET ratio) and reproducibility, 
however CCL28 treatment still had no effect. pEC50 values of b-arrestin 2 recruitment 
achieved by CCL27 were compared between the different experimental conditions tested 
(figure 4.2.9 d) and indicated no significant differences between pEC50 values obtained 
utilising different ‘acceptor’: ‘donor’ ratios. Collectively these data support previous work 
asserting that CCL27 is an arrestin biased ligand of CCR10 and indicate that CCL28 
appears incapable of triggering b-arrestin recruitment by CCR10 at any concentration 
tested. An RA value for CCL27 was generated based on experiments utilising nLuc fused 
b-arrestin 2 only and are listed in table 4.2.1.  
Recruitment of Gi1/2 (figure 4.2.10 a&c) and Gi3 (figure 4.2.10 b&d) to CCR10 in 
response to either CCL27 or CCL28 treatment was assessed using SPASM biosensors in 
the same manner as employed with CCR4 and CCR7. Unfortunately, repeated measures 
using these biosensors either failed to generate a detectable BRET signal, or in the 
experiments listed above generated conflicting data. In one experiment (figure 4.2.10 a&c) 
CCL27 appears to initiate G-protein coupling to CCR10, with a pEC50 of 6.98  for Gi1/2 
recruitment and 6.81  for Gi3. CCL28 conversely triggered no apparent recruitment of 
Gi1/2 by CCR10 (figure 4.2.10 a), similar to CCL17 with CCR4 (figure 4.2.5 a), and 
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relatively poor recruitment of Gi3 with a pEC50 of 6.70, similar to CCL21 with CCR7. 
However, in subsequent experiments CCL28 generated a higher Emax of Gi1/2 
recruitment by CCR10 than is obtained by CCL27 (1.073 and 1.038 respectively, figure 
4.2.10 c), though also a higher pEC50 (5.72 compared with 6.64 for CCL27). Recruitment 
of Gi3 by CCR10 in response to either CCL27 or CCL28 generated similar Emax values 
(1.115 and 1.095 respectively, figure 4.2.10 d), but again demonstrated considerable 
differences in the corresponding pEC50 values (6.01 for CCL27 and 2.95 for CCL28).  
These data would appear to indicate that CCL27 can trigger Gi-protein recruitment by 
CCR10. However, with the substantial differences between experiments, and the 
considerably higher than expected pEC50 values of CCL28 mediated recruitment that have 
been obtained, it is unclear if CCL28 can in fact trigger G-protein recruitment to CCR10.    
pEC50 Emax and RA values are listed in table 4.2.1. Half-time values are summarised in 
table 4.2.2.  
4.5 Development and evaluation of biotinylated 
chemokines 
Given the unexpected signalling profiles of CCL17 and CCL28, there was interest in 
identifying if these chemokines interact with their cognate receptors in our hands. Cells 
expressing chemokine receptors of interest can be analysed by flow cytometry using 
fluorescently labelled chemokines (figure 3.2.3). As well as allowing for the evaluation of 
chemokine receptor expression, it is also possible to gain additional information about 
receptor characteristics using labelled chemokines that is not available from traditional 
antibody staining. For example, by staining with a constant concentration (25 nM) of 
labelled chemokine in the presence of a range of concentrations of unlabelled competitor 
chemokine it is possible to gain information on the affinity of the unlabelled chemokines 
for their cognate receptor in much the same manner as with radiolabel-based assays, but 
without the requirement for special equipment, training or precautionary measures. 
However directly fluorescently labelled chemokines, or those with site-specific biotin 
moieties, are expensive, and in the case of both cognate ligands of CCR10 were simply not 
available at the time of this analysis. It would be advantageous to be able to develop 
biotinylated chemokines in-house if possible.  
To assess this unlabelled CCL19 was biotinylated using a commercial kit according to the 
manufacturer’s instructions (Miltenyi, One-step antibody biotinylation kit). Staining with 
this in-house labelled CCL19 was assessed by flow cytometry on cells transfected with 
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empty vector or CCR7-FLAG and compared with the commercially available site-specific 
biotinylated CCL19 (Almac) when using a constant staining chemokine concentration of 
25 nM (figure 4.2.11). These data indicated that the best staining of CCR7 compared to 
vector control cells was obtained using the site-specific biotinylated chemokine (CCR7 
(almac) MFI= 3868±21.3, Vec (almac) MFI= 343.3±11.3) (figure 4.2.12 a). However, in-
house chemokine labelled cells also demonstrated significantly higher MFI values when 
staining CCR7 expressing cells compared with empty vector controls both when the 
chemokine was pre-conjugated with SAPE (CCR7 (in-house pre)  MFI= 273±3.0, Vec (in-
house pre) MFI= 203±2.3), and when cells were initially incubated with the chemokine 
then subsequently stained with SAPE (CCR7 (in-house post) MFI= 738±11.5, Vec (in-
house post) MFI= 222.7±1.3). These data indicated that in-house biotinylation of 
chemokines is viable in some instances as a means of detecting chemokine receptor 
expressing cells by flow cytometry. Additionally, a 2-step staining protocol generated a 
greater distinction in MFI values between CCR7 and empty vector transfected cells. 
Consequently a 2-step staining protocol was adopted in all subsequent studies of in-house 
biotinylated chemokines.  
CCL22 was biotinylated in the same manner as CCL19 and staining between CCR4-FLAG 
and empty vector transfected HEK293T assessed for a range of CCL22 label 
concentrations of 25-100 nM (figure 4.2.12 b). These data revealed that MFI was 
significantly higher with CCR4 transfected cells than equivalent empty vector controls at 
all concentrations tested (CCR4 (25 nM)=541.3±14.9, Vec (25 nM)=143±2.6, CCR4 (50 
nM)=633±13.1, Vec (50 nM)=162±2, CCR4 (100 nM)=796.3±4.6, Vec (100 
nM)=237.3±3.7), indicating that in-house biotinylated CCL22 can be used for labelling of 
cells expressing CCR4. A staining concentration of 50 nM was selected for subsequent 
analysis as it demonstrated a greater distinction in MFI between CCR4 and empty vector 
transfected cells, with little increase in MFI for empty vector controls from that obtained 
with a staining concentration of 25 nM. 
Unfortunately, when attempting the same with biotinylated CCL27 and CCR10-FLAG 
expressing cells (figure 4.2.12 c), no staining concentration tested resulted in an increase in 
MFI for CCR10 transfected cells compared with empty vector controls (CCR10 (25 
nM)=132±1.0, Vec (25 nM)=142.7±2.8, CCR10 (50 nM)=138.7±0.3, Vec (50 
nM)=157.3±1.8, CCR10 (100 nM)=166.7±5.8, Vec (100 nM)=186.3±5.9). Indeed, at 25 
and 50 nM staining concentrations the MFI values of CCR10 transfected cells were 
significantly lower than their relevant empty vector controls. In an effort to address if this 
represents an issue with binding of the biotinylated chemokine or insufficient CCR10 
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expression for detection, HEK293T cells were seeded onto 6-well plates and transfected 
with increasing quantities of CCR10-YFP plasmid per well (1.5-2.5 µg) and stained with a 
single concentration of biotinylated CCL27 as before (25 nM, figure 4.2.12 a&b). In this 
case SABV421 was used in place of SAPE to avoid spectral overlap with the YFP moiety 
on CCR10. Staining of CCR10 expressing cells was once again compared with empty 
vector controls, as well as empty vector and CCR7-FLAG transfected cells stained with 
commercially available biotinylated CCL19 pre-conjugated with SABV421. Receptor 
expression, as determined by MFI for YFP fluorescence, increased with rising plasmid 
quantities and peaked with the highest used (CCR10 1.5=474.3±7.7, CCR10 
2.0=527.3±15.6, CCR10 2.5=2245±50.9, figure 4.2.13 a), and were all significantly higher 
than MFI obtained for empty vector transfected cells (Vec 1.5=13.5±1.9). However, when 
evaluating staining with in-house labelled CCL27 little difference is apparent between any 
CCR10 transfected group and the empty vector control (CCR10 1.5=1078±9.4, CCR10 
2.0=1018.0±83.2, CCR10 2.5=1076±20.0, Vec 1.5=1273±28.31, figure 4.2.13 b). Similar 
to previous experiments (figure 4.2.12 c) MFI values for empty vector controls were in fact 
significantly higher than that obtained for any CCR10-YFP transfected group. These data 
indicate that while CCR10 expression can be observed (as indicated by YFP fluorescence), 
in-house biotinylated CCL27 does not specifically label CCR10 expressing cells under any 
conditions tested thus far.  
These observations, as well as a noted drop in MFI when using in-house biotinylated 
CCL19 to label CCR7 expressing cells compared to a commercially available counterpart, 
raised the concern that the process of non-specific biotinylation may alter the binding 
properties of a chemokine such that it cannot be considered comparable to the unlabelled 
chemokine. In order to determine if this might be the case biotinylated CCL19 (figure 
4.2.14 a) and CCL22 (figure 4.2.14 b) were compared to their un-biotinylated equivalents 
(labelled “Control” on the relevant figures), in their capacity to recruit b-arrestin 2 to 
CCR7 or CCR4. These data revealed biotinylated chemokines were near equivalent to their 
unlabelled counterparts, with comparable pEC50 (CCR7; control=7.59, biotinylated=7.49. 
CCR4; control=7.98, biotinylated=7.85) and Emax values (CCR7; control=1.20, 
biotinylated=1.16. CCR4; control=0.32, biotinylated=0.32). In this instance it would 
appear that the process of biotinylation has not overtly affected the functional activity of 
these chemokines, and they may be considered comparable to the unlabelled chemokine.   
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4.6 Assessment of ligand affinities of CCR4 and CCR7 
4.6.1 CCL17 and CCL22 demonstrate differing affinities for CCR4 
in a FACS based competition assay 
Using either CCL22 directly conjugated to AF647 (figure 4.2.15 a), or the in-house 
biotinylated version of CCL22 conjugated to SAPE (figure 4.2.15 b), and a range of 
unlabelled competitor chemokine concentrations of 0.03 nM – 1 µM. A labelled 
chemokine concentration of 25 nM for direct conjugated and 50 nM for the in-house 
biotinylated CCL22 was employed. The labelled and unlabelled chemokines were 
introduced to cells simultaneously and incubated on ice for 20 minutes to prevent receptor 
internalisation and ligand degredation. pKi generated using the direct conjugated CCL22 
were 7.13 for CCL17 and 7.65 for CCL22, and 7.32 and 7.70 when using the in-house 
labelled chemokine. These data indicated that both CCL17 and CCL22 can compete for 
receptor occupancy with labelled CCL22, however CCL22 does so more effectively. 
4.6.2  CCL21 appears incapable of displacing labelled CCL19 
from CCR7 expressing HEK293T cells 
Utilising site-specific biotinylated CCL19 conjugated to SAPE, and HEK293T cells 
transiently transfected with CCR7, the capacity of CCL19 or CCL21 to displace 
fluorescently labelled CCL19 was assessed (figure 4.2.16 a&b). These data indicated that, 
while CCL19 could readily out-compete the labelled CCL19, CCL21 was incapable of 
doing so at either a 20x (figure 4.2.16 a) or 40x (figure 4.2.16 b) molar excess. The 
indicated pKi of CCL19 between both sets of experiments was 8.46±0.17 (n=4±SEM). 
Interestingly the highest concentration of CCL21 competitor appeared to actually increase 
staining with CCL19-SAPE. Given previous observations that CCL21 can interact with 
CCR7, resulting in the receptor recruiting b-arrestin 1 and 2 (figure 4.2.6 a&b), CCL21 can 
interact with CCR7 expressed in HEK293T cells. However, it appears to do so with poorer 
affinity than CCL19 and is incapable of competing with labelled CCL19 for receptor 
occupancy at any concentration tested.       
4.7 Discussion 
4.7.1 CCR4 
Further analysis of the perceived ligand bias of CCR4 and CCR7 was conducted, at both 
the transcriptional and signalling machinery recruitment levels. For the former, the 
imiquimod model of skin inflammation was used. This is a well-established model in 
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which daily application of imiquimod cream induces a psoriasiform lesion on mouse dorsal 
skin, characterised by thickening of the skin, induced expression of a number of 
inflammatory cytokines including interferon alpha (INFa) and a resultant influx of 
immune cells such as plasmacytoid DCs, T-cells such as Th17 cells, as well as innate 
lymphocytes (van der Fits et al., 2009). This results in the formation of plaques much akin 
to human psoriatic lesions, however unlike the human disease this is not a chronic 
inflammatory condition. Imiquimod is a potent agonist of Toll-like receptor 7 (TLR7) 
(Forward et al., 2010), an intracellular sensor of single stranded RNA rich in guanosine 
and uridine, which is activated by DCs and macrophages in response to phagocytosis of a 
number of viruses. As such, imiquimod treatment can be considered a molecular mimic of 
viral infection. With this in mind the observation that, somewhat paradoxically, 
inflammation dampens expression of CCL22 does fit with the expected pathophysiology. 
As the predominant chemokine receptor of Th2 and Treg cells (Yoshie and Matsushima, 
2015), CCR4 driven chemotaxis of these cells into tissue inflamed during viral infection 
would be at best unhelpful (in the case of Th2 recruitment), and at worst potentially 
damaging to the resolution of infection in the case of Treg recruitment. 
Subsequent to the analysis described in this chapter it was demonstrated by others that 
topical imiquimod treatment reduces expression of CCL22 by TAMs 48 hours after 
administration in a solid subcutaneous B16F10 tumour model, attenuating Treg 
recruitment and reducing tumour volume (Furudate et al., 2017). Injection of CCL22 
neutralising antibody into tumours similarly reduced tumour burden. It is conceivable that 
we are observing a similar phenotype here. Such studies might also provide mechanistic 
insight into a synergistic effect noted with concurrent imiquimod treatment when treating 
various cancers (Mauldin et al., 2016), in its use as an adjuvant to tumour antigen 
immunisation (O’Hagan and Valiante, 2003), and it’s use in direct treatment of superficial 
basal cell carcinoma (Geisse et al., 2004). Disruption of the CCR4 signalling axis and 
subsequent interference with Treg recruitment by imiquimod may be a key aspect of its 
activity in these contexts. 
Interestingly, while a significant drop in CCL22 expression is noted over the course of the 
imiquimod model, no similar change in CCL17 expression is apparent. This is in contrast 
to a reported reduction in mRNA levels of both CCR4 ligands by TAMs with imiquimod 
treatment (Furudate et al., 2017). This was with topical imiquimod treatment in solid 
melanoma tumours, so would differ biologically from the psoriasiform lesions induced 
here. As such it is unclear what this steady expression could mean. Additional work may 
be necessary to confirm if this steady expression of CCL17 is consistent and if, in 
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accordance with the presumed activities of CCL17 and CCL22, Tregs and Th2 cells are 
still able to extravasate from the blood but are subsequently unable to navigate toward the 
inflammatory lesion. It may also be of interest to see how expression of CCL22 and 
CCL17 change in response to different inflammatory mediators, such as those requiring 
humoral immune responses, or in wound healing models.  
Although odd, the lack of any significant changes in CCL17 expression could simply be 
attributable to the difference in models used but does somewhat conform with the 
signalling profile generated here. These data indicate that, while CCL22 readily recruits 
both b-arrestins and Gi proteins to CCR4, CCL17 appears nearly incapable of doing so, 
with only brief association of b-arrestin 2 with the receptor following incubation with the 
chemokine, and no apparent association of Gi1/2 or 3 peptides. This was expected with b-
arrestin recruitment; CCL22 has been shown to be dominant both in functional CCR4 
internalisation assays of Th2 cells and L1.2 cells transfected with CCR4 (Mariani et al., 
2004), and in direct assessment of b-arrestin 2 recruitment by enzyme complementation 
assays (Ajram et al., 2014). Interestingly the latter demonstrated no b-arrestin recruitment 
in response to CCL17 compared with what is observed here, potentially indicating 
increased sensitivity with BRET based methods.  
However, the complete lack of Gi coupling is in contrast to the reported agonism of 
CCL17. Previous studies indicate that CCL17 induces chemotaxis in endogenously CCR4 
expressing and transfected cells and is PTX sensitive (indicating CCL17/CCR4 coupling 
signals through Gi/o pathways) (Imai et al., 1997; Mangmool and Kurose, 2011). Previous 
evaluation of G-protein recruitment to CCR4 with [35S] GTPγS membrane binding also 
indicated that both CCL17 and CCL22 recruited G-proteins, but that CCL17 produces a 
lower maximal response than CCL22 in these assays (Ajram et al., 2014). This assay does 
not differentiate between recruitment of different Ga subunits however.  
FACS based competition assays appear to indicate that CCL17 does indeed bind CCR4, 
displacing labelled CCL22. However, it does so less well than CCL22 and cannot 
completely abolish labelled CCL22 binding. This is in agreement with previously 
published observations (Viney et al., 2014b). Here, the authors postulate that CCR4 exists 
in at least two distinct conformations, one of which can only bind CCL22. It’s concerning 
that IC50 values obtained here are considerably higher than those determined by other 
means, such as competing with alkaline-phosphatase linked CCL22 (CCL17 = 2.1 nM, 
CCL22 = 0.65 nM), or radiolabelled CCL22 (CCL17 = 4.1 nM, CCL22 = 1.5 nM) (Imai et 
al., 1998; Viney et al., 2014a). This could potentially be due to the difference in labelled 
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chemokine concentration; we have employed a staining concentration of 25 nM CCL22, 
whereas the above studies utilised 0.5 nM and 0.1 nM respectively. It could also be due to 
the different cell lines used; all of our assays are performed in HEK293T cells whereas 
L1.2 cells were used in the above examples, which could be considered more analogous to 
an endogenous CCR4 expressing cell. However, given that pEC50 values generated here for 
b-arrestin (9.7 & 10.7 nM) and Gi (8.9 & 8.5 nM) recruitment induced by CCL22 are in 
broad agreement with those obtained by receptor internalisation (~5 nM) and chemotaxis 
(9.79 nM) assays performed on Th2 and HUT78 cells (Viney et al., 2014a), it may be that 
issues exist in the methodology applied here that require optimisation. It may be that the 
label concentration is simply too high in this assay, and could be titrated down. 
Alternatively, altering incubation time or temperature, introducing the labelled chemokine 
before cold competitor may bring the data generated by this method more in line with that 
seen elsewhere.  
It is possible that CCL17 signals through CCR4 in a Gi independent manner. Given 
previous observations of PTX sensitive chemotaxis to CCL17 (Imai et al., 1997), Go-
proteins could be utilised by the receptor following CCL17 binding. Additionally, CCL17 
has demonstrated a non-chemotactic function in which it is dominant over CCL22, namely 
the potent induction of calcitonin gene–related peptide (CGRP) expression in airway 
epithelial cells (Bonner et al., 2013). CGRP acts as a vasodilator in conjunction with other 
inflammatory mediators and as such it was posited that this activity of CCL17 contributed 
to CCR4 driven pathogenesis in airway hypersensitisation and asthma models. Such a 
skew in G-protein recruitment between different chemokines on the same receptor has not 
been described previously. However, this could be readily assessed in future experiments 
using SPASM biosensors for other Ga subunits. 
4.7.2 CCR7 
CCL19 and CCL21 readily recruit b-arrestin 1 and 2 to CCR7, and CCL19 is both more 
potent and faster acting than CCL21. Interestingly, no difference is noted in recruitment of 
either b-arrestin 1 or 2 in response to either chemokine. This contradicts earlier work 
which indicated CCL21 did not recruit b-arrestin, and that CCL19 mediated internalisation 
of CCR7 was b-arrestin 2 specific. siRNA knockdown of either b-arrestin 1, 2 or both in 
HUT78 cells indicated that CCR7 internalisation in response to CCL19 was b-arrestin 2 
dependent (Byers et al., 2008). A rescue experiment conducted in murine embryonic 
fibroblasts indicated that only co-expression of the receptor and b-arrestin 2 restored 
internalisation of CCR7 in response to CCL19. This disparity could be due to the radically 
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different methodologies used; here BRET based methods were employed, measuring 
specific protein: protein interactions in HEK293T cells. It is conceivable that, in an 
exogenous-expression system such as this, interactions occur that would not naturally. 
However, it is unlikely that such interactions would be indistinguishable from the “natural” 
pairing of CCR7 and b-arrestin 2. Also, in  (Byers et al., 2008) internalisation was 
measured rather than arrestin recruitment directly, and demonstrate their findings initially 
with siRNA knockdown, which can carry the risk of off-target effects.  
CCL21 has previously been reported as equal in G-protein recruitment capacity to CCL19 
(Sullivan et al., 1999), and CCL21 induced chemotaxis has been demonstrated as being 
PTX sensitive (Suzuki et al., 1999). However, when measuring recruitment of G-proteins 
by CCR7 using SPASM biosensors, CCL19 is clearly superior to CCL21 in both efficacy 
and potency. Only a moderate rise in BRET ratio is noted with CCL21 treatment at the 
highest concentrations tested. This is in broad agreement with a recent study characterising 
G-protein recruitment to CCR7 by means of BRET, using co-transfection of whole G-
proteins conjugated to renilla luciferase, and YFP-tagged CCR7 (Corbisier et al., 2015). 
From these data it would appear that in HEK293T cells CCR7 signalling does not 
demonstrate true bias, and CCL21 is simply a poorer ligand for both b-arrestin and Gi-
protein recruitment in these assays. 
This is in contrast to both the reported bias of CCR7 and the pathophysiology in mice 
resulting from knockout of CCR7 ligands. Initial characterisation of CCL21 in L1.2 cells 
expressing CCR7 demonstrated essentially equivalent potency in calcium mobilisation and 
chemotaxis (Yoshida et al., 1998). Both CCL19 and CCL21 were shown to recruit G-
proteins to the membrane via [35S] GTPγS binding and mobilise intracellular calcium near-
equally in a human T-cell lymphoma cells (Kohout et al., 2004). However, CCL19 
appeared more potent in downstream activation of the MAPK pathway and 
phosphorylation of CCR7 when assessed in HEK293 cells (Sullivan et al., 1999). A more 
recent study indicated that CCL21 signals through entirely unique pathways. Here it was 
demonstrated that oligomerisation of CCR7 allowed for the phosphorylation of CCR7 by 
SRC kinases, resulting in signalling through SHP2 by CCL21, but not CCL19 (Hauser et 
al., 2016). This would certainly fit with the differences between CCL19 knockout alone 
and CCL19 and CCL21 abrogation in the plt/plt mouse line. The former demonstrates little 
overt phenotypic changes from wild-type, however the latter demonstrates rapidly altered 
LN structure and attenuated/delayed antigen specific immune responses (Gunn et al., 1999; 
Britschgi, Favre and Luther, 2010). Collectively this would certainly implicate CCL21 as 
the dominant ligand in CCR7 activity, not CCL19. 
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It is interesting that b-arrestin recruitment by CCL21 is robust despite the clearly skewed 
G-protein recruitment profile between CCL19 and CCL21. In general, b-arrestin 
recruitment is considered a later event in receptor activation, following G-protein binding 
and receptor phosphorylation by GPCR kinases (GRKs) (Hanlon and Andrew, 2015). 
Previous work indicated that, in HEK293 cells, CCL19 and CCL21 demonstrated 
comparable G-protein activity (as demonstrated by inhibition of forskolin mediated cAMP 
build up), but CCL19 was a more potent agonist in terms of receptor phosphorylation and 
recruited a wider repertoire of GRKs (GRK3 and GRK6) to CCR7 than CCL21 (GRK6) 
(Zidar et al., 2009). It is certainly possible that, while evaluation of specific G-protein 
recruitment indicated little Gi-coupling resulting from CCL21 interaction, endogenous G-
proteins could bind the receptor, leading to phosphorylation and subsequent b-arrestin 
recruitment.  However, previously a b-arrestin biased mutant of the dopamine D2 receptor 
(D2R) could be seen to directly activate GRK2 without G protein coupling (Pack et al., 
2018), with an additive effect observed when using an artificial agonist known to 
preferentially recruit b-arrestins to D2R. It would be interesting to evaluate if direct GRK 
recruitment to CCR7 by CCL21 can be observed in G-protein knockout cell lines, possibly 
via BRET based means.  
Another interesting observation is that CCL21 is incapable of competing for receptor 
occupancy with labelled CCL19, even at a 40x molar excess. This is despite clear evidence 
of receptor activation in the form of b-arrestin recruitment. These findings contrast with 
previous characterisation of CCR7, again using both alkaline-phosphatase bound and 
radiolabelled ligands, which demonstrated similar affinity of CCL19 and CCL21, and the 
ability of each chemokine to compete with labelled versions of the other (Yoshida et al., 
1998; Sullivan et al., 1999). Again, there are considerable differences in terms of label 
concentration, however in this instance the IC50 values obtained here for CCL19 are 
comparable to those determined before. As such the key difference may be in the different 
cell lines used. L1.2 and other lymphoid derived cells have been utilised previously (giving 
an IC50 of 6.1 nM for CCL19 and 8.2 nM for CCL21 when competing with labelled 
CCL19 in L1.2 cells (Yoshida et al., 1998), as have CHO-K1 cells (8.5 nM and 8.1 nM 
respectively) (Corbisier et al., 2015). There may be subtle differences in the characteristics 
of CCR7 expressed in different cell lineages that results in this intriguing ligand binding 
profile that we do not consider when utilising HEK293T cells. It is interesting that the 
highest concentrations of CCL21 competitor actually appear to improve staining of CCR7 
expressing cells by labelled CCL19. Given the avid binding profile of CCL21, it is possible 
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that CCL21 out-competes the labelled CCL19 for non-specific glycan binding, improving 
specific staining with the chemokine.  
Unfortunately, while a bias factor could be applied to CCL21, this was not possible with 
either CCL17 or CCL28 due to the lack of response in both the b-arrestin and Gi-protein 
pathways.  
4.7.3 CCR10 
Previous assessment of CCR4 and CCR7 recruitment of b-arrestin indicated little 
difference between b-arrestin 1 or 2, so only b-arrestin 2 was assessed with CCR10. Initial 
attempts to characterise b-arrestin recruitment by CCR10 proved difficult. Issues with data 
quality and reproducibility were resolved by increasing the ratio of ‘acceptor’ to ‘‘donor’’ 
(i.e. b-arrestin to receptor). BRET presents the highest “signal” when there is no excess of 
‘‘donor’’ to ‘‘acceptor’’, this could indicate lower expression (or cell surface localisation) 
of CCR10-YFP compared to CCR4 or CCR7. However, in all assessments of b-arrestin 2 
recruitment the same pattern emerged. While interaction with CCL27 recruited b-arrestin 2 
to CCR10, CCL28 interaction resulted in no observable recruitment. This is in-keeping 
with the reported bias of this receptor (Xiong et al., 2012).  
Difficulties were also encountered when assessing recruitment of Gi-proteins by CCR10. 
Previous assessments of CCR10 have indicated that both CCL27 and CCL28 can induce 
calcium mobilisation when CCR10 is expressed in BAF/3 cells (a pro B cell line) (Wang et 
al., 2000). Additionally, a more recent evaluation of the signalling bias of CCR10 utilised 
enzyme fragment complementation-based assays to assess inhibition of cAMP formation 
following forskolin treatment (a readout of Gi activation) and b-arrestin recruitment 
(Rajagopal et al., 2013). In this study it was demonstrated that b-arrestin recruitment to 
CCR10 occurred after CCL27 treatment only, but both CCL27 and CCL28 inhibited 
cAMP accumulation (EC50; CCL27=7.9 nM, CCL28=127 nM). Using SPASM biosensors 
two distinct signalling profiles have been generated; one in which CCL28 generated a 
limited BRET signal compared to CCL27 with Gi3 only (similar to CCL21/CCR7), and 
another where CCL27 and CCL28 generated  a comparable BRET signal with both Gi1/2 
and Gi3 recruitment but a considerably higher pEC50 for CCL28 (Gi1/2; CCL27=-6.63 , 
CCL28=-5.72 . Gi3; CCL27=-6.01 , CCL28=-2.96 ). Despite numerous attempts it has not 
been possible to reproduce either result. Consequently, it isn’t possible to definitively 
determine which represents the most accurate picture of CCR10 signalling behaviour. 
However, given that the pEC50 values generated in the latter experiments are rather high, 
120 
 
and that the signalling profiles generated by the former closely resemble what has been 
observed in similar assessments of CCR4 and CCR7, it is likely that in these assays 
CCL28 also appears to not signal through Gi coupling to CCR10.  
4.7.4 Biotinylation of chemokines 
Using a kit intended for the biotinylation of antibodies it was possible to create biotinylated 
versions of CCL19 and CCL22 that could be used for receptor characterisation by flow 
cytometry and were near-indistinguishable from their unlabelled counterparts in a 
functional assay. These chemokines stained receptor-expressing cells best when a 2-step 
process was employed as opposed to pre-conjugation of the biotinylated chemokine with 
SAPE or SBV421, as done previously. Biotinylation kits non-specifically label any lysine 
residues in a protein, whereas commercially available labelled chemokines have a single 
biotin moiety, or are directly conjugated to a fluorophore, at their C-terminus. As such, 
pre-conjugation of in-house labelled chemokines may result in increased disruption to 
chemokine structure, reducing receptor binding. Unfortunately, similar attempts to 
biotinylate CCL27 and label cells expressing CCR10 proved unsuccessful. CCL19 and 
CCL22 contain 4 lysine residues each, whereas CCL27 contains 7. It is possible that 
biotinylation of CCL27 therefore introduces too much structural disruption for receptor 
binding. 
4.7.5 Conclusion 
In closing it appears that, while CCR4, CCR7 and CCR10 are all reported as following a 
very similar model of biased agonism, there are definite differences in signalling behaviour 
between these receptors. All of the “balanced” ligands (CCL22, CCL19 and CCL27) do 
indeed fit with their presumed signalling properties, readily initiating recruitment of both 
b-arrestin and Gi-proteins by their relevant receptors. However, when assessing 
chemokines previously demonstrated as being G-protein biased differences emerge. 
CCL21 readily recruits b-arrestin to CCR7 with near identical maximal responses to 
CCL19 but poorer potency. CCL17 on the other hand causes little recruitment of b-arrestin 
by CCR4, and CCL28 appears completely incapable of initiating b-arrestin recruitment by 
CCR10. Additionally, CCL17, CCL21 and CCL28 all appear almost incapable of Gi-
protein recruitment with either little (CCL21 and CCL28) or no (CCL17) recruitment 
initiated by their receptors following chemokine treatment. This would indicate that while 
there are certainly differences both within and between each of these ligand pairs, the label 
of biased agonism may have been misapplied. However, given the differences between the 
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data generated here and previous work analysing these receptors and ligands, significant 
further work would be required before definitively drawing such a conclusion. 
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Figure 4.1.1 Schematic representation of BRET based b-arrestin recruitment assay 
(a) C-terminal YFP tagged GPCR is co-transfected into HEK293T cells with renilla 
luciferase tagged b-arrestin 1 or 2. After 24 hours these cells were seeded onto a 
96-well plate and analysed after a further 24 hours using a plate reader capable of 
measuring luciferase and YFP emissions separately. Cells are incubated with 
Coelentrazine H at 37 oC for 5 minutes, which is catalysed by rLuc, producing a 
detectable signal. Gain for the donor and acceptor channels is adjusted so that at 
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rest the ratio of YFP/luciferase signal intensity is around 1. (b) Chemokine is then 
introduced to the wells and left to incubate for 5 minutes at room temperature. 
Incubation with compatible ligands recruits b-arrestin to the receptor, closing the 
gap between luciferase and YFP to under 10 nm. This allows energy transfer to 
occur, resulting in reduction in luciferase signal and a concomitant increase in YFP 
signal, increasing the ratio of YFP/luciferase above 1. This increase in BRET ratio 
is proportional to the degree of receptor recruitment and increases or decreases 
depending on the concentration of ligand applied.  
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Figure 4.1.2 Schematic representation of the use of SPASM Gi reporting biosensors 
(a) The SPASM biosensor consists of a single macromolecular reporter encoding the 
GPCR of interest, a YFP ‘acceptor’ and nano-luciferase ‘donor’ separated by flexible 
ER/K linker. The C-terminus of a Ga subunit, which is sufficient for receptor recruitment, 
separated by flexible ER/K linker is separated from the nano-luciferase moiety by a 
eYFP
Detector
nLuc Gi3
Detector
eYFP
nLuc
Gi3
475 nm535 nm
475 nm535 nm
125 
 
repeating glycine/serine sequence which insures rotational freedom. This is encoded in a 
backbone compatible with the Flp-In T-Rex stable cell line system, allowing for genomic 
insertion in a defined locus and doxycycline inducible expression in HEK293 cells. 
Generated stable cell lines are induced with doxycycline and seeded onto 96-well plates 24 
hours before analysis. From here the same basic methodology used in b-arrestin 
recruitment assays is employed, with the exception of a longer incubation time with the 
chemokine of 10 minutes. (b) Incubation with compatible ligands recruits the G-protein 
peptide to the receptor, resulting in a conformational change that closes the distance 
between ‘donor’ and ‘‘acceptor’’ to under 10 nm, increasing the calculated BRET ratio in a 
ligand concentration dependent manner.  
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Figure 4.2.1 Expression of ligands of CCR4 in the skin during imiquimod treatment 
as assessed by qPCR. 
Expression of CCL17 (a) and CCL22 (b) were evaluated at the mRNA level by RT-qPCR 
in skin treated with the TLR7 agonist imiquimod. Treatment was applied every 24 hours, 
samples harvested at 4, 12 hours and 1 day after the first treatment and 1 day after the 3- 
and 5-day treatments, and RNA extracted. Each data point represents an individual animal, 
error bars represent SD. Statistically significant differences between vehicle and 
imiquimod treated groups were determined by unpaired T-test, p≤0.05=*. 
 
  
(a)
4h
 Ve
h
4h
 Im
q
12
h V
eh
12
h I
mq
1d
 Ve
h
1d
 Im
q
3d
 Ve
h
3d
 Im
q
5d
 Ve
h
5d
 Im
q
0
2
4
6
2-
Δ
Δ
CT
CCL17
(b)
4h
 Ve
h
4h
 Im
q
12
h V
eh
12
h I
mq
1d
 Ve
h
1d
 Im
q
3d
 Ve
h
3d
 Im
q
5d
 Ve
h
5d
 Im
q
0.0
0.5
1.0
1.5
2.0
2.5
2-
Δ
Δ
CT
CCL22
*
*
127 
 
 
Figure 4.2.2 Recruitment of b-arrestin 1&2 to CCR4 by CCL17 or CCL22, as 
assessed by BRET. 
Recruitment of either b-arrestin 1 (a) or 2 (b) to CCR4 in response to increasing 
concentrations of either CCL17 or CCL22 was assessed by BRET. Due to comparatively 
low signal, values obtained for CCL17 were re-plotted excluding those obtained for 
CCL22 (c&d). (n=3 +/- SD, representative plot selected from 3 independent experiments 
each). 
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Figure 4.2.3 Comparison of pEC50 values and Emax obtained for CCL17 or CCL22. 
(a) Values obtained for the pEC50 of b-arrestin recruitment were compared between 
CCL17 and CCL22, and between b-arrestin 1 and 2 for each ligand. (b) Emax was also 
compared between CCL17 and CCL22 with either b-arrestin 1 or 2. (n=3 biological 
replicates. Statistically significant differences between each parameter were determined by 
unpaired T-test, p≤0.05=*, p ≤ 0.01=**, p ≤ 0.001=***). 4-B1=CCR4/b-arrestin 1 
transfection, 4-B2=CCR4/b-arrestin 2 transfection. 
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Figure 4.2.4 Kinetics of b-arrestin 2 recruitment to CCR4 induced by CCL17 or 
CCL22 interaction. 
(a) Recruitment of b-arrestin 2 to CCR4 in response to a single concentration (100 nM) of 
either CCL17 or CCL22 was continuously assessed over a 30-minute period (n=3 +/- SD, 
representative plot selected from 3 independent experiments). (b) The halftime to maximal 
signal obtained in response to either CCL17 or CCL22 in these assays were compared (n=3 
biological replicates +/- SD, statistically significant differences between each parameter 
were determined by paired T-test, p≤0.05=*). 
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Figure 4.2.5 Recruitment of Gi subunits to CCR4 by CCL17 or CCL22 was assessed 
utilising SPASM biosensors. 
Stable cell lines were generated for the expression of SPASM constructs measuring 
recruitment of Gi1/2 (a) or Gi3 (b) to CCR4. Expression was induced with doxycycline for 
24 hours and cell exposed to increasing concentrations of either CCL17 or CCL22 (n=3 +/- 
SD, representative plot selected from 3 independent experiments each). All subsequent 
experiments utilising SPASM biosensors followed the same methodology unless otherwise 
stated. (c) pEC50 values for CCL22 were compared between Gi1/2 and Gi3 recruitment 
assays (n=3 biological replicates. Statistical significance was evaluated by unpaired T-test). 
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Figure 4.2.6 Recruitment of b-arrestin 1&2 to CCR7 by CCL19 or CCL21, as 
assessed by BRET. 
Recruitment of either b-arrestin 1 (a) or 2 (b) to CCR7 in response to increasing 
concentrations of either CCL19 or CCL21 was assessed by BRET (n=3 +/- SD, 
representative plot selected from 3 independent experiments each). (c) Resultant pEC50 
values were compared between CCL19 and CCL21, and between b-arrestin 1 and 2 for 
each ligand. (n=3 biological replicates. Statistically significant differences between each 
parameter were determined by unpaired T-test, p≤0.05=*, p ≤ 0.01=**, p ≤ 0.001=***). 7-
B1=CCR7/b-arrestin 1 transfection, 7-B2=CCR7/b-arrestin 2 transfection. 
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Figure 4.2.7 Kinetics of b-arrestin  2 recruitment to CCR7 induced by CCL19 or 
CCL21 interaction. 
(a) Recruitment of b-arrestin 2 to CCR7 in response to a single concentration (100 nM) of 
either CCL19 or CCL21 was continuously assessed over a 30-minute period (n=3 +/- SD, 
representative plot selected from 3 independent experiments). (b) The halftime to maximal 
signal obtained in response to either CCL19 or CCL21 were compared (n=3 biological 
replicates +/- SD, statistically significant differences between each parameter were 
determined by paired T-test, p≤0.01=**). 
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Figure 4.2.8 Recruitment of Gi subunits to CCR7 by CCL19 or CCL21 was assessed 
utilising SPASM biosensors. 
Stable cell lines were generated for the expression of SPASM constructs measuring 
recruitment of Gi1/2 (a) or Gi3 (b) to CCR7. Expression was induced with doxycycline for 
24 hours, with cells exposed to increasing concentrations of either CCL19 or CCL21 then 
analysed by BRET (n=3 +/- SD, representative plot selected from 3 independent 
experiments each). (c) Emax values were compared between Gi1/2 and Gi3 recruitment 
assays  for both CCL19 and CCL21. (d) pEC50 values from these experiments were also 
compared. (n=3 biological replicates in both instances. Statistical significance was 
evaluated by unpaired T-test, p≤0.05=*, p ≤ 0.01=**, p ≤ 0.001=*** ). 
  
CC
L1
9 G
i1/
2
CC
L2
1 G
i1/
2
CC
L1
9 G
i3
CC
L2
1 G
i3
6.0
6.5
7.0
7.5
8.0
8.5
pEC50
pE
C
50
*
(a) (b)CCR7-Gi1/2 CCR7-Gi3
(c) Emax
-10 -9 -8 -7
1.00
1.05
1.10
log(chemokine)
B
R
ET
 R
at
io
CCR7-Gi1/2
CCL19
CCL21
-10 -9 -8 -7
1.00
1.05
1.10
log(chemokine)
B
R
ET
 R
at
io
CCR7-Gi3
CCL19
CCL21
(d) pEC50
Em
ax
CC
L1
9 G
i1/
2
CC
L2
1 G
i1/
2
CC
L1
9 G
i3
CC
L2
1 G
i3
0.00
0.05
0.10
0.15
0.20
0.25
CCR7 Gi Emax
Em
ax
***
**
***
*
134 
 
 
 
Figure 4.2.9 Recruitment of b-arrestin 2 to CCR10 in response to CCL27 or CCL28, 
as assessed by BRET. 
Recruitment of b-arrestin 2 to CCR10 in response to increasing concentrations of either 
CCL27 or CCL28 was assessed by BRET when ‘acceptor’ (CCR10) and ‘donor’ (b-
arrestin 2) were transfected into HEK293T cells in a ratio of either (a) 4:1, (b) 9:1 or (c) 
4.9:0.1. In (a) and (b) the same construct was used  as before (b-arrestin 2-rLuc). In (c) b-
arrestin 2 is expressed in a different construct, fused to nano-luciferase. (a&b; n=3 ± SD, 
representative plot of 2 independent experiments. c; n=3 ± SD, representative plot of 3 
independent experiments). (d) pEC50 values for CCL27 mediated b-arrestin 2 recruitment 
were compared between experiments utilising different ‘acceptor’:’donor’ ratios (a&b n=2 
± SD, c n=3 ±SD. Statistical differences were assessed by unpaired T-test.) 
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Figure 4.2.10 Recruitment of Gi subunits to CCR10 in response to CCL27 or CCL28 
was assessed utilising SPASM biosensors. 
Stable cell lines were generated for the expression of SPASM constructs measuring 
recruitment of Gi1/2 (a) or Gi3 (b) to CCR10. Expression was induced with doxycycline 
for 24 hours, with cells exposed to increasing concentrations of either CCL27 or CCL28 
then analysed by BRET (n=3 +/- SD).  (a) and (c) represent repeated experiments assessing 
recruitment of Gi1/2 to CCR10, and (b) and (d) represent the same for Gi3 recruitment.  
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Figure 4.2.11 Assessment of receptor staining by flow cytometry with in-house 
biotinylated chemokines. 
HEK293T cells were transfected with empty vector (Vec, a,c&d) or CCR7-FLAG (CCR7, 
b,d&f). Transfected cells were prepared for flow cytometry and stained with either 
biotinylated CCL19 from almac pre-conjugated with SAPE (a&b), in-house biotinylated 
CCL19 pre-conjugated to SAPE (c&d), or in-house biotinylated CCL19 used initially 
unconjugated, with cells stained after chemokine incubation with SAPE (e&f). 
Representative plots from 3 repeat measures are shown. 
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Figure 4.2.12 Assessment of receptor staining by flow cytometry with in-house 
biotinylated chemokines. 
HEK293T cells were transfected with empty vector (Vec), (a) CCR7-FLAG, (b) CCR4-
FLAG or (c) CCR10-FLAG. MFI was determined in the PE channel for all cells in the live 
singlet gate in all instances. (a) Staining with commercially available biotinylated CCL19 
(Vec (almac) & CCR7 (almac)) was compared to in-house biotinylated CCL19 either pre-
conjugated to SAPE (Vec (in-house pre) & CCR7 (in-house pre)) or cells stained by first 
chemokine then SAPE separately (Vec (in-house post) & CCR7 (in-house post)). 
Increasing concentrations (25-100 nM) of biotinylated CCL22 (b) or CCL27 (c) were used 
to stain either empty vector (Vec), CCR4  or CCR10 transfected cells, with SAPE staining 
carried out separately as before. (n=3 ±SD in all instances. Statistical significance was 
evaluated by unpaired T-test, p≤0.05=*, p ≤ 0.001=***, p ≤ 0.0001=**** ). 
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Figure 4.2.13 CCL27 staining was assessed with increasing quantities of CCR10-YFP. 
HEK293T cells seeded on a 6-well plate were transfected when near-confluent with either 
1.5 µg empty vector, 1.5 µg CCR7-FLAG, and either 1.5, 2.0 or 2.5 µg CCR10-YFP. (a) 
Expression of CCR10-YFP was determined by flow cytometry. (b) Staining with a 
constant concentration of biotinylated CCL27 (25 nM) of empty vector/CCR10 transfected 
cells was assessed  as described previously (with SABV421 in place of SAPE) and 
compared with staining of empty vector and CCR7 transfected cells stained with 
commercially biotinylated CCL19 pre-conjugated to SABV421. (n=3 ±SD in all instances. 
Statistical significance was evaluated by unpaired T-test, p ≤ 0.01=**, p ≤ 0.0001=**** ). 
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Figure 4.2.14 Recruitment of b-arrestin in response to biotinylated CCL19 and 
CCL22 was compared with unlabelled chemokine 
Recruitment of b-arrestin 2 to either CCR7 (a) or CCR4 (b) in response to increasing 
concentrations of either unlabelled (Control) or biotinylated CCL19 (a) or CCL22 (b) was 
assessed by BRET. (n=3 ± SD in both experiments) 
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Figure 4.2.15 Affinity of CCL17 or CCL22 for CCR4 expressed on HEK293T cells 
was assessed via a FACS based competition assay.  
HEK293T cells were transiently transfected with CCR4 and subsequently stained with 
either directly labelled (a) or in-house biotinylated (b) CCL22 in the presence of increasing 
concentrations of unlabelled CCL17 or CCL22, and evaluated by flow cytometry.  IC50 
was determined from the MFI obtained from the live singlet population in each respective 
channel at each inhibitor concentration. (a; n=4±SD, b; n=3±SD)  
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Figure 4.2.16 Determination of CCL19 or CCL21 binding to CCR7 expressed on 
HEK293T cells as assessed by competition assays.  
HEK293T cells were transiently transfected with CCR7 and stained with 25 nM CCL19-
SAPE in the presence of increasing concentrations of unlabelled CCL19 or CCL21 as 
described previously. (a) Displacement of labelled CCL19 by 25, 250 or 500 nM of either 
unlabelled CCL19 or CCL21 was determined by obtaining MFI values for live single cells 
in the PE channel, subtracting MFI values obtained with those from the empty vector 
control group as background, and expressing this as a percentage of cells stained without 
unlabelled competitor (NC). (n=6±SD, 3 technical replicates each from 2 independent 
experiments. Statistically significant differences between parameters were determined by 
unpaired T-test, p ≤ 0.0001=**** ). (b) Affinity of CCL19 and CCL21 was evaluated by 
displacement of CCL19-SAPE by unlabelled competitor with a concentration range from 
0.03 nM to 1 mM.  IC50 was determined from the MFI obtained from the live singlet 
population in the PE channel at each inhibitor concentration. (n=3±SD. Representative plot 
of 2 independent experiments). 
  
(a)
(b)
NC
CC
L1
9 2
5 n
M
CC
L1
9 2
50
 nM
CC
L1
9 5
00
 nM
CC
L2
1 2
5 n
M
CC
L2
1 2
50
 nM
CC
L2
1 5
00
 nM
0
50
100
150
200
%
N
C
****
n.s.
-10 -9 -8 -7 -6
0
500
1000
1500
2000
log(chemokine)
M
FI
E149 all SC
CCL19
CCL21
142 
 
 
  
Ta
bl
e 
4.
2.
1:
 S
um
m
ar
y 
of
 p
EC
50
, E
m
ax
 a
nd
 R
A
 v
al
ue
s g
en
er
at
ed
 in
 th
is 
ch
ap
te
r
pE
C5
0 
(lo
gM
±S
EM
)
Em
ax
 (±
SE
M
)
RA
 (x
10
^6
±S
EM
)
pE
C5
0 
(lo
gM
±S
EM
)
Em
ax
 (±
SE
M
)
RA
 (x
10
^6
±S
EM
)
pE
C5
0 
(lo
gM
±S
EM
)
Em
ax
 (±
SE
M
)
RA
 (x
10
^6
±S
EM
)
pE
C5
0 
(lo
gM
±S
EM
)
Em
ax
 (±
SE
M
)
RA
 (x
10
^6
±S
EM
)
CC
L1
7/
CC
R4
7.
63
±0
.0
9
0.
02
5±
0.
00
2
1.
06
7±
0.
17
7
7.
72
±0
.1
1
0.
03
3±
0.
00
2
1.
83
5±
0.
38
5
nd
nd
nd
nd
nd
nd
CC
L2
2/
CC
R4
8.
01
±0
.0
1
0.
22
3±
0.
00
7
23
.0
70
±0
.3
00
8.
00
±0
.1
0
0.
28
0±
0.
02
8
29
.0
70
±7
.8
43
8.
05
±0
.0
3
0.
20
7±
0.
01
0
26
.4
30
±1
.9
28
8.
08
±0
.0
6
0.
21
26
±0
.0
15
27
.3
80
±3
.0
20
CC
L1
9/
CC
R7
7.
77
±0
.1
0
0.
86
9±
0.
21
3
60
.5
50
±2
9.
88
0
7.
85
±0
.0
8
0.
71
8±
0.
04
0
52
.5
00
±9
.4
06
7.
66
±0
.0
3
0.
11
3±
0.
00
7
5.
25
9±
0.
48
0
7.
67
±0
.0
6
0.
17
5±
0.
01
0
8.
23
0 
±0
.7
25
CC
L2
1/
CC
R7
7.
17
±0
.0
8
0.
80
4±
0.
25
1
11
.8
20
±3
.5
79
7.
18
±0
.0
1
0.
65
2±
0.
06
1
9.
87
4±
1.
13
1
7.
24
±0
.3
0
0.
01
68
±0
.0
05
0.
28
9±
0.
10
1
7.
00
±0
.1
5
0.
01
68
±0
.0
05
0.
46
1±
0.
11
24
CC
L2
7/
CC
R1
0
nd
nd
nd
6.
99
±0
.0
6
0.
84
5±
0.
02
3
8.
43
0±
1.
30
7
6.
98
0.
04
9
0.
47
2
6.
8
0.
16
57
1.
05
9
CC
L2
8/
CC
R1
0
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
ar
re
st
in
 1
ar
re
st
in
 2
Gi
1/
2
Gi
3
Ch
em
ok
in
e/
re
ce
pt
or
:
143 
 
 
 
Table 4.2.2: Summary of halftime values obtained for b-arrestin recruitment induced 
by 100 nM chemokine 
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5 Polysialylation of chemokine receptors and its 
impact on the perception of biased agonism  
5.1 Introduction 
In chapter 4 a curiosity in the relationship between CCL21 and its cognate receptor CCR7 
presented itself. It appeared that, rather than demonstrating the widely reported G-protein 
bias, CCL21 signalling in fact seemed skewed in favour of b-arrestin.  Additionally, it 
appeared that CCL21 had such poor affinity for CCR7 that it was incapable of competing 
for receptor occupancy with CCL19, up to a 40x molar excess of labelled chemokine. 
These findings contrast with previous evaluations of the CCL19/CCL21:CCR7 signalling 
axis, and it is perhaps hasty to attribute this contrast solely to differences in methodology. 
Recent work utilising similar BRET based methods and the HEK293 cell line 
demonstrated broadly similar results in terms of b-arrestin and Ga-protein recruitment to 
the studies presented in this thesis, and also concluded that CCR7 does not demonstrate 
true biased agonism (Corbisier et al., 2015). However, CCL21 is considered the dominant 
ligand of CCR7 in vivo; singularly sufficient for migration of DCs to LNs and able to 
engage unique signalling pathways (Gunn et al., 1999; Hauser et al., 2016). In addition, 
combined CCL21 and CCL19 knockout results in a more profound phenotype than CCL19 
KO alone (Britschgi, Favre and Luther, 2010), and more closely mirrors that seen with loss 
of CCR7 itself (Kobayashi et al., 2017). This would imply some difference between the 
characteristics of CCR7 expressed in primary cells, in vivo and in cell lines of the 
lymphoid and myeloid lineages, and in the HEK293T cell line frequently used in more 
detailed assessment of the receptors signalling properties.  
This raised an interesting question; what differences in the translational/post-translational 
machinery of lymphoid/myeloid cells and HEK293T cells might explain this apparent 
discrepancy? Recent work on the sialyltransferase ST8sia4 may provide some insight. 
ST8sia4 catalyses the formation of large a2,8-linked homopolymers of sialic acid ranging 
from a minimum of 8 subunits to over 100, giving rise to a large, highly restricted 
additional PTM of a handful of glycosylated proteins known as polysialic acid (pSia) 
(Mori et al., 2017). pSia is attached to both O- and N-linked glycans and is perhaps best 
characterised on the neural cell adhesion molecule (NCAM). Polysialylation of NCAM 
occurs only on the 140 and 180 kDa forms of NCAM, but not the 120 kDa form of the 
protein found throughout most of the adult central nervous system (CNS). In this context it 
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is considered vital to neurogenesis during foetal development and neuronal plasticity in the 
adult CNS (such as in the olfactory bulb) and mediates its activity through inhibition of 
cell-cell/substrate interactions by attenuating NCAM binding and as a result increasing 
cellular motility (Windfuhr et al., 2000; Röckle and Hildebrandt, 2016; Zerwas et al., 
2016). Polysialylation is catalysed by 2 sialyltransferases, ST8sia2 and ST8sia4, with the 
former considered more vital in neurogenesis during development and the latter vital to 
plasticity in the adult CNS (Zerwas et al., 2016). Knockout of ST8sia4 results in generally 
normal neuronal development however it is associated with a number of learning and 
behavioural defects attributable to loss of neuronal plasticity (Calandreau et al., 2010; 
Zerwas et al., 2016). Alteration of cell-surface glycosylation is also a common feature of 
cancer (Pearce and Läubli, 2015). Indeed, increased polysialylation can be associated with 
late stage non-small cell lung cancer, metastatic neuroblastoma and increased metastatic 
potential of breast cancer, and is believed to aid cancer development via a similar contact-
inhibition dependent increase in cellular motility, as seen in neuronal plasticity (Tanaka et 
al., 2000; Cheung, Vickers and Cheung, 2006; Wang et al., 2016). Targeting of ST8sia4 
expression with microRNAs has been shown to reduce the aggressive phenotype of breast 
cancer cell lines and increase susceptibility of multi-drug resistant leukaemia to 
chemotherapeutic agents, and the use of pharmacological inhibitors of pSia is being 
evaluated as a novel cancer therapy (Al-Saraireh et al., 2013; Ma et al., 2016; Zhao et al., 
2016). 
Of more interest however is the observation that pSia is detectable on the surface of DCs, 
with an increase in surface pSia associated with DC maturation (Curreli et al., 2007). This 
was believed to be mainly attributable to polysialylation of neuropilin 2 (NRP2), more 
typically known as a receptor for vascular endothelial growth factors and semaphorins. 
Additionally, pSia was demonstrated to bind CCL21 both directly and on the surface of 
DCs, and this binding could be abrogated by the pre-treatment of DCs with 
endoneuraminidase-N (endo-N), which cleaves pSia from proteins (Bax et al., 2009). 
Treatment of DCs with endo-N also reduced their migratory capacity to CCL21. It was 
also demonstrated that, while reduction in chemotactic response to full length CCL21 
could be observed following endo-N treatment, no similar reduction was noted in 
migration of DCs to CCL21 lacking its characteristic extended C-terminus, signifying that 
this region of CCL21 is critical in pSia mediated regulation (Rey-Gallardo et al., 2010). In 
the same study it was demonstrated that siRNA knockdown of ST8sia4 also attenuated DC 
migration toward CCL21.  
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More recently though it was revealed in a series of elegant experiments that CCR7 is a 
target of ST8sia4 mediated polysialylation, and that CCL21 signalling is dependent on this 
PTM (Kiermaier et al., 2016). St8sia4 KO demonstrated a similar immunophenotype to 
CCR7 KO, with diminished LN size at rest and poor increase in cellularity under 
inflammatory insult. Bone marrow derived DCs (BMDCs) from ST8sia4 KO animals were 
profoundly attenuated in their ability to migrate to full-length CCL21 but unaffected in 
CCL19 migratory capacity in vitro, and ST8sia4 KO DCs demonstrated almost no 
recruitment to LNs in vivo, or into the afferent lymphatics of skin explants. ST8sia4 KO 
BMDCs also demonstrated attenuated downstream signalling responses from CCL21 
treatment. Migration of NRP2 KO DCs presented no defect in CCL21 migration, 
indicating that while pSia appears critical to CCL21 mediated chemotaxis it is not 
dependent on NRP2 polysialylation. Subsequently CCR7 was shown to be directly 
polysialylated IP experiments, and CCR7 deficient DCs demonstrated reduced pSia levels 
compared to WT cells. Finally, it was revealed by nuclear magnetic resonance 
spectroscopy that, in the absence of pSia CCL21, adopts an auto-inhibitory conformation. 
Interaction with pSia releases CCL21 from this, allowing it to fully interact with CCR7 
(select findings summarised in figure 5.1.1).  
The idea that, in the absence of pSia, CCL21 maintains an auto-inhibitory conformation 
that attenuates its ability to interact with CCR7 might help to address some of the more 
curious findings presented in Chapter 4. Consequently, validation of the FACS based 
competition assay was sought using BMDCs from wild type mice and CCR7 and ST8sia4 
assessed during BMDC differentiation. This would help establish a baseline for affinity of 
CCL19 and CCL21 in a cell model endogenously expressing CCR7, as well as revealing 
the expression dynamics of CCR7 and ST8sia4 during development. Expression of 
ST8sia4 was assessed in HEK293T cells, comparing this to other commonly used adherent 
and readily transfectable cell lines and a selection of myeloid/lymphoid cell lines. 
Recruitment assays for CCR4 and CCR7 were repeated with the inclusion ST8sia4, and the 
resultant data compared with that obtained previously. Lastly, CCR10 was demonstrated as 
a novel target of ST8sia4 mediated polysialylation, with effects on signalling potential of 
both of its cognate ligands. 
5.2 Evaluation of CCR7 ligand affinity and CCR7 and 
ST8sai4 mRNA expression in BMDCs 
BMDCs were generated as described in materials and methods. In brief; bone marrow from 
WT mice was resuspended in complete RPMI+ supplemented with 20 ng/ml GM-CSF. 
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Every two days non-adherent cells were transferred to fresh plates and media refreshed. 
Adherent cells were discarded. On day 7 cells were stimulated with ovalbumin for 4 hours 
before being resuspended in media supplemented with 100 ng/ml LPS and 50 ng/ml TNF 
for overnight stimulation. For FACS analysis day 8 stimulated cells were used. For qPCR, 
aliquots of cells from unstimulated bone marrow (D0), day 4 of the differentiation protocol 
(D4) and day 7 of the protocol (D7) were harvested for mRNA which was converted to 
cDNA, and analysis performed. 
BMDCs were stained with biotinylated CCL19 from almac pre-conjugated with SAPE at a 
concentration of 25 nM, in the presence of increasing concentrations of unlabelled CCL19 
or CCL21, with a range of competitor chemokine from 0.03 nM to 1 µM, performed in the 
same manner as described previously. pKi was calculated from the MFI of live single cells 
in the PE channel by flow cytometry at each competitor concentration (figure 5.2.1 a). 
Both CCL19 and CCL21 could compete for receptor occupancy, with indicated pKi values 
of -.80±0.19 for CCL19 and 7.93±0.10 for CCL21 (n=3±SEM). While previous studies 
determined that affinities between CCL19 and CCL21 were comparable, here CCL19 
demonstrates a significantly lower pKi than CCL21 (p=0.0162, figure 5.2.1 b). These data 
indicated that CCR7 expressed in BMDCs has different ligand binding properties from 
CCR7 expressed in HEK293T cells (figure 4.2.16 a&b).  
Primers were designed for the amplification of murine CCR7 and ST8sia4, qPCR 
performed, and expression normalised to a housekeeping gene (TBP), and induction of 
expression relative to unstimulated bone marrow determined by the 2-DDCT method of 
comparative analysis as before. These data indicated that CCR7 expression was effectively 
absent in bone marrow, however its expression is strongly induced during the 
differentiation protocol, peaking on day 7 (D0=1.0±0.1 n=3±SEM, D4=2.8±0.7 n=3±SEM, 
D7=45.8±7.1 n=10±SEM, figure 5.2.2 a. Units are fold change, n and unit is the same for 
below). ST8sia4 expression meanwhile remained steady during the maturation of BMDCs, 
demonstrating a trend of increased expression between stages of differentiation but no 
significant differences (D0=1.1±0.4, D4=1.1±0.1, D7=1.7±0.2, figure 5.2.2 b). As such it 
would appear that while CCR7 expression is upregulated in response to the maturation 
protocol, ST8sia4 expression is steady and may precede it. This would allow for 
appropriate polysialylation of the receptor once its expression was up-regulated.  
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5.3 The role of ST8sia4 in the perceived ligand bias of 
CCR7 
5.3.1 ST8sia4 is robustly expressed in myeloid/lymphoid cell 
lines, but near absent in HEK293T cells 
Due to the observation that CCL21 appears attenuated in activity when performing assays 
in HEK293T cells, and recent publications indicating that polysialylation by ST8sia4 is 
critical to CCL21:CCR7 interaction, expression of ST8sia4 in HEK293T was evaluated 
and compared with other commonly used cell lines. To address this, mRNA was harvested 
from a selection of other frequently used human/simian (HUT78, U937, THP1, COS-7 & 
HEK293T, figure 5.2.3 a) and murine (L1.2, 3T3 & RAW, figure 5.2.3 b) cell lines and 
converted to cDNA. In this case analysis by 2-DDCT was not appropriate as each cell line 
would need to act as its own control group and analysis of baseline ST8sia4 expression 
was sought, not induction. Consequently, a copy number of ST8sia4 and TBP mRNA was 
determined via qPCR by comparison to known standard curves for each gene. Expression 
of ST8sia4 is displayed relative to 1000 copies of the housekeeping gene(mTBP). These 
data indicated that in both human and murine myeloid/lymphoid derived cell lines, 
ST8sia4 was robustly expressed (HUT78=711.7±139.5, U937=286.9±14.1, 
THP1=289.3±18.9, L1.2=5101±1269 & RAW=7028±11.8. n=4 in all cases except RAW 
cells, where n=2. Units are copy number per 1000 copies of TBP). However, in all 
adherent, fibroblastic/epithelial derived cell lines tested ST8sia4 expression was 
minimal/absent (HEK293T=45.1±5.4, COS-7=18.0±0.5 and 3T3=1.1±0.3). Consequently, 
it would appear that adherent, readily transfectable cell lines are deficient in ST8sia4 
expression when compared to cells of the lymphoid/myeloid lineage. 
5.3.2 CCR7/ST8sia4 co-expression allows CCL21 to out-compete 
labelled CCL19 
Having determined that ST8sia4 expression in HEK293T cells is effectively absent, an 
ST8sia4-HA expression vector was generated, and previous assessments of CCR7 (chapter 
4) repeated, now including ST8sia4 in the transfection strategy. Polysialylation of CCR7 
restores CCL21/CCR7 interaction in HEK293T cells in repeats of the competition assay 
(figure 5.2.4 a&b, compared with figure 4.2.15 b). CCL21 is now capable of competing 
with the labelled CCL19 for receptor occupancy. CCL21/CCR7 interaction is improved 
when an increased quantity of ST8sia4 plasmid was used in the transfection. When 
increased from 1 µg (figure 5.2.4 a) to 4 µg (figure 5.2.4 b), there is a reciprocal drop in 
pKi for CCL21 from 7.25 to 8.01 (pKi for CCL19 was 8.08 and 8.52 respectively). Given 
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that expression vectors for ST8sia4 and CCR7 are of near equal size (6.2 kb and 6.3 kb 
respectively), these data appeared to indicate that a near-equimolar transfection strategy is 
preferable. As such this was used in all subsequent experiments. When directly comparing 
CCL19:CCL19 competition between cells transfected with and without ST8sia4 (figure 
5.2.4 c), no overt differences in CCL19 affinity were noted, with IC50 values of 8.3 and 9 
nM respectively. These data agree with previous assessments of CCR7 polysialylation that 
indicated that pSia had no effect on CCL19 activity, and confirm that the absence of 
polysialylation of CCR7 in HEK293T cells could account for previous discrepancies when 
assessing CCL21/CCR7 interactions.  
5.3.3 Polysialylation of CCR7 considerably alters CCL21 
signalling profile 
Assessment of b-arrestin 2 recruitment to CCR7 was repeated, now including ST8sia4-HA 
in the transfection of cells. A range of concentrations of either CCL19 or CCL21 from 0.1 
nM to 300 nM was applied, and recruitment assessed as described previously. When CCR7 
was polysialylated CCL21 performs better as a ligand of CCR7 (figure 5.2.5 a, in 
comparison with 4.2.6 b) with a significant drop in pEC50 of b-arrestin 2 recruitment from 
previous experiments without ST8sia4 co-transfection (CCL21-=7.18±0.01, 
CCL21+=7.99±0.03, figure 5.2.5 b. p=<0.0001). pEC50 for b-arrestin 2 recruitment by 
polysialylated CCR7 was significantly lower for CCL21 than CCL19 
(CCL19+=7.66±0.04, CCL21+=7.99±0.03, p=0.0018). No significant difference was noted 
between CCL19 pEC50 with or without ST8sia4 co-transfection (CCL19-=7.83±0.08, 
CCL19+=7.66±0.04). In a repeat of previous evaluations of the kinetics of b-arrestin 2 
recruitment, with ST8sia4 now included, CCL21 generated a higher maximal BRET signal 
than CCL19 (CCL19=1.58±0.01 minutes, CCL21=1.63±0.02 minutes, n=3±SEM. Figure 
5.2.6 a, compared with 4.2.7 a). CCL21 also appeared to be a faster acting ligand when 
CCR7 is polysialylated (figure 5.2.6 b), with a reduction in half-time to maximal signal 
from 6.4±0.4 minutes to 4.1±0.3 minutes. Once again, no significant differences in CCL19 
half-times are noted. Collectively, these data indicate that rather than being G-protein 
biased, CCL21 is a more potent ligand than CCL19 in terms of b-arrestin 2 recruitment. 
This is in contrast with previous assessments of b-arrestin recruitment by CCR7 in 
HEK293T cells and may indicate that CCR7 polysialylation had not been accounted for.   
Recruitment of Gi3 proteins to CCR7 was re-assessed with receptor polysialylation now 
included. Initially this was attempted using the previously established stable cell line 
expressing CCR7-Gi3 reporter used in chapter 4 (figure 4.2.8 a&b). Subsequent transient 
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transfection of this cell line with ST8sia4-HA was attempted (figure 5.2.7 a), assessing the 
recruitment of Gi3 to CCR7 with the same concentration range as used previously.  While 
this did result in a lower and more consistent pEC50 for CCL21, this was not significantly 
lower than that achieved previously (CCL21-=7.00±0.15, n=3±SEM. 
CCL21+(stable)=7.16±0.07, n=2±SEM. Figure 5.2.7 c). This moderate effect was 
somewhat surprising given the fundamental effect CCR7 polysialylation had when 
assessing b-arrestin recruitment in response to CCL21. Unpublished observations 
indicated that stable cell lines generated using this system are refractory to subsequent 
transient transfection. Consequently, a purely transient transfection of this cell line with 
ST8sia4-HA was attempted in an effort to address this, co-transfecting the CCR7-Gi3 
biosensor construct and ST8sia4-HA into HEK293T cells (figure 5.2.7 b). These data 
demonstrated a recruitment profile much more in-line with that observed when assessing 
b-arrestin recruitment to the receptor, resulting in an indicated pEC50 of 7.84±0.27 
(n=2±SEM) for CCL21. However, despite the considerable increase in indicate potency 
this did not prove significantly lower than previous measures of pEC50 (figure 5.2.7 c). 
Similar to what was seen when assessing b-arrestin recruitment by CCR7, polysialylation 
of the receptor had no effect on pEC50 of CCL19 mediated Gi3 recruitment (CCL19-
=7.67±0.06, n=3±SEM. CCL19+(stable) = 7.70±0.08, n=3±SEM. CCL19+(trans) 
=7.70±0.08, n=2±SEM). This would indicate that, rather than being G-protein biased, 
CCL21 is a balanced ligand of CCR7 and can initiate recruitment of both b-arrestin and 
Gi-proteins by CCR7. It is also apparent that polysialylation of CCR7 has had no effect on 
CCL19 signalling potential.  
5.4 CCL17 signalling potential through CCR4 is 
unaffected by ST8sia4 co-transfection 
Given the somewhat similar dearth of CCL17 signalling (particularly at the level of Gi 
signalling), and the profound effects polysialylation had on CCL21/CCR7 interaction, 
CCL17/CCR4 interaction was re-evaluated with ST8sia4 included. This was done in an 
effort to determine if CCR4 could potentially also be a target of ST8sia4 mediated 
polysialylation. However, when assessed at the b-arrestin 2 level (figure 5.2.8 a, compared 
with 4.2.2 b), or at the level of Gi3 protein recruitment (figure 5.2.8 b, compared with 4.2.5 
b), CCL17 signalling potential appeared unaffected by the inclusion of ST8sia4 
transfection. pEC50 values obtained for CCL22 were near comparable to those obtained 
previously (b-arrestin 2; -ST8sia4=7.99±0.10, n=3±SEM. +ST8sia4=7.99. Gi3; -
ST8sia4=8.10±0.06, n=3±SEM. +ST8sia4=7.99). These data indicated that ST8sia4 co-
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transfection had no measurable effect on CCL17/CCR4 interaction, and CCR4 is therefore 
unlikely to be a target of ST8sia4 mediated polysialylation.  
5.5 CCR10 is a novel target of ST8sia4 driven 
polysialylation 
5.5.1 Immunoprecipitation of CCR7 and CCR10 confirm 
polysialylation of these receptors 
The posited mode of action for pSia interaction with CCL21 is that the positively charged 
extended C-terminus of the chemokine interacts with the highly negatively charged pSia, 
releasing CCL21 from an otherwise auto-inhibitory conformation and allowing it to 
interact more completely with the receptor. CCL28, like CCL21, has an extended and 
charged C-terminus, and also has a hexa-cysteine motif instead of the typical tetracysteine 
motif of chemokines. Additionally, CCL28 is also considered the G-protein biased ligand 
in a signalling axis with CCL27 and the receptor CCR10, much the same as 
CCL21/CCL19/CCR7. Given these similarities CCL28 might also require polysialylation 
of its receptor in order to fully interact, and therefore CCR10 might represent a novel target 
of ST8sia4 mediated polysialylation.  
CCR7-FLAG and CCR10-FLAG were co-transfected into HEK293T cells with either 
empty vector or ST8sia4-HA. IP was performed against the resulting lysates using an anti-
FLAG antibody to enrich for receptor, and western blotting performed to determine if pSia 
can be detected in the purified lysate of cells transfected with both chemokine receptor and 
ST8sia4. This would indicate that the receptor is potentially polysialylated (figure 5.2.9).  
These data indicated that IP of CCR7-FLAG and CCR10-FLAG display a positive signal 
for pSia only with ST8sia4 co-transfection. As well as confirming the findings of 
Kiermaier et al regarding CCR7 polysialylation, these data indicate that CCR10 may also 
be polysialylated.  
An IP against pSia itself (probing for receptor to confirm polysialylation of CCR7 and 
CCR10) proved technically challenging and required considerable optimisation. In brief; 
the receptor construct used was changed from C-terminally FLAG tagged versions of 
CCR7 and CCR10 to the Gi3 biosensor construct of these receptors. This was done as the 
resultant protein product appeared more immunogenic when detected by western blotting 
using an in-house generated anti-GFP antibody. Immunoprecipitated protein was directly 
denatured in 2x LDS loading buffer with 100 mM DTT, as opposed to elution in glycine 
buffer as performed before, in the hopes of maximising protein yield. Additionally, IP time 
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was shortened from overnight to 4 hours, as pSia is prone to degradation and may have 
been adversely affected by an extended incubation. Finally, a different anti-pSia antibody 
was used for detection by western blotting from that used to perform the IP, as the anti-
pSia used to perform the IP gave a very strong background signal. The result of this is that 
a specific band can be seen for GFP only when CCR10-Gi3 and ST8sia4 are co-transfected 
(figure 5.2.10), further suggesting that CCR10 is polysialylated by ST8sia4. No signal is 
seen for CCR7, indicating it has not been successfully immunoprecipitated with pSia under 
these conditions. Given the relative difference in pSia signal seen previously (figure 5.2.9), 
and the difficulties encountered here, it is possible there simply is not sufficient protein 
obtained for detection of CCR7.  
5.5.2 ST8sia4/CCR10 co-transfection alters signalling properties 
of both CCL27 and CCL28 
In order to determine if polysialylation is likely to contribute to CCR10 signalling, b-
arrestin recruitment by the receptor in response to CCL27 and CCL28 was assessed. These 
experiments were performed in the same manner as previously described (figure 4.2.9 c), 
now with the inclusion of ST8sia4 when transfecting cells (figure 5.2.11 a). These data 
indicated that while b-arrestin 2 recruitment was induced by CCL27 with or without 
ST8sai4 co-transfection, recruitment by CCL28 could only be observed when ST8sia4 was 
included. It should be noted however that CCL28 generated a detectable BRET signal only 
at the highest concentrations tested (>100 nM). Interestingly, indicated pEC50 for CCL27 
dropped significantly from 6.99±0.06 (n=3±SEM) without ST8sia4, to 7.27±0.06  
(n=3±SEM) when the receptor is polysialylated (figure 5.2.11 b). These data further 
suggest that CCR10 is polysialylated, and that polysialylation aids receptor interaction of 
both its cognate ligands. 
5.5.3 Expression of CCR10 and ST8sia4 can be simultaneously 
detected in primary murine cells 
Publicly available RNA-seq data was used to determine if CCR10 and ST8sia4 expression 
are likely to occur in the same cells. The Immunological Genome Project’s Skyline (RNA-
seq) data set was used, with 6 cell types known to express CCR10 (consisting of 3 each of 
B-cell and gd T-cell subsets) evaluated. A selection of DC populations was included as 
means of comparison for ST8sia4 expression. These were then assessed for CCR10 (figure 
5.2.12 a) and ST8sia4 (figure 5.2.12 b) expression. These data indicated that in each cell 
subset expressing CCR10, ST8sia4 expression was also present. This would suggest that 
CCR10 polysialylation is likely in vivo. ST8sia4 expression was comparable between 2 
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DC subsets and the cells expressing CCR10, but considerably lower than 1. This could 
potentially indicate different requirements of pSia between cell types.  
5.5.4 Development of polycistronic vectors compatible with 
stable cell line generation 
While it was possible to assess CCR7 recruitment of Gi3 with receptor polysialylation by 
using the SPASM biosensor in a transient transfection model (figure 5.2.7 b), repeat 
measures proved difficult. This is possibly because these biosensors have been optimised 
for use in an inducible stable cell line, rather than via transient transfection, and perform 
better in this set-up (unpublished observations from the lab). Generally speaking, transient 
transfections result in a highly heterogenous population, with some cells expressing no or 
very little of the desired protein, and others expressing a high copy number of it. In the 
case of the SPASM biosensor, it’s large size increases the probability of it being retained 
intracellularly, particularly when highly expressed. This would result in reporter proteins 
still producing light following Coelentrazine H administration but unable to interact with 
ligand, increasing background luciferase signal and consequently effecting BRET signal. 
However, as observed when attempting a subsequent transfection of ST8sia4 into stable 
cell lines generated with the CCR7-Gi3 biosensor, little effect is noted on CCL21/CCR7 
interaction. This would indicate that ST8sia4 expression was poor or absent, and that these 
stable cell lines are refractory to further transfection. As well, the observation that both 
ligands of CCR10 benefit from receptor polysialylation might provide an indication of why 
previous assessment of CCR10 G-protein recruitment has been problematic. If CCL27 is 
attenuated in its capacity to trigger Gi3 recruitment by CCR10 when the receptor is not 
polysialylated, then it could be that without this G-protein recruitment is not detectable. In 
an effort to address these issues, polycistronic vectors for the expression of both ST8sia4-
HA and the Gi1/2 or GI3 biosensors for CCR4, CCR7 and CCR10 were developed, and 
placed in a plasmid background compatible with the generation of stable cell lines as 
before. Plasmids were also generated for expression of ST8sia4 and the YFP tagged 
versions of CCR4, CCR7 and CCR10 in an effort to simplify transfection strategies going 
forward. These were based on the TaV2A motif; a 20 amino acid virus-derived sequence 
that allows for the expression of multiple protein products from a single ORF by initiating 
what is assumed to be a “skip” in translation by the ribosome upon encountering the 
sequence (Donnelly et al., 2001). A 2-step process was devised for generating these 
plasmids, wherein primers were designed to introduce TaV2A and a compatible restriction 
site downstream of ST8sia4. A new plasmid was generated with this product. Primers were 
then designed to amplify the Gi biosensor constructs with compatible restrictions sites, and 
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this product was ligated into the new ST8sia4/TaV2A plasmid (summarised in figure 
5.2.13).  
Prior to establishing stable cell lines, these constructs were evaluated for expression of 
both proteins by transient transfection into HEK293T and subsequent western blotting. 
These data indicated that ST8sia4-HA expression could be detected at equivalent levels to 
the ST8sia4-HA only transfected controls, and that pSia was generated as a result (a-HA & 
a-pSia respectively, figure 5.2.14). Unfortunately, protein levels of the chemokine 
receptors were low for every construct tested (a-GFP (low)), and only readily detectable 
with longer exposure times (a-GFP (high)). As such it would appear that, while both 
proteins can be expressed from the single vector, there are significant issues with 
expression of the second product and these constructs are unlikely to express both required 
proteins at suitable levels in a stable cell line.  
5.6 Discussion 
A number of novel findings are described in this chapter, related to the role played by 
ST8sia4 driven polysialylation in the function of multiple chemokine receptors.  
5.6.1 CCR7 
Following from observations in the previous chapter regarding CCL21/CCR7 interaction, 
CCL21/CCR7 affinity was evaluated in a cell type endogenously expressing CCR7. 
BMDCs were used in a FACS based competition assay, and both CCL19 and CCL21 were 
shown to compete for receptor occupancy with the CCL19-SAPE, in stark contrast to the 
same assay performed with CCR7 expressing HEK293T cells (figure 4.2.10 b). While 
these data are more in-line with previous characterisation of CCR7 and its ligands, CCL21 
competes with CCL19-SAPE less effectively than CCL19, generating a significantly 
higher IC50 value. As stated before, CCL19 and CCL21 are considered to be essentially of 
equal affinity for CCR7. Again, this could be attributable to differences in methodology, 
such as the increased staining concentration, or that in this instance non-species matched 
ligands were used. However, this clear contrast in CCL21 activity in the same assay 
between BMDCs and HEK293T cells added credence to the hypothesis that specific 
differences in the molecular characteristics of CCR7 exist between different expression 
systems. No overt difference is noted in IC50 of CCL19 between assays performed in 
BMDCs or HEK293T cells. 
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CCR7 and ST8sia4 expression was assessed during various stages of BMDC 
differentiation. As expected, CCR7 expression significantly increased during maturation of 
BMDCs, however somewhat surprisingly ST8sia4 expression remained comparatively 
steady. This is in contrast with previous studies which demonstrated increasing ST8sia4 
expression between monocytes, immature and mature DCs (Curreli et al., 2007). In these 
studies, human monocytes were sorted and differentiated into DCs. Here however a mixed 
population (bone marrow) was used to generate DCs. It is possible that, in comparing the 
induction of expression from a mixed population such as bone marrow instead of purified 
monocytes it is not possible to determine differences in expression. However, there is also 
little increase in ST8sia4 expression between cells harvested midway through the 
differentiation protocol (D4) and those harvested near the end (D7), making this less likely 
to be the case.  
Instead these differences could be attributable to how the DCs were generated from human 
monocytes. In these studies, Il-4 was used in addition to GM-CSF to induce differentiation 
into DCs. Beyond the obvious difference in species, it is possible that this change in 
cytokine treatment results in a DC population with subtly different properties. This might 
provide something of an explanation for CCL21 demonstrating poorer affinity than CCL19 
for CCR7 on BMDCs. It is possible that, if ST8sia4 expression is not induced as potently 
as it can be, CCR7 expressed in these cells might not be fully polysialylated and therefore 
attenuated in its capacity to interact with CCL21. DCs can be generated in vitro in two 
main ways; treatment with GM-CSF and IL-4 or treatment with Flt3 ligand. The latter has 
been described previously as superior in migratory capacity to LNs, and more akin to 
steady-state resident DCs (Xu et al., 2007). The observation that the GM-CSF derived DCs 
used here appear less capable of interacting with CCL21 and have little/no increase in 
ST8sia4 expression during differentiation could provide a mechanistic explanation for 
these observations. It would be interesting to see if generating DCs via Flt3 ligand 
treatment altered ST8sia4 expression profiles and therefore CCL21 binding properties. 
The fact that CCL21 was able to compete for receptor occupancy on BMDCs at all 
however raised an obvious question; do HEK293T cells express ST8sia4? Lack of receptor 
polysialylation would account for the poor affinity and diminished signalling potential of 
CCL21. ST8sia4 expression was evaluated in a panel of human and murine cell lines. 
Interestingly, all cells of the lymphoid/myeloid lineage robustly expressed ST8sia4, 
whereas expression was either entirely, or near, absent in 3T3, COS-7 and HEK293T cells. 
An expression vector for ST8sia4 was developed and previous assessments of CCR7 
signalling properties were repeated now including polysialylation of the receptor. 
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Polysialylation of CCR7 in HEK293T cells allowed CCL21 to compete with CCL19-
SAPE, with comparable IC50 values to those obtained with BMDCs when CCR7 and 
ST8sia4 were transfected in near equimolar proportions. No difference was seen in CCL19 
affinity, in agreement with previous assessments of CCR7. Interestingly, CCL21 is not 
able to completely out-compete CCL19-SAPE at a 40x molar excess in this assay, as was 
seen with BMDCs. This is possibly due to the simultaneous introduction of CCR7 and 
ST8sia4 into the cells. qPCR data on BMDC indicated that expression of ST8sia4 preceded 
that of CCR7. By introducing both simultaneously there could be a lag period in which 
CCR7 is produced but not polysialylated, resulting in a proportion of CCR7 still attenuated 
in CCL21 binding. There might also be additional PTMs of CCR7 not considered here. For 
example, CCR7 sulfation has been shown to enhance CCL21 binding (Phillips et al., 
2017), and sulfation of CCR7 (or lack thereof) has not been addressed here. It is also 
possible that, inclusion of a C-terminal epitope tag for ease of detection may have altered 
ST8sia4 function. Comparison could be made quite easily with new constructs expressing 
an untagged version of ST8sia4.  
Polysialylation profoundly alters the signalling properties of CCL21. When CCR7 is 
polysialylated, CCL21 appeared dominant to CCL19 in initiating b-arrestin recruitment. 
pEC50 of CCL21 in these assays drops dramatically and is significantly lower than CCL21 
when CCR7 is not polysialylated, but also lower than CCL19 when it is. However, while 
CCL21 is faster acting in the presence of pSia, it is still slower than CCL19. This increase 
in b-arrestin recruitment potency above that of CCL19 is interesting when considering 
previous observations that receptor internalisation is instigated either entirely or 
predominantly by CCL19 (Bardi et al., 2001; Otero, Groettrup and Legler, 2006). These 
studies were performed using T-cells and peripheral blood lymphocytes, and it has been 
suggested that T-cell and B-cells exhibit lower surface pSia compared to DCs (Kiermaier 
et al., 2016), which could account for this difference. However, given that CCL21 avidly 
binds glycan there may be issues with steric hinderance that could complicate 
internalisation of non-soluble chemokine in vivo. It would be of interest to determine if 
CCL21 is internalised efficiently by HEK293T cells expressing CCR7 and ST8sia4. As 
mentioned previously, CCL19 and CCL21 have been shown to recruit different GRKs to 
CCR7 (Zidar et al., 2009). Given that this study was conducted in HEK293 cells it would 
be prudent to repeat this analysis including ST8sia4 transfection and evaluate if this 
apparent bias still exists when CCR7 is polysialylated. 
There were technical issues when attempting to assess recruitment of Gi3 by polysialylated 
CCR7. The CCR7-Gi3 stable cell line appears to be refractory to subsequent transient 
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transfection, with little effect noted when attempting to introduce ST8sia4 expression. 
Although difficult to repeat, transient transfection with CCR7-Gi3/ST8sia4 resulted in a 
considerable drop in pEC50 of CCL21 compared to that obtained when ST8sia4 was either 
entirely absent or introduced by subsequent transfection. Collectively these data indicate 
that polysialylation of CCR7 improves receptor affinity and signalling capacity of CCL21, 
however has no effect on CCL19/CCR7 interaction.  
5.6.2 CCR4 
Inclusion of ST8sia4 while assessing signalling properties of CCR4 did not alter the 
signalling profile of either CCL17 or CCL22. CCL22 generated recruitment responses 
much in line with our previous assessments, while CCL17 still appeared near silent. This is 
perhaps not surprising when considering the proposed mode of action of pSia; that it 
interacts with the extended C-terminus of CCL21. CCL17 presents a more classic 
chemokine structure and does not have an extended C-terminus. As mentioned previously, 
it is possible that CCL17 acts through other signalling pathways not assessed here. 
Previous evaluations of CCL17/CCL22 affinity indicate that CCL17 binds CCR4 (Godiska 
et al., 1997), so assessing receptor activation in a blunter fashion (pERK induction for 
example), would confirm that CCL17 is active on the receptor. It would then be a matter of 
determining with other G-protein biosensors if CCL17 is selectively signalling through 
other G-protein couplings to CCR4 to induce chemotaxis or CGRP expression.  
5.6.3 CCR10 
Based on the proposed activity of CCL21/pSia interaction, CCR10 presented itself as a 
likely candidate for ST8sia4 mediated polysialylation. Like CCR7, CCR10 has previously 
been reported to demonstrate biased agonism between a ligand pair, one of which has an 
extended and positively charged C-terminus (CCL28) (Rajagopal et al., 2013). Indeed, 
when performing an IP against receptor there is a clear signal for pSia when CCR10 and 
ST8sia4 are co-transfected into HEK293T cells, which is considerably stronger than that 
observed for CCR7. While pSia and receptor cannot be readily co-localised on the blot, 
this appears to be quite common when blotting for ST8sia4 and has previously been 
attributed to the antibody against pSia detecting multiple epitopes along a single molecule 
and the fact that pSia self-cleaves, rendering it unstable in solution (Manzi et al., 1994). 
Additionally, although it is not possible to determine with CCR7, a higher molecular 
weight band is seen with CCR10-only transfection that is not visible with ST8sia4 co-
transfection. If this represents the mature glycosylated form of CCR10 it is conceivable 
that, when polysialylated, this shifts from this position. As mentioned previously, pSia can 
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degrade resulting in a highly mixed MW, it may therefore not be possible to visualise a 
single discreet band for polysialylated receptor. Performing IP against pSia itself did prove 
technically challenging when using antibody capture. Kiermaier et al had performed this 
using catalytically inactivate endo-N coupled to magnetic beads, however this was not a 
feasible option here. After considerable optimisation it was possible to visualise a specific 
band for the receptor with CCR10/ST8sia4 co-transfection, confirming that CCR10 
represents an entirely novel target of ST8sia4 mediated polysialylation. 
To determine if CCR10 polysialylation affected ligand activity, b-arrestin recruitment in 
response to CCL27 or CCL28 was assessed when CCR10 was polysialylated. 
Polysialylation resulted in CCL28 consistently recruiting b-arrestin to the receptor, albeit 
with poor efficiency and only at the highest concentrations tested. Perhaps more interesting 
is that the pEC50 of CCL27 is significantly lower when CCR10 is polysialylated. Analysis 
of CCR7 in this chapter, and by others, demonstrated that the previously reported b-
arrestin biased ligand (CCL19) was completely unaffected by receptor polysialylation in 
multiple different assays. This is clearly not the case with CCL27 however. At 12.6 kDa 
CCL27 is larger than typical for a chemokine (8-10 kDa), though is not quite as sizable as 
CCL21 and CCL28 (14.6 and 14.3 kDa respectively). CCL27 has been described as having 
a large and unstructured C-terminus (Jansma et al., 2010), which is dissimilar to the 
majority of chemokines but quite like CCL21 and CCL28. The C-terminal region of the 
chemokine also harbours a number of positively charged residues, another similarity it 
shares with CCL21 and CCL28. It is possible that, like CCL21, both CCL27 and CCL28 
exist in auto-inhibitory conformations maintained by their extended C-terminus, until 
released by interaction with the negatively charged pSia decorating their receptor. This 
may also be representative of a common mode of action of pSia in chemokine biology.  
By mining publicly available RNA-seq databases it is clear that, if a cell expresses CCR10, 
it expresses ST8sia4 as well. This would suggest that the observation that CCR10 is 
polysialylated, and that this PTM alters signalling properties of both CCL27 and CCL28, is 
unlikely to be an artefact of utilising in-vitro systems and is likely critical to its biological 
functions. It is also clear that, unlike with CCR7, the previously reported arrestin bias 
cannot be attributed simply to an absence of pSia. While CCL28 is capable of recruiting 
b-arrestin it can only do so poorly and at the highest concentrations tested.  Given that 
other studies have previously shown signalling events downstream of CCR10 consistent 
with Gi activation by CCL28, this would appear to confirm that, unlike with CCR7, the 
reported bias of this receptor is not attributable to a lack of pSia modifications in these 
studies.  
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5.6.4 Polycistronic vector development 
Obtaining reproducible measures of Gi protein recruitment using purely transient 
transfection proved challenging. Consequently, it was decided to develop a double 
expression system for these biosensors and ST8sia4-HA compatible with the development 
of stable cell lines. Unfortunately, although expression of ST8sia4-HA was comparable to 
single transfected controls, little expression of the chemokine receptor could be observed 
with these new plasmids. Although slightly larger than ST8sia4-HA from a single 
expression vector (presumably due to remaining residues from the TaV2A sequence), the 
sialyltransferase appeared to still be functional in the generation of pSia. This would 
indicate that TaV2A self-processing has occurred successfully and separated the 2 protein 
products from the same ORF, and that either translation of the downstream chemokine 
receptor has been attenuated, or the resulting protein product was rapidly degraded. Poor 
expression of the secondary product downstream of TaV2A has been reported previously 
(Momose and Morikawa, 2016), suggested to be the result of proteasomal degradation of 
the downstream product. However, it has also been shown that re-introducing the initiating 
methionine (removed from the second ORF) can improve stability of downstream 
products, as can changing the order in which proteins are encoded. As such it may be 
possible to generate a new construct with these conditions in mind that can successfully 
express both cassettes. However, it might ultimately be necessary to repeat the assays 
described here in an adherent cell line of an immune lineage, such as RAW cells, to insure 
robust expression of ST8sia4, CCR7/CCR10 and any BRET donor proteins required.  
5.6.5 Conclusion 
Described here are a number of novel findings related to the polysialylation of chemokine 
receptors. For example, CCL21/CCR7 signalling behaviour is rapidly altered in HEK293T 
cells when the receptor is polysialylated. This could go some way to explain the noted 
discrepancy in assessments of CCR7 signalling between studies using different cell types, 
as CCL21 now appears to be dominant in CCR7 activation over CCL19 in HEK293T cells 
which is more in keeping with the observable biology of this receptor. In addition, CCR4 
appears to not be polysialylated, or at the least polysialylation has no impact on signalling 
activity of either CCL22 or CCL17. Previous work does indicate that CCL17 can interact 
with CCR4 in HEK293T cells (figure 4.2.2 & 4.2.14), so questions remain as to what this 
interaction initiates downstream of the receptor. Finally, CCR10 presented itself as a 
previously undescribed  candidate for ST8sia4 polysialylation. The presence of pSia on 
CCR10 improved signalling in response to both CCL27 and CCL28, which distinguishes it 
from CCR7 which demonstrates effects of receptor polysialylation with CCL21 only. 
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When considering the ligand characteristics this does make some sense, as unlike CCL19, 
CCL27 can also be described as having an extended and positively charged C-terminus. 
This also suggests to a common mode of action of pSia on chemokine receptors, namely 
the release of chemokines from auto-inhibitory conformations via interaction with their C-
terminus.   
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Figure 5.1.1 Polysialylation of CCR7 is critical to CCL21 migratory activity 
(a) BMDCs generated from ST8sia4 KO mice demonstrate unchanged migratory capacity 
to CCL19 but are nearly incapable of migration to CCL21 when compared to BMDCs 
from WT animals. (b) IP against CCR7 and pSia results in positive signal for both the 
receptor and the pSia in both cases, indicating that CCR7 is a polysialylated protein. 
Adapted from Kiermaier et al, 2016.  
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Figure 5.2.1 Determination of CCL19 and CCL21 affinity on endogenous CCR7 
expressing BMDCs. 
(a) In vitro differentiated BMDCs were labelled with 25 nM fluorescently labelled CCL19 
in the presence of increasing concentrations of unlabelled CCL19 or CCL21. MFI was 
determined for all live single cells in the PE channel (n=3 +/- SD, representative plot 
selected from 3 independent experiments). (b) pKi values obtained were compared between 
CCL19 and CCL21 (n=3 biological replicates +/- SD, statistically significant differences 
between each parameter were determined by unpaired T-test, p≤0.05=*). 
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Figure 5.2.2 Expression of CCR7 and ST8sia4 during BMDC differentiation were 
compared by qPCR 
BMDCs were derived from murine bone marrow by repeated treatment with GM-CSF at 
day 0, 2 and 4. Levels of either (a) CCR7 or (b) ST8sia4 mRNA were assessed by RT-
qPCR relative to day 0 bone marrow (D0) at day 4 of BMDC differentiation (D4) and on 
day 7 (D7) (each data point represents a biological replicate, error bars = +/- SD, 
statistically significant differences between each parameter were determined by unpaired 
T-test, p≤0.01=**). 
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Figure 5.2.3 ST8sia4 expression in a panel of lymphoid/myeloid and adherent cell 
lines was compared by qPCR 
Quantities of ST8sia4 mRNA in a panel of commonly used (a) human and (b) mouse cell 
lines were assessed by RT-qPCR, compared to a known standard curve and expressed 
relative to the quantity of a housekeeping gene (TBP)  (each data point represents a 
biological replicate, error bars = +/- SD, statistically significant differences between 
parameters were determined by unpaired T-test, p≤0.01=**, p≤0.0001=****). 
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Figure 5.2.4 ST8sia4 expression restores CCL21’s ability to compete for receptor 
occupancy 
HEK293T cells were seeded on a 10 cm2 tissue culture dish and transfected when near-
confluent with CCR7 and ST8sia4 in a ratio of either (a) 4 µg: 1 µg or (b) 4 µg; 4 µg. 
Transfected cells were analysed 48 hours later and affinity of either CCL19 or CCL21 
determined using a FACS-based competition assays as described previously, staining with 
25 nM labelled CCL19. (c) Affinity of CCL19 was compared between HEK293T 
expressing CCR7 alone (CCL19-) and those expressing CCR7 and ST8sia4 (CCL19+). 
Percentage of non-competitor controls (%NC) was calculated by obtaining MFI values for 
live single cells in the PE channel, subtracting MFI values obtained with those from the 
empty vector control group as background, and expressing this as a percentage of cells 
stained with labelled CCL19 only. (n = 3 +/- SD, in all instances). 
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Figure 5.2.5 CCL21 is more effective for b-arrestin recruitment in the presence of 
polysialic acid 
(a) Potency of either CCL19 or CCL21 for recruitment of b-arrestin 2 was assessed in 
HEK293T cells expressing both the receptor and b-arrestin 2 as well as ST8sia4 (n = 3 +/- 
SD, representative plot selected from 3 independent experiments). (b) pEC50 values 
obtained for each chemokine (CCL19+ & CCL21+) were compared to those obtained 
previously in the same assay without ST8sia4 co-transfection (CCL19- & CCL21-) (n=3 
biological replicates +/- SD, statistically significant differences between parameters were 
determined by unpaired T-test, p≤0.01=**, p ≤0.0001=****). 
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Figure 5.2.6 CCL21 is also faster acting when CCR7 is polysialylated 
(a) Once again recruitment of b-arrestin 2 to 100 nM of either CCL19 or CCL21 was 
continuously assessed over a 30-minute period using HEK293T cells transfected with b-
arrestin 2, CCR7-YFP and ST8sia4-HA (n = 3 +/- SD, representative plot selected from 3 
independent experiments). (b) Halftime to maximal BRET ratio obtained by each 
chemokine was compared without (CCL19- & CCL21-) and with (CCL19+ & CCL21+) 
ST8sia4 co-transfection (n=3 biological replicates +/- SD, statistically significant 
differences between parameters were determined by unpaired T-test, p≤0.01=**). 
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Figure 5.2.7 Polysialylation of CCR7 alters Gi3 recruitment profile of CCL21 
(a) Stable cell lines expressing the CCR7-Gi3 biosensor were transiently transfected with 
ST8sia4-HA 48 hours prior to analysis. 24-hours later expression of the biosensor was 
induced with doxycycline, cells seeded on a 96-well plate and analysis performed a further 
24 hours later  (n = 3 +/- SD, representative plot selected from 3 independent experiments). 
(b) HEK293T cells seeded on a 10 cm2 dish were transiently transfected when near 
confluent with the CCR7-Gi3 biosensor and ST8sia4 in a ratio of 1 µg sensor: 1 µg 
ST8sia4. 24 hours later cells were transferred to a 96-well plate and Gi3 recruitment 
assessed a further 24 hours after this (n = 3 +/- SD, representative plot selected from 2 
independent experiments). (c) The pEC50 values obtained for each chemokine were 
compared between those generated previously (CCL19- & CCL21-), those achieved with 
stable cell lines subsequently transfected with ST8sia4 (CCL19+(stable) & 
CCL21+(stable)), and those obtained with fully transiently transfected cells 
(CCL19+(trans) & CCL21+(trans)) (each point represents a biological replicate, error bars 
represent SD. Statistically significant differences between parameters were evaluated by 
unpaired T-test, p≤0.05=*).  
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Figure 5.2.8 Co-transfection of CCR4 with ST8sia4 does not appear to affect CCL17 
signalling potential  
(a) Assessment of b-arrestin recruitment was performed with cells expressing CCR4-YFP, 
b-arrestin 2-rluc and ST8sia4-HA (n = 3 +/- SD). (b) Recruitment of Gi3 was assessed by 
transient transfection of the appropriate biosensor with ST8sia4 in a 1:1 ratio into 
HEK293T cells as described previously (n=3 +/- SD). 
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Figure 5.2.9 IP experiments indicated polysialylation of both CCR7 and CCR10  
HEK293T cells were seeded onto 10 cm2 dishes and co-transfected when near-confluent 
with either 4 µg empty vector, CCR7-FLAG or CCR10-FLAG and either a further 4 µg 
empty vector or ST8sia4-HA. Whole cell lysate was obtained 48 hours later, pre-cleared 
with isotype antibody and  Protein L PLUS-Agarose beads, and receptor then pulled down 
with anti-FLAG (M2) antibody and agarose beads, with protein eluted in glycine-elution 
buffer (pH2.5). Eluted protein was denatured and run as previously described for western 
blotting, and the resultant blots interrogated with antibodies against FLAG and polysialic 
acid. a-FLAG (low) and a-FLAG (high) represent different exposure times of the same 
membrane. (representative example of 4 independent experiments) 
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Figure 5.2.10 IP against pSia confirms polysialylation of CCR10  
HEK293T cells were seeded and transfected as described previously except that the Gi3 
biosensor for either CCR7 or CCR10 was used in place of the FLAG tagged versions of 
these receptors. IP was performed as before using anti-pSia(735) antibody and protein 
eluted by direct pellet disruption and denatured/reduced in 2x loading buffer + 100 mM 
DTT.  This was then run as previously described for western blotting, and blots probed 
with antibodies against GFP (receptor) and polysialic acid. a-GFP (low) and a-GFP (high) 
represent different exposure times of the same membrane. (representative example of 2 
independent experiments)  
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Figure 5.2.11 Polysialylation of CCR10 alters the recruitment profile of CCL27 and 
CCL28 
(a) CCR10-YFP and b-arrestin 2-nluc were transfected into HEK293T cells in a ratio of 
4.9 µg:100 ng (+ 4 µg ST8sia4), and recruitment of b-arrestin 2 by CCL27 and CCL28 
assessed as before (n = 3 +/- SD, representative plot selected from 3 independent 
experiments). (b) pEC50 values obtained for CCL27 with (CCL27+) and without (CCL27-) 
polysialylation were compared (n=3 biological replicates +/-SD. Statistically significant 
differences were determined by unpaired T-test, p≤0.05=*). 
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Figure 5.2.12 Expression of CCR10 correlates with expression of ST8sia4 in primary 
murine cells 
The publicly available Gene Skyline (RNA-seq) dataset of murine primary immune cells 
was accessed via the Immunological Genome Project’s web portal 
(http://rstats.immgen.org/Skyline/skyline.html). The 6 highest CCR10 expressing cell 
subsets available were selected and graphs generated to display (a) CCR10 and (b) ST8sia4 
expression.  In addition, 3 DC sub-populations are included for comparison purposes. 
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Figure 5.2.13 Schematic representation of TaV2A double-expression plasmid 
development 
(a) A first generation plasmid was developed that encoded for ST8sia4-HA and the TaV2A 
sequence, flanked by restriction sites allowing for insertion of chemokine 
receptors/reporter constructs downstream. (b) Subsequently, the chemokine receptors were 
inserted downstream of TaV2A, generating a new series of polycistronic expression 
vectors. 
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Figure 5.2.14 Assessment of expression by TaV2A plasmids 
HEK293T cells were transiently transfected with all of the TaV2A plasmids generated. 
Whole cell lysate was then tested by western blotting for expression of ST8sia4 (a-HA), 
chemokine receptor/SPASM biosensor (a-GFP (low) & a-GFP (high)), a housekeeping 
protein (a-GAPDH) as well as pSia (a-pSia). a-GFP (low) and a-GFP (high) represent 
different exposure times of the same membrane. 
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6 Discussion 
The data described in this thesis present a number of novel findings that may have wide 
reaching implications. Firstly, CCR10 is novel target of ST8sia4 mediated polysialylation. 
This in and of itself is interesting, however potentially also alludes to a common feature of 
pSia in chemokine biology. This being that chemokines featuring an extended C-terminus 
with multiple positively charged amino acids may require polysialylation of their receptors 
in order to fully signal through them. This would mean that CCR3 (which also binds 
CCL28), CCR6 (CCL20) and CCR9 (CCL25) could for example be polysialylated proteins 
(Svensson et al., 2002; Schutyser, Struyf and Van Damme, 2003; Danilova et al., 2015). 
This does make a certain measure of sense. Analysis of publicly available expression data 
from the likes of Immgen or the Human Protein Atlas indicates that ST8sia4 is widely 
expressed in the immune system. However, pSia is considered a highly restricted PTM, 
described on only a handful of proteins, namely NCAM, NRP2, CD36, synaptic cell 
adhesion molecule 1, the a subunit of voltage dependent sodium channel, the poly-
sialyltransferase themselves, and most recently CCR7 (Colley, Kitajima and Sato, 2014; 
Kiermaier et al., 2016). This would certainly imply that there are more targets of ST8sia4 
mediated polysialylation expressed by cells of the immune system than have been 
identified thus far.  
The profound effects that polysialylation (or lack thereof) can have on signalling behaviour 
and biological activity also raises another intriguing possibility. As described by Kiermaier 
et al, DCs exhibit higher surface pSia than T-cell and B-cells, presumably as a 
consequence of varying expression of ST8sia4 between these cell types. As has been 
mentioned previously, CCL21 recruits fewer GRKs than CCL19 when CCR7 is 
presumably not polysialylated in HEK293 cells. Additionally, the data presented here 
indicate that CCL21 is also deficient in recruitment of certain G-proteins, demonstrating a 
skewed signalling profile when CCR7 is not polysialylated. It is conceivable that, by 
altering the level of polysialylation, the same receptor expressed in different cell types 
could demonstrate divergent ligand preferences, which would represent a subtle means of 
fine-tuning the chemotactic response to certain chemokines. The observation that Flt3 
ligand derived BMDCs are more chemotactic than those derived from GM-CSF treatment 
could represent an example of this, however this has not been specifically addressed yet.  
It would be of interest to determine if, as with CCR7, primary cells expressing CCR10 
demonstrate varying levels of pSia, and see if this consideration fits with the observable 
biology of these cells. This also raises another interesting prospect; that it might be 
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possible to selectively target one ligand over another on the same receptor by disrupting 
pSia formation. As has been seen, removal of pSia can fundamentally impair the signalling 
functions of a chemokine, so conceptually this could be replicated in vivo via 
pharmacological intervention. As mentioned previously targeting of pSia 
pharmacologically is already being considered as a novel cancer therapy, and small 
molecule antagonists that effectively abrogate cell surface sialylation have been evaluated 
in models of cancer where they demonstrate no cytotoxicity but inhibit the metastatic 
phenotype of cancer cell lines (Chiang et al., 2010). Targeting of the chemokine system in 
this manner could hold a number of benefits. Antagonists targeting chemokine receptors 
rarely reach their intended clinical outcomes in trials, frequently attributed to the inability 
of these drugs to reach a threshold of receptor coverage sufficient to block chemotactic 
activity entirely. By targeting pSia one could conceptually bypass this issue, as cells 
expressing these receptors would be highly refractory to any chemokine like CCL21 
CCL28 that require pSia to be released from an auto-inhibitory conformation. As well, the 
lack of cytotoxicity would mean that cells expressing polysialylated receptors would still 
be able to migrate in response to other chemokines that don’t require this release, and as 
such could selectively silence one ligand on a receptor while otherwise leaving the 
signalling axis unperturbed. However, polysialyltransferases do target a number of 
proteins. While it is regarded as a highly-restricted PTM, consideration would need to be 
made of side-effects associated with potentially abrogating polysialylation on other 
targeted proteins. 
The findings presented here also allude to an important but often overlooked consideration 
when using cell lines and in vitro means of evaluating receptors; that different cells exhibit 
differences in PTMs. ST8sia4 expression was readily detectable in every immune derived 
cell evaluated, however it is either completely  absent (3T3, COS-7) or only found at the 
limits of detection (HEK293T) in the epithelial/fibroblast like cells tested. This makes 
some sense biologically as these are immortalised somatic cells from non-neuronal 
lineages that form a cohesive monolayer in culture. As such they are unlikely to have 
expressed ST8sia4 before being cultured and would have little use for pSia in culture given 
its contact inhibitory properties. These are all cell lines frequently used in detailed receptor 
analysis and molecular biology generally. This is because they are adherent, easily grown 
and maintained and can be readily transfected in transient and stable expression systems. 
This is especially true when compared with lymphoid/myeloid derived cells, which are 
often difficult to transfect.  
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However, as demonstrated here, the lack of this very specific PTM in these cells can 
fundamentally alter the data obtained from these studies. In the case of CCR7, 
consideration of polysialylation alters the perception of signalling bias of this receptor 
substantially. As mentioned, the previously reported bias of CCR7 is that CCL19 readily 
recruits G-proteins and b-arrestin to the receptor, but that CCL21 preferentially signals 
through G-protein coupling (Förster, Davalos-Misslitz and Rot, 2008).  However, unlike in 
previous direct evaluations of recruitment of signalling machinery to CCR7, evaluation 
here indicates that CCL21 is, if anything, more potent in triggering recruitment of b-
arrestin by CCR7 than CCL19. It is likely that previous reports to the contrary are due to 
the lack of polysialylation of the receptor in the cell lines used, and that while bias has 
been observed in terms of signalling (SHP2) it is not the classical bias described 
previously.  
Interestingly, in a similar BRET based study evaluating CCR7 bias, HEK293 cells were 
used in all assays directly assessing recruitment but CHO-K1 cells were used to evaluate 
receptor affinity (Corbisier et al., 2015). In this study a signalling profile of CCL19 and 
CCL21 was presented that closely mirrored the findings presented in Chapter 4 of this 
thesis. However, when ligand affinity was assessed in this study, using CCR7 expressed in 
CHO-K1 cells, CCL19 and CCL21 were effectively equivalent in displacing radiolabelled 
CCL19. Wild-type CHO-K1 cells do express ST8sia4 and NCAM, so have pSia on their 
surface (Windfuhr et al., 2000). Consequently, CCR7 expressed in these cells is likely 
polysialylated and the observation of equivalent receptor affinity of CCL19 and CCL21 for 
CCR7 expressed in these cells is perhaps unsurprising.  
However, this does raise an interesting point; that while evaluating polysialylated proteins 
careful consideration of the specific properties of the cell line used need to be made. It 
simply is not feasible to easily perform the kinds of BRET based assays presented here in 
lymphoid/myeloid cell lines, and while CHO-K1 and RAW cells (an adherent macrophage 
line) represent an attractive test-bed for working with polysialylated proteins, these carry 
caveats also. In our hands they are less readily transfectable than HEK293T (unpublished 
observations), and in the BRET based assays we have been using, the ratio of donor to 
acceptor proteins needs to be well controlled. A more difficult transfection could 
complicate this. However, as was seen when assessing Gi3 recruitment to CCR7, 
subsequent transient transfections of ST8sia4 into the stable cell lines used for this analysis 
is difficult. Also, relying on purely transient transfection is either sub-optimal or simply 
not possible when using SPASM biosensors. As such considerations must be made when 
designing future experiments working with polysialylated proteins to ensure a workable 
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balance of sufficient expression of the sialyltransferase, its target and any reporter/donor 
proteins, in a cell type amenable to the intended analysis to be performed.   
6.1 Future directions 
The data presented here appeared to indicate that CCL21 is a balanced ligand, rather than a 
G-protein biased one. This is in contrast with previous reports on CCL21 which indicate 
that it is poorly internalised. However, as mentioned before, differences in the kind of cells 
used, and in particular the lack of polysialylation of CCR7, are likely to have contributed 
to this disparity. It would be of interest to measure internalisation directly in HEK293T 
cells, potentially utilising a pH dependent dye such as pHrodo avidin conjugated to a biotin 
labelled CCL21, should one become available. This would determine if the recruitment of 
b-arrestin by CCL21 observed here results in the expected functional consequence of 
CCR7 internalisation, or if this finding is incidental or serves other signalling functions for 
the receptor. 
It would also be a priority to establish a means of consistently evaluating G-protein 
recruitment in cells expressing ST8sia4. This would be of particular interest for CCR10 as 
it would help to affirm that pSia is important in its biological activity and could help to 
confirm the perceived bias of this receptor. Polycistronic vectors were established to 
express both ST8sia4 and chemokine receptors of interested, with the intention being to 
establish stable cell lines that would express both near-equally. However, while expression 
of the first protein (ST8sia4) could be readily demonstrated, little to no expression was 
noted for the second (chemokine receptors/SPASM biosensors). Seemingly this is a known 
issue when using the TaV2A domain to express multiple proteins from a single ORF and 
has been  attributed to both poor translation of the second protein and rapid proteasomal 
degredation of the resulting product (Momose and Morikawa, 2016). Conceptually a vector 
expressing multiple copies of the second protein each separated by a distinct 2A peptide, or 
reintroducing the initiating methionine of the second protein, might be able to overcome 
this issue. It might be simpler to transfect the stable cell lines already generated with an 
expression vector for ST8sia4 that can be selected for with an additional antibiotic. 
However, there may be some issues with such an approach. As demonstrated when trying 
to introduce ST8sia4 via transient transfection, these stable cell lines are refractory to 
subsequent transfection. As well, a step-wise establishment of double-stable cell lines in 
this manner is likely to require selection, expansion and evaluation of individual clones. 
This would result in a high passage number before cells are even useable. It might 
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therefore be easier to establish stable expression of SPASM biosensors in a cell lineage 
known to express ST8sia4 at rest, such as CHO-K1 or RAW cells.  
Establishing if low/no ST8sia4 expression is a common feature of HEK293 cells and their 
derivatives would also be of considerable interest. It has been demonstrated that, in the 
HEK293T cells used here, ST8sia4 expression is effectively absent. Additionally, inclusion 
of ST8sia4 in transfections of HEK293T with CCR7 restored CCL21 interaction. 
Similarly, evaluation of Gi-protein recruitment by CCR7 in response to CCL21 indicated 
that signalling potential of the chemokine is blunted. This would imply that the HEK293 
derived Flp-In TRex cell line used to generate the stable lines used in these assays is 
similarly deficient in ST8sia4 expression. However, at least one study evaluated 
CCL19/CCL21 affinity for CCR7 in a HEK293 derived cell line (HEK293E) and 
demonstrated the same comparable affinity of these chemokines as has been seen 
elsewhere (Sullivan et al., 1999). The HEK293E were generated by inducing stable 
expression of the Epstein barr virus protein EBNA1, and are most frequently used in the 
large-scale production of recombinant proteins (Tom, Bisson and Durocher, 2008). When 
used in this manner they are grown in suspension rather than as an adherent cell layer. 
Consequently, it is possible that they may bear pSia on their cell surface as it’s contact 
inhibitory properties might aid this phenotype. Differences in methodology are again quite 
apparent, namely that affinity was assessed on cell membranes rather than whole live cells, 
using picomolar concentrations of radiolabelled CCL19 or CCL21. However, given the 
total absence of CCL21 competition observed in Chapter 4 of this thesis, it is difficult to 
ignore the disparity. Variable receptor polysialylation could account for the differences 
noted when evaluating CCR7 signalling in different cell lineages. Additionally, HEK293 
derived cells are used almost universally in receptor characterisation and compound 
screenings. It would be important to evaluate ST8sia4 expression in HEK293 cells from 
multiple sources. This would help to establish if the lack of ST8sia4 expression observed 
here is indicative of all/most HEK293 derived cell lines, or simply a peculiarity of the cells 
used in this thesis 
Finally, it would be beneficial to determine if primary cells expressing CCR10 do indeed 
bear pSia on their surface, and if this PTM modifies CCR10 activity in vivo. The former 
would be a relatively simple matter of harvesting CCR10 expressing cells, such as gd T-
cells or plasmablasts, from mouse tissues and evaluating surface pSia and CCR10 by flow 
cytometry. The latter however requires additional consideration. Purifying CCR10 
expressing cell types, treating them with endo-N or PNGase F and evaluating chemotaxis 
by transwell or 3D migration could determine if stripping CCR10 of polysialylation affects 
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the chemotactic potential of CCL27 and CCL28 for primary cells in a similar manner to 
simply deglycosylating them. Alternatively, purifying these cells from ST8sia4 KO mice 
could achieve a similar effect without the need for additional enzymatic treatment of cells. 
It would also be possible to assess if there is altered cellularity in tissues where CCR10 
expressing cells could be expected, such as in the skin and mucosal epithelium. In either 
case, this would indicate if pSia on CCR10 results in functional consequences for 
endogenously CCR10 expressing cells, and hopefully validate the in vitro findings 
presented here.  
  
182 
 
 References 
Airoldi, I. and Ribatti, D. (2011) ‘Regulation of angiostatic chemokines driven by IL-12 
and IL-27 in human tumors’, Journal of Leukocyte Biology. doi: 10.1189/jlb.0511237. 
Ajram, L. et al. (2014) ‘Internalization of the chemokine receptor CCR4 can be evoked by 
orthosteric and allosteric receptor antagonists’, European Journal of Pharmacology. doi: 
10.1016/j.ejphar.2014.02.007. 
Al-Saraireh, Y. M. J. et al. (2013) ‘Pharmacological Inhibition of polysialyltransferase 
ST8SiaII Modulates Tumour Cell Migration’, PLoS ONE. doi: 
10.1371/journal.pone.0073366. 
Alexeev, V. et al. (2013) ‘Analysis of chemotactic molecules in bone marrow-derived 
mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to 
cutaneous tissues’, Cytotherapy. doi: 10.1016/j.jcyt.2012.11.006. 
Allavena, P. et al. (2008) ‘The inflammatory micro-environment in tumor progression: The 
role of tumor-associated macrophages’, Critical Reviews in Oncology/Hematology. doi: 
10.1016/j.critrevonc.2007.07.004. 
Allen, S. J., Crown, S. E. and Handel, T. M. (2007) ‘Chemokine:Receptor Structure, 
Interactions, and Antagonism’, Annual Review of Immunology, 25(1), pp. 787–820. doi: 
10.1146/annurev.immunol.24.021605.090529. 
Anders, H. J., Romagnani, P. and Mantovani, A. (2014) ‘Pathomechanisms: Homeostatic 
chemokines in health, tissue regeneration, and progressive diseases’, Trends in Molecular 
Medicine. doi: 10.1016/j.molmed.2013.12.002. 
Anderson, C. A., Solari, R. and Pease, J. E. (2016) ‘Biased agonism at chemokine 
receptors: obstacles or opportunities for drug discovery?’, Journal of Leukocyte Biology. 
doi: 10.1189/jlb.2MR0815-392R. 
Ansel, K. M. et al. (2000) ‘A chemokine-driven positive feedback loop organizes 
lymphoid follicles’, Nature. doi: 10.1038/35018581. 
Ara, T. et al. (2005) ‘The role of CXCL12 in the organ-specific process of artery 
183 
 
formation’, Blood. doi: 10.1182/blood-2004-07-2563. 
Banfield, G. et al. (2010) ‘CC Chemokine Receptor 4 (CCR4) in human allergen-induced 
late nasal responses’, Allergy: European Journal of Allergy and Clinical Immunology. doi: 
10.1111/j.1398-9995.2010.02327.x. 
Bannert, N. et al. (2001) ‘Sialylated O-Glycans and Sulfated Tyrosines in the NH 2 -
Terminal Domain of CC Chemokine Receptor 5 Contribute to High Affinity Binding of 
Chemokines’, The Journal of Experimental Medicine. doi: 10.1084/jem.194.11.1661. 
Bardi, G. et al. (2001) ‘The T cell chemokine receptor CCR7 is internalized on stimulation 
with ELC, but not with SLC’, European Journal of Immunology. doi: 10.1002/1521-
4141(200111)31:11<3291::AID-IMMU3291>3.0.CO;2-Z. 
Bax, M. et al. (2009) ‘Interaction of polysialic acid with CCL21 regulates the migratory 
capacity of human dendritic cells’, PLoS ONE. doi: 10.1371/journal.pone.0006987. 
Behm, B. et al. (2012) ‘Cytokines, chemokines and growth factors in wound healing’, 
Journal of the European Academy of Dermatology and Venereology. doi: 10.1111/j.1468-
3083.2011.04415.x. 
Belperio, J. A. et al. (2000) ‘CXC chemokines in angiogenesis.’, Journal of leukocyte 
biology. doi: 10.1160/TH07. 
Berchiche, Y. A. et al. (2011) ‘Different Effects of the Different Natural CC Chemokine 
Receptor 2b Ligands on  -Arrestin Recruitment, G i Signaling, and Receptor 
Internalization’, Molecular Pharmacology. doi: 10.1124/mol.110.068486. 
Berger, E. A., Murphy, P. M. and Farber, J. M. (1999) ‘CHEMOKINE RECEPTORS AS 
HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease’, Annual Review of 
Immunology. doi: 10.1146/annurev.immunol.17.1.657. 
Bermudez, D. M. et al. (2011) ‘Inhibition of stromal cell-derived factor-1α further impairs 
diabetic wound healing’, Journal of Vascular Surgery. doi: 10.1016/j.jvs.2010.10.056. 
Bizzarri, C. et al. (2006) ‘ELR+ CXC chemokines and their receptors (CXC chemokine 
receptor 1 and CXC chemokine receptor 2) as new therapeutic targets’, Pharmacology and 
Therapeutics. doi: 10.1016/j.pharmthera.2006.04.002. 
184 
 
Bonecchi, R. et al. (1998) ‘Differential Expression of Chemokine Receptors and 
Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s’, The Journal of 
Experimental Medicine. doi: 10.1084/jem.187.1.129. 
Bonner, K. et al. (2013) ‘CCL17/thymus and activation-regulated chemokine induces 
calcitonin gene-related peptide in human airway epithelial cells through CCR4’, Journal of 
Allergy and Clinical Immunology. Elsevier Ltd, 132(4), p. 942–950.e3. doi: 
10.1016/j.jaci.2013.04.015. 
Boring, L. et al. (1997) ‘Impaired monocyte migration and reduced type 1 (Th1) cytokine 
responses in C-C chemokine receptor 2 knockout mice’, Journal of Clinical Investigation. 
doi: 10.1172/JCI119798. 
Borsig, L. et al. (2014) ‘Inflammatory chemokines and metastasis-tracing the accessory’, 
British Dental Journal. doi: 10.1038/onc.2013.272. 
Britschgi, M. R., Favre, S. and Luther, S. A. (2010) ‘CCL21 is sufficient to mediate DC 
migration, maturation and function in the absence of CCL19’, European Journal of 
Immunology. doi: 10.1002/eji.200939921. 
Le Brocq, M. L. et al. (2014) ‘Chemokines as Novel and Versatile Reagents for Flow 
Cytometry and Cell Sorting’, The Journal of Immunology. doi: 
10.4049/jimmunol.1303371. 
Brown, N. E., Blumer, J. B. and Hepler, J. R. (2015) ‘Bioluminescence resonance energy 
transfer to detect protein-protein interactions in live cells’, in Protein-Protein Interactions: 
Methods and Applications: Second Edition. doi: 10.1007/978-1-4939-2425-7_30. 
Burg, J. S. et al. (2015) ‘Structural basis for chemokine recognition and activation of a 
viral G protein-coupled receptor’, Science. doi: 10.1080/11038128.2016.1198419. 
Byers, M. A. et al. (2008) ‘Arrestin 3 Mediates Endocytosis of CCR7 following Ligation 
of CCL19 but Not CCL21’, The Journal of Immunology. doi: 
10.4049/jimmunol.181.7.4723. 
Calandreau, L. et al. (2010) ‘Differential impact of polysialyltransferase ST8SiaII and 
ST8SiaIV knockout on social interaction and aggression’, Genes, Brain and Behavior. doi: 
10.1111/j.1601-183X.2010.00635.x. 
185 
 
Carlsen, H. S. et al. (2005) ‘Disparate lymphoid chemokine expression in mice and men: 
No evidence of CCL21 synthesis by human high endothelial venules’, Blood. doi: 
10.1182/blood-2004-11-4353. 
Cha, H.-R. et al. (2011) ‘Mucosa-Associated Epithelial Chemokine/CCL28 Expression in 
the Uterus Attracts CCR10+ IgA Plasma Cells following Mucosal Vaccination via 
Estrogen Control’, The Journal of Immunology. doi: 10.4049/jimmunol.1100402. 
Charo, I. F. and Ransohoff, R. M. (2006) ‘The Many Roles of Chemokines and Chemokine 
Receptors in Inflammation’, New England Journal of Medicine. doi: 
10.1056/NEJMra052723. 
Chatterjee, A. et al. (2012) ‘Chemokines and Chemokine Receptors in susceptibility to 
HIV-1 infection and progression to AIDS’, Disease Markers. doi: 10.3233/DMA-2011-
0874. 
Chatterjee, A. et al. (2013) ‘Efficient viral delivery system for unnatural amino acid 
mutagenesis in mammalian cells’, Proceedings of the National Academy of Sciences. doi: 
10.1073/pnas.1309584110. 
Chen, L. et al. (2014) ‘Upregulation of chemokine receptor CCR10 is essential for glioma 
proliferation, invasion and patient survival’, Oncotarget. doi: 10.18632/oncotarget.2134. 
Cheung, I. Y., Vickers, A. and Cheung, N. K. V (2006) ‘Sialyltransferase STX (ST8SiaII): 
A novel molecular marker of metastatic neuroblastoma’, International Journal of Cancer, 
119(1), pp. 152–156. doi: 10.1002/ijc.21789. 
Chi, B. J. et al. (2015) ‘Silencing of CCR7 inhibits the growth, invasion and migration of 
prostate cancer cells induced by VEGFC’, International Journal of Clinical and 
Experimental Pathology. 
Chiang, C. H. et al. (2010) ‘A novel sialyltransferase inhibitor AL10 suppresses invasion 
and metastasis of lung cancer cells by inhibiting integrin-mediated signaling’, Journal of 
Cellular Physiology. doi: 10.1002/jcp.22068. 
Clark-Lewis, I. et al. (1994) ‘Structural requirements for interleukin-8 function identified 
by design of analogs and CXC chemokine hybrids’, Journal of Biological Chemistry. 
186 
 
Coin, I. et al. (2013) ‘XGenetically encoded chemical probes in cells reveal the binding 
path of urocortin-i to CRF class B GPCR’, Cell. doi: 10.1016/j.cell.2013.11.008. 
Colley, K. J., Kitajima, K. and Sato, C. (2014) ‘Polysialic acid: Biosynthesis, novel 
functions and applications’, Critical Reviews in Biochemistry and Molecular Biology. doi: 
10.3109/10409238.2014.976606. 
Comerford, I. et al. (2013) ‘A myriad of functions and complex regulation of the 
CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system’, Cytokine and 
Growth Factor Reviews. doi: 10.1016/j.cytogfr.2013.03.001. 
Corbisier, J. et al. (2015) ‘Biased signaling at chemokine receptors’, Journal of Biological 
Chemistry. doi: 10.1074/jbc.M114.596098. 
Corsiero, E. et al. (2012) ‘Role of lymphoid chemokines in the development of functional 
ectopic lymphoid structures in rheumatic autoimmune diseases’, Immunology Letters. doi: 
10.1016/j.imlet.2012.04.013. 
Cotton, M. and Claing, A. (2009) ‘G protein-coupled receptors stimulation and the control 
of cell migration’, Cellular Signalling. doi: 10.1016/j.cellsig.2009.02.008. 
Cowan, J. E. et al. (2014) ‘Differential Requirement for CCR4 and CCR7 during the 
Development of Innate and Adaptive   T Cells in the Adult Thymus’, The Journal of 
Immunology. doi: 10.4049/jimmunol.1400993. 
Culley, F. J. et al. (2006) ‘Role of CCL5 (RANTES) in Viral Lung Disease’, Journal of 
Virology. doi: 10.1128/JVI.00496-06. 
Curiel, T. J. et al. (2004) ‘Specific recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival’, Nature Medicine. doi: 
10.1038/nm1093. 
Curreli, S. et al. (2007) ‘Polysialylated neuropilin-2 is expressed on the surface of human 
dendritic cells and modulates dendritic cell-T lymphocyte interactions’, Journal of 
Biological Chemistry. doi: 10.1074/jbc.M702965200. 
Dai, Y. et al. (2017) ‘Association of CXCR4, CCR7, VEGF-C and VEGF-D expression 
with lymph node metastasis in patients with cervical cancer’, European Journal of 
187 
 
Obstetrics Gynecology and Reproductive Biology. doi: 10.1016/j.ejogrb.2017.04.043. 
Dairaghi, D. J. et al. (2011) ‘Pharmacokinetic and pharmacodynamic evaluation of the 
novel CCR1 antagonist CCX354 in healthy human subjects: Implications for selection of 
clinical dose’, Clinical Pharmacology and Therapeutics. doi: 10.1038/clpt.2011.33. 
Danilova, E. et al. (2015) ‘A role for CCL28-CCR3 in T-cell homing to the human upper 
airway mucosa’, Mucosal Immunology. doi: 10.1038/mi.2014.46. 
Davalos-Misslitz, A. C. M. et al. (2007) ‘Generalized multi-organ autoimmunity in CCR7-
deficient mice’, European Journal of Immunology. doi: 10.1002/eji.200636656. 
Devine, S. M. et al. (2008) ‘Rapid mobilization of functional donor hematopoietic cells 
without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction’, Blood. 
doi: 10.1182/blood-2007-12-130179. 
Donnelly, M. L. L. et al. (2001) ‘Analysis of the aphthovirus 2A/2B polyprotein 
“cleavage” mechanism indicates not a proteolytic reaction, but a novel translational effect: 
A putative ribosomal “skip”’, Journal of General Virology, 82(5), pp. 1013–1025. doi: 
10.1099/0022-1317-82-5-1013. 
Ehrlich, L. I. R. et al. (2009) ‘Differential Contribution of Chemotaxis and Substrate 
Restriction to Segregation of Immature and Mature Thymocytes’, Immunity. doi: 
10.1016/j.immuni.2009.09.020. 
Eyerich, S. et al. (2009) ‘Th22 cells represent a distinct human T cell subset involved in 
epidermal immunity and remodeling’, Journal of Clinical Investigation. doi: 
10.1172/JCI40202. 
Farajzadeh Valilou, S. et al. (2018) ‘The role of inflammatory cytokines and tumor 
associated macrophages (TAMs) in microenvironment of pancreatic cancer’, Cytokine and 
Growth Factor Reviews. doi: 10.1016/j.cytogfr.2018.01.007. 
Farzan, M. et al. (1999) ‘Tyrosine sulfation of the amino terminus of CCR5 facilitates 
HIV-1 entry’, Cell. doi: 10.1016/S0092-8674(00)80577-2. 
van der Fits, L. et al. (2009) ‘Imiquimod-Induced Psoriasis-Like Skin Inflammation in 
Mice Is Mediated via the IL-23/IL-17 Axis’, The Journal of Immunology. doi: 
188 
 
10.4049/jimmunol.0802999. 
Förster, R. et al. (1999) ‘CCR7 coordinates the primary immune response by establishing 
functional microenvironments in secondary lymphoid organs’, Cell. doi: 10.1016/S0092-
8674(00)80059-8. 
Förster, R., Davalos-Misslitz, A. C. and Rot, A. (2008) ‘CCR7 and its ligands: Balancing 
immunity and tolerance’, Nature Reviews Immunology. doi: 10.1038/nri2297. 
Forward, N. a et al. (2010) ‘Signaling through TLR7 enhances the immunosuppressive 
activity of murine CD4+CD25+ T regulatory cells’, J.Leukoc.Biol. doi: 
10.1189/jlb.0908559. 
Fujita, Y. et al. (2006) ‘Presence of circulating CCR10+ T cells and elevated serum 
CTACK/CCL27 in the early stage of mycosis fungoides’, Clinical Cancer Research. doi: 
10.1158/1078-0432.CCR-05-1513. 
Furudate, S. et al. (2017) ‘Immunomodulatory Effect of Imiquimod Through CCL22 
Produced by Tumor-associated Macrophages in B16F10 Melanomas’, Anticancer 
Research, 37(7), pp. 3461–3471. doi: 10.21873/anticanres.11714. 
Gangadhar, T., Nandi, S. and Salgia, R. (2010) ‘The role of chemokine receptor CXCR4 in 
lung cancer’, Cancer Biology and Therapy. doi: 10.4161/cbt.9.6.11233. 
Geisse, J. et al. (2004) ‘Imiquimod 5% cream for the treatment of superficial basal cell 
carcinoma: Results from two phase III, randomized, vehicle-controlled studies’, Journal of 
the American Academy of Dermatology. doi: 10.1016/j.jaad.2003.11.066. 
Ghosh, E. et al. (2015) ‘Methodological advances: The unsung heroes of the GPCR 
structural revolution’, Nature Reviews Molecular Cell Biology. doi: 10.1038/nrm3933. 
Gobert, M. et al. (2009) ‘Regulatory T cells recruited through CCL22/CCR4 are 
selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to 
an adverse clinical utcome’, Cancer Research. doi: 10.1158/0008-5472.CAN-08-2360. 
Godiska, R. et al. (1997) ‘Human macrophage-derived chemokine (MDC), a novel 
chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.’, 
The Journal of experimental medicine. doi: 10.1084/jem.185.9.1595. 
189 
 
Grant, A. J. et al. (2002) ‘Hepatic expression of secondary lymphoid chemokine (CCL21) 
promotes the development of portal-associated lymphoid tissue in chronic inflammatory 
liver disease’, American Journal of Pathology. doi: 10.1016/S0002-9440(10)62570-9. 
Groer, C. E. et al. (2011) ‘Agonist-directed interactions with specific β-arrestins determine 
μ-opioid receptor trafficking, ubiquitination, and dephosphorylation’, Journal of Biological 
Chemistry. doi: 10.1074/jbc.M111.248310. 
Gundry, J. et al. (2017) ‘A practical guide to approaching biased agonism at G protein 
coupled receptors’, Frontiers in Neuroscience, 11(JAN), pp. 1–6. doi: 
10.3389/fnins.2017.00017. 
Gunn, M. D. et al. (1999) ‘Mice Lacking Expression of Secondary Lymphoid Organ 
Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization’, The 
Journal of Experimental Medicine. doi: 10.1084/jem.189.3.451. 
Hanahan, D. and Weinberg, R. A. (2011) ‘Hallmarks of cancer: The next generation’, Cell. 
doi: 10.1016/j.cell.2011.02.013. 
Hanlon, C. D. and Andrew, D. J. (2015) ‘Outside-in signaling - a brief review of GPCR 
signaling with a focus on the Drosophila GPCR family’, Journal of Cell Science. doi: 
10.1242/jcs.175158. 
Hauser, A. S. et al. (2017) ‘Trends in GPCR drug discovery: New agents, targets and 
indications’, Nature Reviews Drug Discovery. doi: 10.1038/nrd.2017.178. 
Hauser, M. A. et al. (2016) ‘Inflammation-Induced CCR7 Oligomers Form Scaffolds to 
Integrate Distinct Signaling Pathways for Efficient Cell Migration’, Immunity. doi: 
10.1016/j.immuni.2015.12.010. 
Hendrix, C. W. et al. (2004) ‘Safety, pharmacokinetics, and antiviral activity of 
AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection’, Journal of Acquired 
Immune Deficiency Syndromes. doi: 10.1097/01.qai.0000137371.80695.ef. 
Hieshima, K. et al. (2003) ‘CCL28 Has Dual Roles in Mucosal Immunity as a Chemokine 
with Broad-Spectrum Antimicrobial Activity’, The Journal of Immunology. doi: 
10.4049/jimmunol.170.3.1452. 
190 
 
Hirahara, K. et al. (2006) ‘The Majority of Human Peripheral Blood 
CD4+CD25highFoxp3+ Regulatory T Cells Bear Functional Skin-Homing Receptors’, The 
Journal of Immunology. doi: 10.4049/jimmunol.177.7.4488. 
Homey, B. et al. (2000) ‘Cutting Edge: The Orphan Chemokine Receptor G Protein-
Coupled Receptor-2 (GPR-2, CCR10) Binds the Skin-Associated Chemokine CCL27 
(CTACK/ALP/ILC)’, The Journal of Immunology. doi: 10.4049/jimmunol.164.7.3465. 
Homey, B. et al. (2002) ‘CCL27-CCR10 interactions regulate T cell-mediated skin 
inflammation’, Nature Medicine. doi: 10.1038/nm0202-157. 
Horuk, R. (2009) ‘Chemokine receptor antagonists: Overcoming developmental hurdles’, 
Nature Reviews Drug Discovery. doi: 10.1038/nrd2734. 
Hu, C. et al. (2013) ‘CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization 
to burn wounds and contributes to wound repair’, Journal of Surgical Research. doi: 
10.1016/j.jss.2013.01.019. 
Hu, Z. et al. (2015) ‘CCR4 promotes medullary entry and thymocyte–dendritic cell 
interactions required for central tolerance’, The Journal of Experimental Medicine. doi: 
10.1084/jem.20150178. 
Hughes, C. E. and Nibbs, R. J. B. (2018) ‘A guide to chemokines and their receptors’, 
FEBS Journal. doi: 10.1111/febs.14466. 
Huskens, D. et al. (2007) ‘The role of N-glycosylation sites on the CXCR4 receptor for 
CXCL-12 binding and signaling and X4 HIV-1 viral infectivity’, Virology. doi: 
10.1016/j.virol.2007.01.031. 
Imai, T. et al. (1996) ‘Molecular cloning of a novel T cell-directed CC chemokine 
expressed in thymus by signal sequence trap using Epstein-Barr virus vector’, Journal of 
Biological Chemistry. doi: 10.1074/jbc.271.35.21514. 
Imai, T. et al. (1997) ‘The T cell-directed CC chemokine TARC is a highly specific 
biological ligand for CC chemokine receptor 4’, Journal of Biological Chemistry. doi: 
10.1074/jbc.272.23.15036. 
Imai, T. et al. (1998) ‘Macrophage-derived chemokine is a functional ligand for the CC 
191 
 
chemokine receptor 4.’, The Journal of biological chemistry, 273(3), pp. 1764–8. doi: 
10.1074/jbc.273.3.1764. 
Imai, T. et al. (1999) ‘Selective recruitment of CCR4-bearing T(h)2 cells toward antigen-
presenting cells by the CC chemokines thymus and activation-regulated chemokine and 
macrophage-derived chemokine’, International Immunology. doi: 10.1093/intimm/11.1.81. 
Ishida, T. et al. (2013) ‘Stevens-Johnson Syndrome associated with mogamulizumab 
treatment of adult T-cell leukemia/lymphoma’, Cancer Science. doi: 10.1111/cas.12116. 
Janetopoulos, C., Jin, T. and Devreotes, P. (2016) ‘Receptor-Mediated Activation of 
Heterotrimeric G-Proteins in Living Cells Author(s)’:, 60(3), pp. 348–360. 
Jansma, A. L. et al. (2010) ‘NMR analysis of the structure, dynamics, and unique 
oligomerization properties of the chemokine CCL27’, Journal of Biological Chemistry. 
doi: 10.1074/jbc.M109.091108. 
Jin, Y. et al. (2010) ‘CCR10 Is Important for the Development of Skin-Specific   T Cells 
by Regulating Their Migration and Location’, The Journal of Immunology. doi: 
10.4049/jimmunol.1001612. 
Jørgensen, A. S., Rosenkilde, M. M. and Hjortø, G. M. (2018) ‘Biased signaling of G 
protein-coupled receptors – From a chemokine receptor CCR7 perspective’, General and 
Comparative Endocrinology. doi: 10.1016/j.ygcen.2017.07.004. 
Karube, K. et al. (2004) ‘Expression of FoxP3, a key molecule in CD4+CD25+ regulatory 
T cells, in adult T-cell leukaemia/lymphoma cells’, British Journal of Haematology. doi: 
10.1111/j.1365-2141.2004.04999.x. 
Katada, T. (2012) ‘The inhibitory G protein G(i) identified as pertussis toxin-catalyzed 
ADP-ribosylation.’, Biological {&} pharmaceutical bulletin. doi: 10.1248/bpb.b212024. 
Katou, F. et al. (2003) ‘Differential expression of CCL19 by DC-lamp+mature dendritic 
cells in human lymph node versus chronically inflammed skin’, Journal of Pathology. doi: 
10.1002/path.1255. 
Kenakin, T. and Christopoulos, A. (2013) ‘Signalling bias in new drug discovery: 
Detection, quantification and therapeutic impact’, Nature Reviews Drug Discovery. doi: 
192 
 
10.1038/nrd3954. 
Kiermaier, E. et al. (2016) ‘Polysialylation controls dendritic cell trafficking by regulating 
chemokine recognition’, Science. doi: 10.1126/science.aad0512. 
Kobayashi, D. et al. (2017) ‘Regulation of CCR7-dependent cell migration through CCR7 
homodimer formation’, Scientific Reports. doi: 10.1038/s41598-017-09113-4. 
Kohout, T. A. et al. (2004) ‘Differential desensitization, receptor phosphorylation, ??-
arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC 
chemokine receptor 7’, Journal of Biological Chemistry, 279(22), pp. 23214–23222. doi: 
10.1074/jbc.M402125200. 
Koressaar, T. and Remm, M. (2007) ‘Enhancements and modifications of primer design 
program Primer3’, Bioinformatics. doi: 10.1093/bioinformatics/btm091. 
Kraynyak, K. A. et al. (2010) ‘Systemic immunization with CCL27/CTACK modulates 
immune responses at mucosal sites in mice and macaques’, Vaccine. doi: 
10.1016/j.vaccine.2009.10.095. 
Kühnelt-Leddihn, L. et al. (2012) ‘Overexpression of the chemokine receptors CXCR4, 
CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: A potential prognostic 
value for CCR7 and CCR10?’, Archives of Dermatological Research. doi: 
10.1007/s00403-012-1222-8. 
Lazareno, S. and Birdsall, N. J. M. (1993) ‘Estimation of competitive antagonist affinity 
from functional inhibition curves using the Gaddum, Schild and Cheng‐Prusoíf equations’, 
British Journal of Pharmacology. doi: 10.1111/j.1476-5381.1993.tb13737.x. 
Leach, K., Charlton, S. J. and Strange, P. G. (2007) ‘Analysis of second messenger 
pathways stimulated by different chemokines acting at the chemokine receptor CCR5’, 
Biochemical Pharmacology. doi: 10.1016/j.bcp.2007.06.019. 
Lebre, M. C. et al. (2011) ‘Why CCR2 and CCR5 blockade failed and why ccr1 blockade 
might still be effective in the treatment of rheumatoid arthritis’, PLoS ONE. doi: 
10.1371/journal.pone.0021772. 
Lee, I. et al. (2005) ‘Recruitment of Foxp3 + T regulatory cells mediating allograft 
193 
 
tolerance depends on the CCR4 chemokine receptor’, The Journal of Experimental 
Medicine. doi: 10.1084/jem.20041709. 
Li, K. et al. (2016) ‘CCR7 regulates Twist to induce the epithelial-mesenchymal transition 
in pancreatic ductal adenocarcinoma’, Tumor Biology. doi: 10.1007/s13277-015-3819-y. 
Li, M. et al. (2013) ‘A role for CCL2 in both tumor progression and immunosurveillance’, 
OncoImmunology. doi: 10.4161/onci.25474. 
Lin, H. yu et al. (2017) ‘CCR10 activation stimulates the invasion and migration of breast 
cancer cells through the ERK1/2/MMP-7 signaling pathway’, International 
Immunopharmacology. doi: 10.1016/j.intimp.2017.07.018. 
Link, A. et al. (2007) ‘Fibroblastic reticular cells in lymph nodes regulate the homeostasis 
of naive T cells’, Nature Immunology. doi: 10.1038/ni1513. 
Loughran, G. et al. (2018) ‘Stop codon readthrough generates a C-terminally extended 
variant of the human vitamin D receptor with reduced calcitriol response’, Journal of 
Biological Chemistry. doi: 10.1017/S096702629700139X. 
Lovell, K. M. et al. (2015) ‘Structure-Activity Relationship Studies of Functionally 
Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation while 
Preserving G Protein over βarrestin2 Signaling Bias’, ACS Chemical Neuroscience. doi: 
10.1021/acschemneuro.5b00092. 
Luttrell, L. M. et al. (1999) ‘β-arrestin-dependent formation of β2 adrenergic receptor-src 
protein kinase complexes’, Science. doi: 10.1126/science.283.5402.655. 
Ma, Q. et al. (1998) ‘Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar 
neuron migration in CXCR4- and SDF-1-deficient mice’, Proceedings of the National 
Academy of Sciences. doi: 10.1073/pnas.95.16.9448. 
Ma, X. et al. (2016) ‘Functional roles of sialylation in breast cancer progression through 
miR-26a/26b targeting ST8SIA4’, Cell death & disease. doi: 10.1038/cddis.2016.427. 
Makita, S. and Tobinai, K. (2017) ‘Mogamulizumab for the treatment of T-cell 
lymphoma’, Expert Opinion on Biological Therapy. doi: 
10.1080/14712598.2017.1347634. 
194 
 
Malik, R. U. et al. (2017) ‘ER/K linked GPCR-G protein fusions systematically modulate 
second messenger response in cells’, Scientific Reports. doi: 10.1038/s41598-017-08029-3. 
Malpica, L. et al. (2018) ‘Epidemiology, clinical features, and outcome of HTLV-1–related 
ATLL in an area of prevalence in the United States’, Blood Advances. doi: 
10.1182/bloodadvances.2017011106. 
Mangmool, S. and Kurose, H. (2011) ‘Gi/oprotein-dependent and -independent actions of 
pertussis toxin (ptx)’, Toxins, 3(7), pp. 884–899. doi: 10.3390/toxins3070884. 
Mantovani, A. (1999) ‘The chemokine system: Redundancy for robust outputs’, 
Immunology Today. doi: 10.1016/S0167-5699(99)01469-3. 
Manzi, A. E. et al. (1994) ‘Intramolecular self-cleavage of polysialic acid’, Journal of 
Biological Chemistry. 
Maolake, A. et al. (2016) ‘Tumor-associated macrophages promote prostate cancer 
migration through activation of the CCL22&amp;#x2013;CCR4 axis’, Oncotarget. doi: 
10.18632/oncotarget.14185. 
Marchese, A. and Benovic, J. L. (2001) ‘Agonist-promoted Ubiquitination of the G 
Protein-coupled Receptor CXCR4 Mediates Lysosomal Sorting’, Journal of Biological 
Chemistry. doi: 10.1074/jbc.C100527200. 
Mariani, M. et al. (2004) ‘Dominance of CCL22 over CCL17 in induction of chemokine 
receptor CCR4 desensitization and internalization on human Th2 cells’, European Journal 
of Immunology. doi: 10.1002/eji.200324429. 
Matloubian, M. et al. (2004) ‘Lymphocyte egress from thymus and peripheral lymphoid 
organs is dependent on S1P receptor 1’, Nature. doi: 10.1038/nature02284. 
Mauldin, I. S. et al. (2016) ‘Topical treatment of melanoma metastases with imiquimod, 
plus administration of a cancer vaccine, promotes immune signatures in the metastases’, 
Cancer Immunology, Immunotherapy. doi: 10.1007/s00262-016-1880-z. 
Mirshahpanah, P. et al. (2008) ‘CCR4 and CCR10 ligands play additive roles in mouse 
contact hypersensitivity’, Experimental Dermatology. doi: 10.1111/j.1600-
0625.2007.00630.x. 
195 
 
Miyazato, P. and Matsuoka, M. (2014) ‘Human T-cell leukemia virus type 1 and Foxp3 
expression: Viral strategy in vivo’, International Immunology. doi: 
10.1093/intimm/dxu048. 
Mizukami, Y. et al (2008) ‘CCL17 and CCL22 chemokines within tumor 
microenvironment are related to accumulation of Foxp3+ regula- tory T cells in gastric 
cancer.’, Int J Cancer. doi: 10.1002/ijc.23392. 
Momose, F. and Morikawa, Y. (2016) ‘Polycistronic expression of the influenza A virus 
RNA-dependent RNA polymerase by using the Thosea asigna virus 2A-like self-
processing sequence’, Frontiers in Microbiology. doi: 10.3389/fmicb.2016.00288. 
Morales, J. et al. (1999) ‘CTACK, a skin-associated chemokine that preferentially attracts 
skin-homing memory T cells’, Proceedings of the National Academy of Sciences. doi: 
10.1073/pnas.96.25.14470. 
Mori, A. et al. (2017) ‘Different properties of polysialic acids synthesized by the 
polysialyltransferases ST8SIA2 and ST8SIA4’, Glycobiology, 27(9), pp. 834–846. doi: 
10.1093/glycob/cwx057. 
Morimoto, Y. (2005) ‘Induction of surface CCR4 and its functionality in mouse Th2 cells 
is regulated differently during Th2 development’, Journal of Leukocyte Biology. doi: 
10.1189/jlb.0305139. 
Morteau, O. et al. (2008) ‘An Indispensable Role for the Chemokine Receptor CCR10 in 
IgA Antibody-Secreting Cell Accumulation’, The Journal of Immunology. doi: 
10.4049/jimmunol.181.9.6309. 
Na, I. K. et al. (2008) ‘Identification of truncated chemokine receptor 7 in human 
colorectal cancer unable to localize to the cell surface and unreactive to external ligands’, 
International Journal of Cancer. doi: 10.1002/ijc.23704. 
Nibbs, R. J. B. and Graham, G. J. (2013) ‘Immune regulation by atypical chemokine 
receptors’, Nature Reviews Immunology. doi: 10.1038/nri3544. 
Nomiyama, H., Osada, N. and Yoshie, O. (2011) ‘A family tree of vertebrate chemokine 
receptors for a unified nomenclature’, Developmental and Comparative Immunology. doi: 
10.1016/j.dci.2011.01.019. 
196 
 
Notohamiprodjo, M. et al. (2005) ‘CCR10 is expressed in cutaneous T-cell lymphoma’, 
International Journal of Cancer. doi: 10.1002/ijc.20922. 
O’Hagan, D. T. and Valiante, N. M. (2003) ‘Recent advances in the discovery and delivery 
of vaccine adjuvants’, Nature Reviews Drug Discovery. doi: 10.1038/nrd1176. 
Ohl, L. et al. (2003) ‘Cooperating Mechanisms of CXCR5 and CCR7 in Development and 
Organization of Secondary Lymphoid Organs’, The Journal of Experimental Medicine. 
doi: 10.1084/jem.20030169. 
Ohl, L. et al. (2004) ‘CCR7 governs skin dendritic cell migration under inflammatory and 
steady-state conditions’, Immunity. doi: 10.1016/j.immuni.2004.06.014. 
Ondondo, B. et al. (2013) ‘Home sweet home: The tumor microenvironment as a haven for 
regulatory T cells’, Frontiers in Immunology. doi: 10.3389/fimmu.2013.00197. 
Oppermann, M. et al. (1999) ‘Differential effects of CC chemokines on CC chemokine 
receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the 
CCR5 carboxyl terminus’, Journal of Biological Chemistry. doi: 10.1074/jbc.274.13.8875. 
Otero, C., Groettrup, M. and Legler, D. F. (2006) ‘Opposite Fate of Endocytosed CCR7 
and Its Ligands: Recycling versus Degradation’, The Journal of Immunology. doi: 
10.4049/jimmunol.177.4.2314. 
Ourne, H. E. R. B. (1997) ‘Receptors induce chemotaxis by releasing the ␤␥ subunit of G 
i ’, 94(December), pp. 14489–14494. 
Pack, T. F. et al. (2018) ‘The dopamine D2 receptor can directly recruit and activate GRK2 
without G protein activation’, Journal of Biological Chemistry. doi: 
10.1074/jbc.RA117.001300. 
Palczewski, K. et al. (1991) ‘Mechanism of rhodopsin kinase activation’, Journal of 
Biological Chemistry. 
Pan, J. et al. (2000) ‘Cutting Edge: A Novel Chemokine Ligand for CCR10 And CCR3 
Expressed by Epithelial Cells in Mucosal Tissues’, The Journal of Immunology. doi: 
10.4049/jimmunol.165.6.2943. 
197 
 
Park, C. et al. (2012) ‘Lymph node B lymphocyte trafficking is constrained by anatomy 
and highly dependent upon chemoattractant desensitization’, Blood. doi: 10.1182/blood-
2011-06-364273. 
Pearce, O. M. T. and Läubli, H. (2015) ‘Sialic acids in cancer biology and immunity’, 
Glycobiology. doi: 10.1093/glycob/cwv097. 
Percherancier, Y. et al. (2001) ‘Palmitoylation-dependent Control of Degradation, Life 
Span, and Membrane Expression of the CCR5 Receptor’, Journal of Biological Chemistry. 
doi: 10.1074/jbc.M104013200. 
Pere, H. et al. (2011) ‘ACCR4 antagonist combined with vaccines induces antigen-specific 
CD8+T cells and tumor immunity against self antigens’, Blood. doi: 10.1182/blood-2011-
01-329656. 
Peterson, Y. K. and Luttrell, L. M. (2017) ‘The Diverse Roles of Arrestin Scaffolds in G 
Protein–Coupled Receptor Signaling’, Pharmacological Reviews. doi: 
10.1124/pr.116.013367. 
Phillips, A. J. et al. (2017) ‘CCR7 sulfotyrosine enhances CCL21 binding’, International 
Journal of Molecular Sciences. doi: 10.3390/ijms18091857. 
Proudfoot, A. E. I. et al. (1996) ‘Extension of recombinant human RANTES by the 
retention of the initiating methionine produces a potent antagonist’, Journal of Biological 
Chemistry. doi: 10.1074/jbc.271.5.2599. 
Qin, L. et al. (2015) ‘Crystal structure of the chemokine receptor CXCR4 in complex with 
a viral chemokine’, Science. doi: 10.1126/science.1261064. 
Rainone, V. et al. (2011) ‘CCL28 induces mucosal homing of HIV-1-specific IgA-
secreting plasma cells in mice immunized with HIV-1 virus-like particles’, PLoS ONE. 
doi: 10.1371/journal.pone.0026979. 
Rajagopal, S. et al. (2013) ‘Biased agonism as a mechanism for differential signaling by 
chemokine receptors’, Journal of Biological Chemistry. doi: 10.1074/jbc.M113.479113. 
Rajagopalan, L. and Rajarathnam, K. (2006) ‘Structural basis of chemokine receptor 
function - A model for binding affinity and ligand selectivity’, Bioscience Reports. doi: 
198 
 
10.1007/s10540-006-9025-9. 
Raman, D., Sobolik-Delmaire, T. and Richmond, A. (2011) ‘Chemokines in health and 
disease’, Experimental Cell Research. doi: 10.1016/j.yexcr.2011.01.005. 
Rankin, S. M. (2012) ‘Chemokines and adult bone marrow stem cells’, Immunology 
Letters. doi: 10.1016/j.imlet.2012.04.009. 
Rankovic, Z., Brust, T. F. and Bohn, L. M. (2016) ‘Biased agonism: An emerging 
paradigm in GPCR drug discovery’, Bioorganic and Medicinal Chemistry Letters. doi: 
10.1016/j.bmcl.2015.12.024. 
Reiss, Y. et al. (2001) ‘CC Chemokine Receptor (CCR)4 and the CCR10 Ligand 
Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafficking to Inflamed 
Skin’, The Journal of Experimental Medicine. doi: 10.1084/jem.194.10.1541. 
Rey-Gallardo, A. et al. (2010) ‘Polysialylated neuropilin-2 enhances human dendritic cell 
migration through the basic C-terminal region of CCL21’, Glycobiology. doi: 
10.1093/glycob/cwq078. 
Röckle, I. and Hildebrandt, H. (2016) ‘Deficits of olfactory interneurons in 
polysialyltransferase- and NCAM-deficient mice’, Developmental Neurobiology. doi: 
10.1002/dneu.22324. 
Rollins, B. J. (1997) ‘Chemokines’, Blood Journal. doi: 10.1111/j.1365-
2036.2011.04980.x. 
Rot, A. and von Andrian, U. H. U. H. (2004) ‘Chemokines in innate and adaptive host 
defense: basic chemokinese grammar for immune cells.’, Annual review of immunology. 
doi: 10.1146/annurev.immunol.22.012703.104543. 
Rummel, P. C. et al. (2013) ‘Extracellular Disulfide Bridges Serve Different Purposes in 
Two Homologous Chemokine Receptors, CCR1 and CCR5’, Molecular Pharmacology. 
doi: 10.1124/mol.113.086702. 
Sallusto, F. et al. (1998) ‘Rapid and coordinated switch in chemokine receptor expression 
during dendritic cell maturation’, European Journal of Immunology. doi: 
10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N. 
199 
 
Sallusto, F. et al. (2014) ‘Two subsets of memory T lymphocytes with distinct homing 
potentials and effector functions’, Journal of Immunology. doi: 10.1126/science.1058867. 
Sanz, M. J. and Kubes, P. (2012) ‘Neutrophil-active chemokines in in vivo imaging of 
neutrophil trafficking’, European Journal of Immunology. doi: 10.1002/eji.201142231. 
Sather, B. D. et al. (2007) ‘Altering the distribution of Foxp3 + regulatory T cells results in 
tissue-specific inflammatory disease’, The Journal of Experimental Medicine. doi: 
10.1084/jem.20070081. 
Schaeuble, K. et al. (2011) ‘Cross-talk between TCR and CCR7 signaling sets a temporal 
threshold for enhanced T lymphocyte migration.’, The Journal of Immunology. doi: 
10.4049/jimmunol.1101850. 
Schmid, C. L. and Bohn, L. M. (2010) ‘Serotonin, But Not N-Methyltryptamines, 
Activates the Serotonin 2A Receptor Via a  -Arrestin2/Src/Akt Signaling Complex In 
Vivo’, Journal of Neuroscience. doi: 10.1523/JNEUROSCI.1665-10.2010. 
Schmied, W. H. et al. (2014) ‘Efficient multisite unnatural amino acid incorporation in 
mammalian cells via optimized pyrrolysyl tRNA synthetase/tRNA expression and 
engineered eRF1’, Journal of the American Chemical Society. doi: 10.1021/ja5069728. 
Schneider, M. A. et al. (2007) ‘CCR7 is required for the in vivo function of CD4 + CD25 + 
regulatory T cells’, The Journal of Experimental Medicine. doi: 10.1084/jem.20061405. 
Schutyser, E., Struyf, S. and Van Damme, J. (2003) ‘The CC chemokine CCL20 and its 
receptor CCR6’, Cytokine and Growth Factor Reviews. doi: 10.1016/S1359-
6101(03)00049-2. 
Shannon, L. A. et al. (2012) ‘CCR7/CCL19 controls expression of EDG-1 in T cells’, 
Journal of Biological Chemistry. doi: 10.1074/jbc.M111.310045. 
Shao, N. et al. (2015) ‘Site Specific Genetic Incorporation of Azidophenylalanine in 
Schizosaccharomyces pombe’, Scientific Reports. doi: 10.1038/srep17196. 
Soler, D. et al. (2003) ‘CCR4 versus CCR10 in human cutaneous TH lymphocyte 
trafficking’, Blood. doi: 10.1182/blood-2002-07-2348. 
200 
 
Stone, M. J. et al. (2017) ‘Mechanisms of regulation of the chemokine-receptor network’, 
International Journal of Molecular Sciences. doi: 10.3390/ijms18020342. 
Strieter, R. M. et al. (1995) ‘The functional role of the ELR motif in CXC chemokine-
mediated angiogenesis’, Journal of Biological Chemistry. doi: 10.1074/jbc.270.45.27348. 
Sugiyama, D. et al. (2013) ‘Anti-CCR4 mAb selectively depletes effector-type 
FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans’, 
Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.1316796110. 
Sullivan, S. K. et al. (1999) ‘Pharmacological and signaling analysis of human chemokine 
receptor CCR-7 stably expressed in HEK-293 cells: High-affinity binding of recombinant 
ligands MIP-3β and SLC stimulates multiple signaling cascades’, Biochemical and 
Biophysical Research Communications. doi: 10.1006/bbrc.1999.1442. 
Sun, L. et al. (2015) ‘CCL21/CCR7 up-regulate vascular endothelial growth factor-D 
expression via ERK pathway in human non-small cell lung cancer cells’, International 
Journal of Clinical and Experimental Pathology. 
Sun, X. et al. (2010) ‘CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer 
progression’, Cancer and Metastasis Reviews. doi: 10.1007/s10555-010-9256-x. 
Suzuki, G. et al. (1999) ‘Pertussis toxin-sensitive signal controls the trafficking of 
thymocytes across the corticomedullary junction in the thymus’, Journal of immunology 
(Baltimore, Md : 1950). doi: 10.4049/jimmunol.176.1.401. 
Svensson, H. et al. (2012) ‘Accumulation of CCR4+CTLA-4hiFOXP3+CD25hiregulatory 
T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells’, 
PLoS ONE. doi: 10.1371/journal.pone.0030695. 
Svensson, M. et al. (2002) ‘CCL25 mediates the localization of recently activated 
CD8αβ+lymphocytes to the small-intestinal mucosa’, Journal of Clinical Investigation. 
doi: 10.1172/JCI0215988. 
Szekanecz, Z. et al. (2006) ‘Chemokines in rheumatic diseases’, CURRENT DRUG 
TARGETS. doi: 10.2174/138945006775270231. 
Szpakowska, M. et al. (2012) ‘Function, diversity and therapeutic potential of the N-
201 
 
terminal domain of human chemokine receptors’, Biochemical Pharmacology. doi: 
10.1016/j.bcp.2012.08.008. 
Takabatake, Y. et al. (2009) ‘The CXCL12 (SDF-1)/CXCR4 Axis Is Essential for the 
Development of Renal Vasculature’, Journal of the American Society of Nephrology. doi: 
10.1681/ASN.2008060640. 
Takahama, Y. (2006) ‘Journey through the thymus: Stromal guides for T-cell development 
and selection’, Nature Reviews Immunology. doi: 10.1038/nri1781. 
Takimoto, J. K. et al. (2009) ‘Improving orthogonal tRNA-synthetase recognition for 
efficient unnatural amino acid incorporation and application in mammalian cells’, 
Molecular BioSystems. doi: 10.1039/b904228h. 
Tan, Q. et al. (2013) ‘Structure of the CCR5 chemokine receptor-HIV entry inhibitor 
maraviroc complex’, Science. doi: 10.1126/science.1241475. 
Tanaka, F. et al. (2000) ‘Expression of polysialic acid and STX, a human 
polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer’, 
Cancer Research. doi: 10.1016/s0959-4388(97)80083-9. 
Tom, R., Bisson, L. and Durocher, Y. (2008) ‘Culture of HEK293-EBNA1 cells for 
production of recombinant proteins’, Cold Spring Harbor Protocols. doi: 
10.1101/pdb.prot4976. 
Ulvmar, M. H. et al. (2014) ‘The atypical chemokine receptor CCRL1 shapes functional 
CCL21 gradients in lymph nodes’, Nature Immunology. doi: 10.1038/ni.2889. 
Ulvmar, M. H., Hub, E. and Rot, A. (2011) ‘Atypical chemokine receptors.’, Experimental 
cell research. doi: 10.1016/j.yexcr.2011.01.012. 
Vestergaard, C. et al. (2003) ‘Expression of the T-helper 2-specific chemokine receptor 
CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin’, 
British Journal of Dermatology. doi: 10.1046/j.1365-2133.2003.05505.x. 
Viney, J. M. et al. (2014a) ‘Distinct Conformations of the Chemokine Receptor CCR4 
with Implications for Its Targeting in Allergy’, The Journal of Immunology. doi: 
10.4049/jimmunol.1300232. 
202 
 
Viney, J. M. et al. (2014b) ‘Distinct Conformations of the Chemokine Receptor CCR4 
with Implications for Its Targeting in Allergy’, The Journal of Immunology, 192(7), pp. 
3419–3427. doi: 10.4049/jimmunol.1300232. 
Violin, J. D. et al. (2010) ‘Selectively Engaging  -Arrestins at the Angiotensin II Type 1 
Receptor Reduces Blood Pressure and Increases Cardiac Performance’, Journal of 
Pharmacology and Experimental Therapeutics. doi: 10.1124/jpet.110.173005. 
Violin, J. D., Soergel, D. G. and Lark, M. W. (2012) ‘Beta-arrestin-biased ligands at the 
AT1R: A novel approach to the treatment of acute heart failure’, Drug Discovery Today: 
Therapeutic Strategies. doi: 10.1016/j.ddstr.2014.01.001. 
Wang, L. and Schultz, P. G. (2002) ‘Expanding the genetic code’, Chemical 
Communications. doi: 10.1039/b108185n. 
Wang, W. et al. (2000) ‘Identification of a novel chemokine (CCL28), which binds CCR10 
(GPR2)’, Journal of Biological Chemistry. doi: 10.1074/jbc.M001461200. 
Wang, X. et al. (2016) ‘Enhanced expression of polysialic acid correlates with malignant 
phenotype in breast cancer cell lines and clinical tissue samples’, International Journal of 
Molecular Medicine. doi: 10.3892/ijmm.2015.2395. 
Ward, R. J., Alvarez-Curto, E. and Milligan, G. (2011) ‘Using the Flp-InTM T-RexTM 
system to regulate GPCR expression’, Methods in Molecular Biology. doi: 10.1007/978-1-
61779-126-0_2. 
Ward, W. W. and Cormier, M. J. (1979) ‘An energy transfer protein in coelenterate 
bioluminescence. Characterization of the Renilla green-fluorescent protein.’, Journal of 
Biological Chemistry. 
Watanabe, Y. et al. (2010) ‘Tumor-infiltrating lymphocytes, particularly the balance 
between CD8+T cells and CCR4+regulatory T cells, affect the survival of patients with 
oral squamous cell carcinoma’, Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology and Endodontology. doi: 10.1016/j.tripleo.2009.12.015. 
Weber, M. et al. (2013) ‘Interstitial Dendritic Cell Guidance by Haptotactic Chemokine 
Gradients’, Science. doi: 10.1126/science.1228456. 
203 
 
Wengner, A. M. et al. (2007) ‘CXCR5- and CCR7-dependent lymphoid neogenesis in a 
murine model of chronic antigen-induced arthritis’, Arthritis and Rheumatism. doi: 
10.1002/art.22939. 
Willenborg, S. et al. (2012) ‘CCR2 recruits an inflammatory macrophage subpopulation 
critical for angiogenesis in tissue repair’, Blood. doi: 10.1182/blood-2012-01-403386. 
Windfuhr, M. et al. (2000) ‘Molecular defects that cause loss of polysialic acid in the 
complementation group 2A10’, Journal of Biological Chemistry. doi: 
10.1074/jbc.M003507200. 
Worbs, T. et al. (2007) ‘CCR7 ligands stimulate the intranodal motility of T lymphocytes 
in vivo’, The Journal of Experimental Medicine. doi: 10.1084/jem.20061706. 
Xia, M. et al. (2014) ‘CCR10 regulates balanced maintenance and function of resident 
regulatory and effector T cells to promote immune homeostasis in the skin’, Journal of 
Allergy and Clinical Immunology. doi: 10.1016/j.jaci.2014.03.010. 
Xiong, N. et al. (2012) ‘CCR10 and its ligands in regulation of epithelial immunity and 
diseases’, Protein and Cell. doi: 10.1007/s13238-012-2927-3. 
Xiong, Y. et al. (2017) ‘CCL21/CCR7 interaction promotes cellular migration and 
invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with 
lymphatic metastatic spread and poor prognosis in urinary bladder cancer’, International 
Journal of Oncology. doi: 10.3892/ijo.2017.4003. 
Xu, B. et al. (2017) ‘CCR7 mediates human breast cancer cell invasion, migration by 
inducing epithelial–mesenchymal transition and suppressing apoptosis through AKT 
pathway’, Cancer Medicine. doi: 10.1002/cam4.1039. 
Xu, Y. et al. (2007) ‘Differential Development of Murine Dendritic Cells by GM-CSF 
versus Flt3 Ligand Has Implications for Inflammation and Trafficking’, The Journal of 
Immunology. doi: 10.4049/jimmunol.179.11.7577. 
Ye, J. et al. (2012) ‘Primer-BLAST: a tool to design target-specific primers for polymerase 
chain reaction.’, BMC bioinformatics. doi: 10.1186/1471-2105-13-134. 
Yoshida, R. et al. (1998) ‘Secondary lymphoid-tissue chemokine is a functional ligand for 
204 
 
the CC chemokine receptor CCR7’, Journal of Biological Chemistry. doi: 
10.1074/jbc.273.12.7118. 
Yoshie, O. et al. (2002) ‘Frequent expression of CCR4 in adult T-cell leukemia and human 
T-cell leukemia virus type 1-transformed T cells’, Blood. doi: 10.1182/blood.V99.5.1505. 
Yoshie, O. and Matsushima, K. (2015) ‘CCR4 and its ligands: From bench to bedside’, 
International Immunology. doi: 10.1093/intimm/dxu079. 
Yu, S. et al. (2011) ‘The chemokine receptor CXCR7 functions to regulate cardiac valve 
remodeling’, Developmental Dynamics. doi: 10.1002/dvdy.22549. 
Zerwas, M. et al. (2016) ‘Environmental enrichment rescues memory in mice deficient for 
the polysialytransferase ST8SiaIV’, Brain Structure and Function. doi: 10.1007/s00429-
015-0991-1. 
Zhang, L. et al. (2017) ‘Inhibition of CCR7 promotes NF-KB-dependent apoptosis and 
suppresses epithelial-mesenchymal transition in non-small cell lung cancer’, Oncology 
Reports. doi: 10.3892/or.2017.5524. 
Zhang, Y. et al. (2017) ‘A new antagonist for CCR4 attenuates allergic lung inflammation 
in a mouse model of asthma’, Scientific Reports. doi: 10.1038/s41598-017-11868-9. 
Zhao, L. et al. (2016) ‘Upregulation of miR-181c inhibits chemoresistance by targeting 
&lt;i&gt;ST8SIA4&lt;/i&gt; in chronic myelocytic leukemia’, Oncotarget. doi: 
10.1007/978-3-319-70742-6_20. 
Zhong, G. et al. (2017) ‘Chemokine (C-C motif) ligand 21/C-C chemokine receptor type 7 
triggers migration and invasion of human lung cancer cells by epithelial-mesenchymal 
transition via the extracellular signal-regulated kinase signaling pathway’, Molecular 
Medicine Reports. doi: 10.3892/mmr.2017.6534. 
Zhou, L. et al. (2013) ‘Development of functionally selective, small molecule agonists at 
kappa opioid receptors’, Journal of Biological Chemistry. doi: 10.1074/jbc.M113.504381. 
Zhu, B. et al. (2012) ‘CXCL12 enhances human neural progenitor cell survival through a 
CXCR7- and CXCR4-mediated endocytotic signaling pathway’, Stem Cells. doi: 
10.1002/stem.1239. 
205 
 
Zhu, Y. and Murakami, F. (2012) ‘Chemokine CXCL12 and its receptors in the developing 
central nervous system: Emerging themes and future perspectives’, Developmental 
Neurobiology. doi: 10.1002/dneu.22041. 
Ziarek, J. J. et al. (2017) ‘Structural basis for chemokine recognition by a G protein–
coupled receptor and implications for receptor activation’, Science Signaling. doi: 
10.1126/scisignal.aah5756. 
Zidar, D. A. et al. (2009) ‘Selective engagement of G protein coupled receptor kinases 
(GRKs) encodes distinct functions of biased ligands’, Proceedings of the National 
Academy of Sciences. doi: 10.1073/pnas.0904361106. 
Zlotnik, A. and Yoshie, O. (2000) ‘Chemokines: A new classification system and their role 
in immunity’, Immunity. doi: 10.1016/S1074-7613(00)80165-X. 
Zlotnik, A. and Yoshie, O. (2012) ‘The Chemokine Superfamily Revisited’, Immunity. doi: 
10.1016/j.immuni.2012.05.008. 
Zlotnik, A., Yoshie, O. and Nomiyama, H. (2006) ‘The chemokine and chemokine 
receptor superfamilies and their molecular evolution’, Genome Biology. doi: 10.1186/gb-
2006-7-12-243. 
 
